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Alzheimer’s disease (AD) is the most common cause of dementia worldwide 
and a leading cause of death in the United States. Rare cases of autosomal dominant 
familial AD (fAD) result from genetic mutations in three key genes: amyloid precursor 
protein (APP), and two APP processing-related genes (presenilin-1 (PSEN1), and 
presenilin-2 (PSEN2)), supporting the theory that altered APP metabolism is a central 
cause of AD.  However, which product of APP metabolism is causal remains a matter 
of investigation. A probable source of this lack of understanding stems from the poor 
disease model systems that have been utilized in the field for many years.  Recently, 
advances in human induced pluripotent stem cell (iPSC) technology has enabled the 
study of uniquely human diseases, such as AD, in human tissue.  However, the 
inability to precisely and efficiently genetically engineer human iPSCs has limited their 
use in effectively studying monogenic human diseases like fAD.   
 
 
In this thesis I first describe my work involved in developing CRISPR/Cas9 
gene editing technology for use in human stem cells.  Our CRISPR/Cas9-based 
genome-editing framework allows the selective introduction of mono- and bi-allelic 
sequence changes, such as single fAD-causing pathogenic mutations, with high 
efficiency and accuracy. We show that editing accuracy is increased dramatically by 
incorporating silent CRISPR/Cas-blocking mutations along with pathogenic mutations. 
As well, by characterizing and exploiting a stereotyped inverse relationship between 
a mutation’s incorporation rate and its distance to the CRISPR/Cas9 cleavage site, 
we achieve predictable control of zygosity. Homozygous introduction requires using a 
guide RNA targeting close to the intended mutation, whereas heterozygous 
introduction can be accomplished by distance-dependent suboptimal mutation 
incorporation or by using mixed repair templates.  Additionally, we establish a method 
termed “CORRECT” for precise and scarless gene editing.  Together, our findings will 
greatly facilitating the study of human disease and development of more human 
disease models by enabling efficient introduction of specific sequence changes in 
human stem cells using CRISPR/Cas9. 
In later chapters I discuss how we used our novel CRISPR/Cas9 gene editing 
framework to investigate in human neurons how APP and PSEN1 mutations may 
converge in their actions in promoting AD-related phenotypes. We generated a 
comprehensive panel of isogenic knock-in human iPSCs, which were differentiated 
into disease-vulnerable cortical neurons. Initial global transcriptomic profiling of 
 
 
mutant neurons revealed overlapping effects of the mutations on expression of AD-
related genes, suggesting an AD gene associated-network effect, as well as 
endosomal-related genes.  Endocytic dysfunction, as measured by enlargement of 
Rab5+ early endosomes, was found in all APP and PSEN1 pathogenic mutant 
neurons analyzed. By comparing heterozygous and homozygous cells we found APP 
and PSEN1 mutations have discordant effects on Aβ production but similar effects on 
the precursor to Aβ, β-C-terminal fragment of APP (β-CTF), which accumulates in all 
APP and PSEN1 mutant neurons. Importantly, endosomal dysfunction in these human 
neurons correlates with endogenous accumulation of β-CTF, and not with longer Aβ 
peptides, and could be rescued by pharmacological modulation of β-secretase 
(BACE) but not g-secretase.  These data provide a new piece of evidence for β-CTF 
being an important common product of APP metabolism that significantly contributes 
to AD pathology.   
In summary, by developing the technology to engineer next-generation human 
AD model systems using CRISPR/Cas9 and iPSCs, our results not only provide 
insight into the mechanism by which familial APP and PSEN1 mutations may cause 
AD, but also provide knowledge that could be critical for the development of novel 
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CHAPTER I: INTRODUCTION 
 
Rationale for thesis work 
 
Ever since the German physician Alois Alzheimer discovered abnormal 
deposits in the brain of a 51year-old patient suffering from memory impairments in 
1906 (Alzheimer, 1916; Alzheimer et al., 1995), the effort to better understand and 
treat what we now know as Alzheimer’s disease (AD) has endured.  More than one 
century later, and after years of research into the basic biological mechanisms 
underlying AD, researchers are still hard at work trying to discover a cure for this 
unthinkably devastating disease.  The lack of any effective AD therapeutics 
underscores the underlying complexities of the disease and indicates that new and 
improved ways of studying AD may be invaluable to the field.  
AD is currently defined by the presence of two key neuropathological findings, 
extracellular plaques composed of amyloid-beta (Aβ) (Tanzi et al., 1987), and 
intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau 
(Grundke-Iqbal et al., 1986; Wischik et al., 1988). While the majority of AD cases 
occur sporadically (sAD), genetic studies have demonstrated that single mutations in 
either the amyloid precursor protein (APP) gene, or presenilin genes (PSEN1 and 
PSEN2), are sufficient to cause a rare, early-onset, familial form of AD (fAD) 
(Alzheimer's Disease Collaborative Group, 1995; Goate et al., 1991; Levy-Lahad et 
al., 1995; Rogaev et al., 1995; Schellenberg et al., 1992; St George-Hyslop et al., 
1992; Van Broeckhoven et al., 1992). These genetic findings, along with the 
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discovery that presenilins form the catalytic component of the γ-secretase complex 
responsible for cleaving APP and generating Ab, implies that APP metabolism is 
essential to AD pathogenesis (De Strooper et al., 1998; Goldgaber et al., 1987; 
Kang et al., 1987; St George-Hyslop et al., 1987; Tanzi et al., 1987).  As a result, the 
leading theory of AD pathogenesis is known as the “amyloid cascade hypothesis”, 
which places extracellular Ab as the most upstream trigger of neurodegenerative 
processes in the disease (Hardy and Higgins, 1992; Hardy, 2006).    
 To date, more than 200 fAD mutations in APP, PSEN1 and PSEN2 have 
been described, and while the effects of many of these mutations on Aβ production 
have been studied extensively, a common unifying mechanism describing how these 
mutations lead to the development of AD has yet to be determined (Barber, 2012).  
Confounding many of these early studies is their use of non-human and/or non-
neuronal cellular systems that rely on massive overexpression of AD-associated 
proteins, typically in rodent models (Götz and Ittner, 2008).  Moreover, these widely 
used non-physiological models fail to adequately recapitulate all known human AD 
hallmark pathologies, and therefore may limit the discovery of effective AD 
therapeutics. Generation of a physiologically relevant human neuronal model system 
may be the key to unlocking future discoveries of basic disease mechanisms and 
novel therapeutic targets.  This thesis describes an effort to develop gene editing 
and human stem cell technologies, and ultimately implement these tools to better 




Epidemiology and clinical manifestation of AD 
 
AD is classified as a type of neurodegenerative dementia, which is a broad 
description of a family of brain disorders that cause chronic and gradual loss of 
memory, language, problem solving skills and executive functioning.  Ultimately, the 
disease culminates in a loss of ability to perform everyday activities as well as a loss 
of one’s independence (Alzheimer's Association, 2017).  AD comprises 
approximately 60-70% of all dementias, making it the most common type of 
neurodegenerative disease, affecting over 5 million people in the US and more than 
40 million people worldwide (Alzheimer's Association, 2017; Scheltens et al., 2016).  
The primary risk factor for AD is aging, as epidemiological studies have shown that 
the risk of developing AD approximately doubles every five years after the age of 65 
(Alzheimer's Association, 2017).  Prevalence of AD correlates with population 
lifespan and as global population demographics change in the coming decades, the 
number of cases of AD worldwide is also expected to dramatically shift.  Specifically, 
it is estimated that today approximately 5.7 million Americans are living with AD, 
however with predicted future population aging, this number is expected to triple by 
2050 (Alzheimer's Association, 2017).    
AD is the only one of the top 10 leading causes of death that cannot be 
prevented, cured or slowed (Alzheimer's Association, 2017).  Between years 2000 
and 2015 the number of deaths known to be associated with AD has increased 125 
percent, while deaths due to the most common cause of death (heart disease) has 
significantly decreased (Alzheimer's Association, 2017).   The lifetime cost of care 
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for an individual living with AD dementia is estimated to be over $300,000, and it is 
expected that in the US the total payments in 2018 for all individuals with AD is more 
than 250 billion dollars.  Therefore, if no effective therapies are discovered, the 
financial burden of AD will increase to a projected 1.1 trillion dollars by 2050 
(Alzheimer's Association, 2017). 
Clinically, symptoms may present differently amongst patients with AD.  Early 
in AD progression individuals are often able to function independently.  However, in 
more moderate and severe stages of AD individuals may become frequently 
confused about where they are, have personality and behavioral changes, and 
ultimately require assistance in basic activities of daily living and may lose their 
ability to communicate (Alzheimer's Association, 2017).  Once the AD progresses to 
the latest stages, brain regions involved in motor control and other basic bodily 
functions become affected, ultimately impairing movement and requiring the patient 
to be cared for full-time or hospitalized.  Lung infection (aspiration pneumonia) is a 
common concomitant issue in late stage AD, contributing to death in many cases 
(Alzheimer's Association, 2017). 
Diagnosis of AD is not straightforward, as many presenting symptoms overlap 
with other dementias of a different cause.  Therefore, diagnosing AD requires careful 
examination obtaining family medical records, patient reporting, cognitive testing, 
blood testing to rule out other potential causes of dementia, and, in more recent 
years, brain imaging for Ab or tau (Alzheimer's Association, 2017).  Despite these 
improved methods of clinical examination, bona fide AD can only be fully diagnosed 
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upon autopsy and identification of hallmark AD neuropathological features.  In the 
future, with the development of biomarkers, revised strategies to diagnose AD early 
are anticipated.  While this improvement in no way offsets the demand for novel 
therapeutics to treat AD, early diagnosis will help ease the burden of the disease by 
allowing a patient’s family and caregivers to adequately prepare for treatment and 
may aid in the development of interventions to delay AD progression. 
 
AD neuropathology: APP and generation of Ab 
 
 Neurologically, AD is associated with global brain atrophy and loss of 
synapses (Scheltens et al., 2016).  In addition, there are two key hallmark 
neuropathological features that define AD:  1) Extracellular plaques comprised of an 
aggregated peptide called amyloid beta (Ab) (Tanzi et al., 1987), and 2) intracellular 
neurofibrillary tangles comprised of hyperphosphorylated microtubule-associated 
protein tau (Grundke-Iqbal et al., 1986; Wischik et al., 1988).  Ab is generated by 
sequential cleavages of the amyloid precursor protein (APP).  Human APP, located 
on chromosome 21, is a ubiquitously expressed transmembrane protein with 
particularly high expression in the central nervous system (CNS).  APP is normally 
alternatively spliced into approximately one of 10 variants 639-770 amino acids in 
length.  The major isoform in the CNS is APP695, however all isoforms can lead to 
the generation of Ab (Wang et al., 2017a).  Although a consensus as to the normal 
function of APP has yet to be reached, much is known about how the protein is both 
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trafficked and metabolized in normal and disease conditions (Gandy and Greengard, 
1994; O'Brien and Wong, 2011; Van Der Kant and Goldstein, 2015).   
 Although Ab is the most well-known disease-associated derivative of APP, 
APP actually is both processed by both non-amyloidogenic and amyloidogenic 
pathways via a series of secretase enzymes or enzyme complexes (Figure 1).  APP 
predominantly (~90-99% of the time) is processed in the non-amyloidogenic 
pathway.  APP is first cleaved by a-secretase to generate an N-terminal fragment 
called soluble APPa (sAPPa) and a C-terminal fragment (CTF) 83 amino acids in 
length (C83, or a-CTF).  a-CTF is then further processed by another secretase 
complex called g-secretase, releasing the APP intracellular domain (AICD) and a 3 
kDa peptide product (P3).  To generate Ab, APP must be cleaved first by b-
secretase at Asp1 (the first amino acid in the Ab sequence), which yields an N-
terminal soluble APPb fragment (sAPPb) as well as a CTF that is 99 amino acids in 
length (C99 or b-CTF).  b-CTF can then be further processed by γ-secretase to yield 




Figure 1.  Amyloidogenic and non-amyloidogenic processing of APP.  
APP undergoes a serious of catalytic cleavages by different secretase 
enzymes and enzyme complexes.  In the non-amyloidogenic pathway (left) 
APP is initially cleaved by a-secretase, which results in the production of a-
CTF (C83) and sAPPa.  a-CTF can then be further processed by g-secretase, 
yielding the soluble P3 fragment and the AICD.  In the amyloidogenic 
pathway, APP is instead first cleaved by b-secretase, which results in 
generation of b-CTF (C99) and sAPPb.  b-CTF is then further cleaved by g-
secretase, which results in the production of AICD as well as full length Ab.  
In pathological conditions, Ab can form aggregates and deposit into 
extracellular amyloid plaques. 
 
 In actuality, the majority of b-secretase processing actually occurs at the 
Glu11 position in Ab (b’ site), which generates a shorter b’-CTF 89 amino acids in 
length.  b’-CTF can also be further cleaved by g-secretase, generating AICD as well 
as truncated Ab (Figure 2) (Wang et al., 2017a). Additionally, APP can be 
processed by a b-secretase homologue called BACE2, which, as a q-secretase, 
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precludes the generation of Ab (Figure 2) (Wang et al., 2017a).  BACE 2 is not 
highly expressed in the brain (Bennett et al., 2000; Sun et al., 2006; 2005). 
 
 
Figure 2.  Non-canonical processing of APP 
APP is predominantly cleaved by a-secretase (blue) to generate sAPPa and 
a-CTF (C83), which is further processed by g-secretase to generate truncated 
non-pathogenic Ab peptides.  A minority of APP is processed by b-secretase 
cleavage enzyme 1 (BACE1; b-secretase), which cleaves APP at both 
Asp1(b, minority of BACE1 cleavage) and Glu11 (b’) (numbering of Ab 
sequence), generating b-CTFs that are either 99 (C99) or 89 (C89) amino 
acids in length, respectively.  These b-CTFs can be further processed by g-
secretase, however only C99 b-CTF produces full length Ab.  APP can also 
be cleaved by BACE2 (a q-secretase) which generates a CTF 80 amino acids 
in length (C80) and can be further processed by g-secretase to generate 
truncated Ab and AICD.  Red portion depicts Ab sequence of APP.  Adapted 




 g-secretase is a highly conserved protein complex composed of homomeric 
assembly of the catalytic subunit PSEN1 (or PSEN2), nicastrin, anterior pharynx 1 
(Aph1) and the presenilin enhancer 2 (PEN2).  Recent characterization of g-
secretase structure and function has been illuminating in that we now better 
understand how g-secretase processes b-CTF to generate Ab (Figure 3).  In an 
initial endopeptidase cleavage between amino acids 50/49 or 49/48, g-secretase 
cleaves b-CTF and releases one of two AICD fragments of different lengths (Figure 
3).  g-secretase then continues to make several successive tri- or tetra-peptide 
carboxypeptidase cleavages of the longer Ab substrate (Takami et al., 2009).  This 
processive activity most commonly yields shorter and less hydrophobic fragments of 
Ab, typically 38 or 40 amino acids in length (Ab38 and Ab40, respectively) (Figure 
3).  Ab40 is the most abundant Ab species generated by g-secretase processing in 
normal conditions, however levels of longer Abs like the 42 or 43 amino acid form 
(Ab42 or Ab43) are increased in disease (Iwatsubo et al., 1995; Scheuner et al., 
1996a).  Longer Abs are much more hydrophobic and prone to aggregation and 
therefore are more predominant in the extracellular Ab plaques characteristic in AD 
(Jarrett et al., 2002).  Typically, soluble Ab that is regularly generated and released 
into the extracellular space can be readily cleared from the brain parenchyma 
(Castellano et al., 2011; Paresce et al., 1996; Wyss-Coray et al., 2003).  In disease 
conditions, however, Ab clearance mechanisms can also be impaired, resulting in 
the greater likelihood of accumulated soluble Ab to oligomerize, fibrillize and 
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ultimately aggregate into bona fide amyloid plaques (Selkoe, 2006; Selkoe and 
Hardy, 2016).     
 
 
Figure 3.  g-secretase processing of bCTF and Ab generation. 
b-CTF is cleaved intramembranously by the g-secretase complex.  Initially, g-
secretase makes an endopeptidase cleavage of b-CTF between amino acids 
49-48 or 50-49, generating Ab peptides of either 48 or 49 amino acids in 
length. Additionally, AICDs are generated that differ in length by 1 amino acid.  
Subsequently, through a series of carboxypeptidase cleavages 3 or 4 amino 
acids of the Ab peptides are removed, most commonly resulting in the 
generation of Abs 38 or 40 amino acids in length.  In AD, there is an 






APP trafficking and proteolytic processing 
 
 APP is a type 1 single-pass transmembrane protein that is trafficked through 
the constitutive secretory pathway (Figure 4).  After being synthesized in the 
endoplasmic reticulum (ER), nascent APP polypeptides are transported to the Golgi 
apparatus and trans-golgi network (TGN) where it undergoes numerous 
posttranslational modifications (Haass et al., 2012).  The TGN is the major residence 
of APP in neurons (Hartmann et al., 1997; Xu et al., 1997).  Only a small fraction of 
APP (approximately 10%) ultimately reaches the plasma membrane (Haass et al., 
2012; Thinakaran and Koo, 2008).  At the cell surface, APP can be rapidly 
internalized by clathrin-mediated endocytosis and is sorted into the early endosome 
(Haass et al., 2012; Thinakaran and Koo, 2008).  Internalized APP is then trafficked 
into the late endosome-lysosomal pathway for degradation, or trafficked back to the 
plasma membrane or to the TGN (Haass et al., 2012; Small and Petsko, 2015; 




Figure 4.  Trafficking and processing of APP. 
APP is a single-pass transmembrane protein that matures through the 
classical secretory pathway.  (1) Nascent APP molecules (shown as black 
bars) are generated and modified through the secretory pathway.  Once APP 
reaches the cell surface it can be rapidly internalized via clathrin-mediated 
endocytosis (2).  (3) Once endocytosed APP is trafficked through early 
endosomes it can subsequently be trafficked either to the TGN or cell surface 
through retromer or recycling endosomes, respectively.  APP can also be 
trafficked to late endosomes and lysosomes for degradation.  Reprinted with 
permission from (Haass et al., 2012). 
 
APP is predominantly cleaved by a-secretase at the cell surface (Haass et al., 
2012; Sisodia, 1992), whereas amyloidogenic b-secretase cleavage of APP 
predominantly occurs in endosomal compartments (Haass et al., 2012; Huse et al., 
2000; Rajendran et al., 2008) (Figure 5).  As an aspartyl protease, b-secretase 
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(BACE1) has an optimal activity at low pH and is therefore most active in both early 
and late endosomes (Vassar, 1999).  Mature and active g-secretase complexes are 
located predominantly within both the plasma membrane at the cell surface as well 
as within endosomal-lysosomal compartments (Dries and Yu, 2008; Kaether et al., 
2006).  While g-secretase subunits can be found in other organelles associated with 
the secretory pathway, these are thought to be unassembled complexes and 
inactive.  Therefore, Ab is predominantly generated in endosomal compartments, 
while P3 is mostly generated at the cell surface (Figure 5).  Ab resulting from 
amyloidogenic processing of APP in endosomes can either be secreted or trafficked 





Figure 5.  Amyloidogenic versus non-amyloidogenic processing is 
regulated by trafficking and compartmentalization of APP. 
Non-amyloidogenic processing of APP predominantly occurs at the cell 
surface, as this is where the majority of a-secretase resides.  Amyloidogenic 
processing occurs within endocytic organelles, where b-secretase is more 
abundant and active.  g-secretase is present both at the cell surface and 
within endocytic compartments (Haass et al., 2012). 
 
Endocytosis and trafficking of APP is intricately regulated.  Much of this 
regulation is mediated by members of the low-density lipoprotein receptor (LDLR) 
family (Bu, 2009; Li et al., 2001) (Figure 6).  Many LDLR family members serve as 
receptors for apolipoprotein E (APOE) (Bu, 2009; Pitas et al., 1987), which is highly 
associated with AD pathogenesis, thereby implicating LDLRs in AD biology.  
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Moreover, variants in a number of LDLRs have been shown to be associated with 
late-onset AD risk (Gopalraj et al., 2005; Kang et al., 1997; Karch and Goate, 2015; 
Wang et al., 2017b).   LRP1, one LDLR family member, can bind APP directly or 
indirectly and promote rapid APP endocytosis, which has been shown to significantly 
increase Ab production (Bu, 2009; Cam et al., 2005; Liu et al., 2007).  In contrast, 
another LDLR, LRP1B, competes for interaction with APP and retains APP at the 
cell surface leading to reduced Ab production (Cam et al., 2004).  Similarly, 
APOER2 decreases APP endocytosis and Ab generation by enhancing APP 
interaction with other cell surface proteins and increases its retention at the plasma 
membrane (Bu, 2009; Hoe et al., 2005).  The most widely studied LDLR related to 
AD is SORL1.  SORL1 (and also the related SORCS1) is associated with AD in a 
variety of ways, most significant, is the discovery of SORL1 variants associated with 
sAD (Kuwano et al., 2013; Rogaeva et al., 2009).  More recently, even coding 
mutations in SORL1 have been found to cause an extremely rare inherited version 
of AD (Cuccaro et al., 2016; Vardarajan et al., 2015; 2014).  SORL1 shares 
homology with intracellular sorting receptors and is trafficked from endosomes back 
to the plasma membrane or TGN by the retromer complex.  SORL1 binds APP, and 
therefore co-traffics APP away from endosomes, reducing the likelihood of 
amyloidogenic processing of APP in endocytic vesicles and Ab production 
(Andersen et al., 2005; O'Brien and Wong, 2011; Offe et al., 2006).  It is thought that 
disease-associated SNPs in SORL1 exert pathogenicity by reducing SORL1 
expression or affinity for APP, leading to enhanced amyloidogenic APP processing 
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(Vardarajan et al., 2015; Young et al., 2015).  Trafficking of APP is further regulated 
by a complex network of sorting nexins (SNXs), Rab-GTPases as well as 
intracellular adaptor proteins (Haass et al., 2012) (Figure 6).  In sum, perturbations 
in intracellular trafficking processes may be inherently and intricately associated with 




Figure 6.  Regulation of APP trafficking in the endosomal-lysosomal 
system. 
APP is predominantly processed in the non-amyloidogenic pathway at the cell 
surface.  When APP is endocytosed APP can be processed to generate Ab in 
endocytic compartments.  Most Ab is ultimately secreted into the extracellular 
space however some is trafficked to late endosomes or lysosomes where it 
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can accumulate intracellularly.  Endocytosis of APP (and therefore regulation 
of amyloidogenic processing) is coordinated by low-density lipoprotein family 
members and APOE.  LRP1, which is endocytosed rapidly, enhances APP 
endocytosis and amyloidogenic processing, whereas LRP1B and APOER2 
helps to retain APP at the cell surface and promote non-amyloidogenic 
processing. APOE4 promotes APP endocytosis and amyloidogenic 
processing.  SORL1 is a retromer receptor and shuttles APP out of 
endosomes back to the TGN (or cell surface) thereby reducing amyloidogenic 
APP processing.  Additionally, trafficking and transit through the endosomal-
lysosomal system is regulated by Rab-GTPases (which function by 
hydrolyzing GTP as shown in the adjacent box).  Reprinted and modified with 
permission (Bu, 2009). 
 
AD neuropathology: Tau 
 
 In addition to amyloid plaques, the second hallmark neuropathological feature 
of AD is neurofibrillary tangles (NFTs).  These intracellular inclusions are comprised 
of hyperphosphorylated microtubule associated protein tau (MAPT or tau) (Grundke-
Iqbal et al., 1986).  Tau is a soluble cytosolic protein that that normally functions to 
bind, stabilize, and promote the flexibility of microtubules (Weingarten et al., 1975).  
In neurons, microtubules are a critical component of axons, serving as a track for 
shuttling of proteins and vesicles between the cell body and synapse (Avila et al., 
2002; Ebneth et al., 1998; Millecamps and Julien, 2013; Spires-Jones and Hyman, 
2014).  Typically, in neurons tau is not present in dendrites, however in AD, axonal 
tau becomes hyperphosphorylated, resulting in its dissociation from microtubules 
and mislocalization to the somatodendritic compartment (Götz et al., 1995; Hoover 
 
 18 
et al., 2010; Miller et al., 2014).  Mislocalized hyperphosphorylated tau can also 
aggregate, forming fibrils and the characteristic NFTs (Götz and Ittner, 2008; Guo 
and Lee, 2011).  These pathological changes are detrimental to the health of a 
neuron, as aggregated hyperphosphorylated tau can form seeds and sequester 
normal functioning tau and other essential microtubule-associated proteins (MAPs) 
(Alonso et al., 1997; Guo and Lee, 2011).  Together, these changes lead to 
disruptions in normal microtubule assembly and function, disrupting axon integrity 
and transport, which may ultimately lead to degeneration. 
 Interestingly, tau pathology (NFTs) correlates better with cognitive decline 
and AD severity than does Ab burden, suggesting that tau may serve as a 
downstream causal feature of neurodegeneration (Braak and Braak, 1991).  
Furthermore, within the last decade, there has been a growing consensus that tau 
may act as a prion-like protein and spread from diseased neurons to non-diseased 
neurons to propagate pathology (Fu et al., 2016; Kaufman et al., 2016; Sanders et 
al., 2014; Wu et al., 2016).  These two fundamental discoveries provide undeniable 
evidence that tau plays a critical role in AD progression.  However, whether tau truly 
is the causal effector of degeneration in AD, and how tau neuropathology is related 
to changes in Ab metabolism remains a topic of great debate in the field. 
 
AD genetics:  Familial AD and the amyloid cascade hypothesis 
 
 The majority of AD cases (over 99%) occurs late in life and sporadically 
(sporadic AD or sAD), that is with no known genetic cause.  Approximately less than 
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1% of AD occurs much earlier in life, due to the inheritance of an autosomal 
dominant familial AD (fAD) mutation (Karch and Goate, 2015).   The idea that rare 
forms of AD could be inherited came prior to even the identification of APP, from 
studying patients with Down Syndrome (DS), which is caused by the presence of an 
additional part or all of chromosome 21.  It was discovered that individuals with DS 
caused by an additional full copy of chromosome 21 develop AD neuropathology 
(Masters et al., 1985), however patients with a partial trisomy (not including the APP 
gene) do not (Guerreiro et al., 2012).  This discovery was particularly meaningful 
only once Ab was identified as the major component of the amyloid plaque, and APP 
was genetically mapped to chromosome 21 (Goldgaber et al., 1987; Kang et al., 
1987; Robakis et al., 1987; Roher et al., 1986; St George-Hyslop et al., 1987; Tanzi 
et al., 1987).  Together, this was the earliest evidence that excess Ab produced in 
DS is due an additional copy of APP may be sufficient to cause AD.   
 It is now known that early-onset fAD can be caused by mutations in either 
APP, PSEN1 or PSEN2.  To date more than 30 fAD APP mutations, including rare 
fAD caused by APP gene duplication (Rovelet-Lecrux et al., 2006), have been 
identified and account for approximately 14% of all fAD cases.  The majority of fAD 
APP point mutations cluster around the sites of Ab processing (Figure 7).  Initially, 
APP fAD mutations were extremely valuable discoveries as they revealed numerous 
aspects of the molecular underpinnings of AD pathology.  The widely studied APP 
Swedish mutation (APPswe, KM670/671NL) was shown to increases Ab in patient 
plasma up to 3-fold by enhancing b-secretase cleavage efficiency and generation of 
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b-CTF (Citron et al., 1992; 1994; Mullan et al., 1992).  Recently, a protective APP 
mutation (APP-A673T) lying adjacent to the Swedish mutation was discovered, 
thereby further implication altered APP processing at the b-secretase cleavage site 
as inherently associated with development of AD (Jonsson et al., 2012).  Similarly, 
the disease-causing APP Flemish mutation (APP-A692G) is situated at the site of a-
secretase processing and is therefore predicted to exert its pathogenicity by limiting 
a-secretase cleavage and as a result enhancing amyloidogenic processing by b-
secretase (De Jonghe et al., 1998; Hendriks et al., 1992).  Some evidence also 
points to a role of the APP-A692G mutation in altering processing of APP by g-
secretase, which leads to enhanced amyloid production(Tian et al., 2010).  Multiple 
pathogenic APP mutations exist at the C-terminal region of the Ab sequence in APP 
(Chartier-Harlin et al., 1991; Goate et al., 1991; Murrell et al., 2000; 1991).  These 
mutations cluster around the g-secretase processing site and therefore are thought 
to exert their pathogenicity by altering g-secretase function.  Past cellular studies 
have demonstrated that these C-terminal APP mutations may not alter total Ab 
levels, but instead shift processing to increase the levels of longer more 
amyloidogenic Ab42, highlighting a potential important role of Ab aggregation in AD 
pathogenesis (De Jonghe et al., 2001; Tamaoka et al., 1994).  Together, the 
discovery of multiple fAD patients with characteristic pathology and mutations in the 
APP gene makes it clear that the processing of APP plays a central causal role in 




Figure 7.  APP fAD mutations. 
Schematic of APP, fAD mutations and processing sites.  Mutations 
associated with early-onset familial AD are shown.  APP fAD mutations tend 
to cluster around sites of secretase cleavages, thereby influencing processing 
patterns.  One mutation is protective against AD (A673T, shown in green).  
The Ab region of APP is indicated in red.  Mutations studied in this thesis 
(APPswe, APP-A763T, APP-A692G, APP-V717G) are colored. 
 
 Since the discovery of APP fAD mutations, nearly 200 other fAD mutations 
have been discovered, mapping to chromosome 14 and chromosome 1 (Kelleher 
and Shen, 2017a; Levy-Lahad et al., 1995; Rogaev et al., 1995; Schellenberg et al., 
1992; St George-Hyslop et al., 1992).  These two genes are now known to be 
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PSEN1 and PSEN2, respectively, which, as describes above, encode the catalytic 
component of the g-secretase complex necessary for the generation of Ab (De 
Strooper et al., 1998; De Strooper, 2007).  While only 13 dominant mutations in 
PSEN2 have been identified, over 180 mutations have been found in PSEN1, 
accounting for nearly 80% of all fAD cases (Giri et al., 2016).  Generally, mutations 
in PSEN1 and PSEN2 are distributed throughout the protein.  Similar to the C-
terminal mutations in APP, PSEN1 and PSEN2 mutations have been shown to also 
shift processing of APP to generate relatively more of the longer Ab42 peptides 
compared to the shorter Ab40 (increasing the Ab 42:40 ratio) (Borchelt et al., 1996; 
Citron et al., 1992; Duff et al., 1996; Kelleher and Shen, 2017a; Scheuner et al., 
1996b).  While the mechanistic explanation for how these mutations affect g-
secretase are still being fully fleshed out, the discovery of mutations in these two 
genes that are inherently related to Ab generation amplifies the causal relationship 
between AD and APP processing, and places emphasis on the relative amounts of 
longer Abs as the primary contributing factor important in AD pathogenesis. 
 These abovementioned discoveries of causal direct genetic links between 
altered APP processing, Ab and disease, bolstered the development of the “amyloid 
cascade hypothesis”.  The amyloid cascade hypothesis posits that changes in APP 
processing and/or brain Ab homeostasis can result in the aggregation of Ab and 
formation of amyloid plaques (Hardy and Higgins, 1992).  Importantly, the 
hypothesis predicts that these early changes in Ab metabolism are sufficient to 
initiate a series of related pathological changes including the hyperphosphorylation 
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and aggregation of tau into NFTs, and ultimately neurodegeneration.  While the 
strongest evidence supporting this hypothesis comes from the familial AD genetics 
described above, a large amount of in vitro and in vivo evidence has also 
accumulated over the past two decades.  In particular, in vitro evidence has shown 
that Ab can be toxic to primary mouse neurons, and that toxicity appears to be 
abolished when tau is knocked-out (Rapoport et al., 2002; Roberson et al., 2007). 
Moreover, Ab has been shown to induce tau phosphorylation, promote synapse loss, 
and trigger neuroinflammation, all of which are characteristic of AD pathogenesis 
(Jin et al., 2011; Koffie et al., 2009).  In vivo, overexpression of mutant APP and 
PSEN1 dramatically enhances tau aggregation in a mouse model expressing human 
tau, and augments cognitive and behavioral impairments in these animals (Oddo et 
al., 2003). 
 Although these genetic and experimental data provide a considerable amount 
of support for the amyloid cascade hypothesis, other findings call the hypothesis into 
question.  Most notable is the finding that some individuals have very high amyloid 
burden in their brains but up until death they are cognitively normal, suggesting that 
amyloid deposits may not always trigger toxicity (Davis et al., 1999).  Moreover, in a 
related neurodegenerative disorder called frontotemporal dementia (FTD) – caused 
by familial mutations in the MAPT (tau) gene – there is tau pathology (NFTs) and 
neurodegeneration in the absence of changes in Ab (Dumanchin et al., 1998; Hong 
et al., 1998; Hutton et al., 1998).  This indicates that Ab is not always necessary to 
trigger tau pathology and neurodegeneration.  Regardless, it seems undeniable that 
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APP and Ab play a critical role in AD development, although the exact mechanism 
by which altered APP metabolism results in disease remains elusive. 
 
AD genetics:  Sporadic AD and genetic risk factors 
 
 The complexity of AD pathogenicity has been further underscored by more 
recent discoveries of genetic risk factors of late-onset sAD.  For a long time, the only 
known late-onset AD-associated risk gene was APOE.  APOE encodes the protein 
apolipoprotein E and is located in humans on chromosome 19.  There are 3 APOE 
alleles called e2, e3 and e4.  One copy of the APOE e4 allele increases risk for 
developing late-onset AD by 3-fold while two copies of e4 increases risk for AD 12-
fold (Corder et al., 1993; Scheltens et al., 2016; Strittmatter et al., 1993; Verghese et 
al., 2011).  APOE e2 allele carriers tend to be protected from development of AD 
(Corder et al., 1994).  APOE is the primary cholesterol carrier in the brain and plays 
a role in a variety of biological processes in the central nervous system.  Specifically, 
APOE is associated with cholesterol metabolism, lipid trafficking, inflammation, 
synaptic function, neurogenesis, as well as APP trafficking, endocytosis and Ab 
production (Bu, 2009; Liu et al., 2013).  The underlying mechanism linking APOE e4 
to AD is seemingly complex and has been shown to involve aberrant changes in Ab 
deposition and aggregation as well as clearance (Corder et al., 1993; Scheltens et 
al., 2016; Strittmatter et al., 1993; Verghese et al., 2011).  Non Ab-associated 
mechanisms linking APOE e4 and AD include an effect on the endosomal-lysosomal 
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system, tau homeostasis, synaptic plasticity, neuroinflammation and lipid 
homeostasis (Chung et al., 2016; Krasemann et al., 2017; Nuriel et al., 2017a; 
2017b; Shi et al., 2017). 
 Recent technological advances in genome-wide association studies (GWAS) 
and next generation sequencing (NGS) have been revolutionary in discovering other 
sAD-associated genes.  sAD risk genes broadly can be categorized into three main 
pathways –immune response, lipid metabolism and endocytosis – with many of 






Table 1.  Late-onset AD risk genes and their biological associations. 
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Epigenetic regulation, 
neural development  




mRNA splicing  
(Giudice et al., 2016; Hinney et al., 




(ADGC, Alzheimer’s Disease 
Neuroimaging Initiative et al., 2016; 
Apostolova et al., 2018; Karch and 
Goate, 2015) 
SLC24A4/RIN3 
Cell signaling, neural 
development, 
endocytosis Endocytosis 
(Giri et al., 2016; Kajiho et al., 2003; 
Karch and Goate, 2015; Nixon, 
2017) 
DSG2 Cell-cell adhesion  
(Hartlieb et al., 2014; Karch and 






defects Lipid metabolism 
(Cruchaga et al., 2014; Fazzari et 
al., 2017; Karch and Goate, 2015) 
UNC5C Neural development  (Wetzel-Smith et al., 2014) 
AKAP9 
Signal transduction, 
tau dynamics  























(Bu, 2009; Shinohara et al., 2017; 




 Neuroinflammation is a central feature in AD and several immune-associated 
genes with variants that are associated with late-onset AD have been identified 
(Karch and Goate, 2015).  It has been shown in numerous rodent and human 
studies that amyloid plaques in the brain are surrounded by activated immune cells 
(Condello et al., 2015; Nimmerjahn et al., 2005; Yuan et al., 2016) and that many of 
the late-onset associated genes that have been identified by GWAS are uniquely 
expressed at high levels in brain immune cells (e.g., microglia) (Efthymiou and 
Goate, 2017; Sims et al., 2017).  Some of these immune-related risk genes include 
CR1, CD33, CLU, EPHA1, MS4A and TREM2.  Neuroimmune cells are important 
phagocytic scavenging cells necessary for the maintenance of a healthy brain.  
Therefore, it is thought that perturbations in these processes may alter protein 
homeostasis in the brain parenchyma and lead to the accumulation of Ab (Hickman 
et al., 2008; Nimmerjahn et al., 2005).  For example, CD33 and TREM2 are thought 
to contribute to disease by impairing clearance of Ab (Griciuc et al., 2013; Rivest, 
2015; Ulrich et al., 2017).  It has also been shown that the complement cascade is 
elevated in AD and can contribute to disease pathology (Eikelenboom et al., 1989; 
Hong et al., 2016; Shen et al., 1997), therefore variants in CR1, which could confer 
risk to AD or be neuroprotective, may be associated with disease by either 
enhancing or attenuating the complement response (Karch and Goate, 2015). 
 Besides APOE, late-onset AD genes associated with lipid metabolism include 
CLU, ABCA7, SORL1, DSG2.  APOE and CLU (also known as Apolipoprotein J, 
APOJ) are thought to share similar roles in AD pathogenesis, with their contribution 
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to Ab clearance being most widely studied (Castellano et al., 2011; DeMattos et al., 
2004; Verghese et al., 2013; Zandl-Lang et al., 2018).   These lipoproteins can 
directly bind to Ab and also lipoprotein receptors that may play a role in Ab 
clearance and APP metabolism (Bu, 2009; Cam et al., 2004; Offe et al., 2006; 
Sagare et al., 2007).  ABCA7 is important mediator of cholesterol metabolism and is 
associated with plaque burden in AD brains as well as cognitive decline (Karch et 
al., 2012; Kim et al., 2013; Shulman et al., 2013).  Genes involved in lipid 
metabolism also play a pivotal role in regulating endocytosis and intracellular 
trafficking, all of which depend on the regulation and coordination of lipoproteins and 
lipoprotein receptors (Bu, 2009; Holtzman et al., 2012; Pitas et al., 1987).   
Many genes known to regulate endocytic processes, which are important in 
APP processing and synaptic activity, have been implicated in late-onset AD risk.  
These endocytosis genes include SORL1, SORCS1, LRP1, BIN1, PICALM, CD2AP, 
EPHA1, RIN3, MEF2C (Giri et al., 2016; Karch and Goate, 2015).  SORL1, SORCS1 
and LRP1 are all APOE receptors and are known to regulate endocytosis and 
intracellular trafficking of multiple cargos including APP (Andersen et al., 2005; 
Karch and Goate, 2015; Reitz et al., 2011; Rogaeva et al., 2009; Shinohara et al., 
2017; Young et al., 2015).  BIN1, PICALM and CD2AP are associated with receptor-
mediated endocytosis and not only play a role in trafficking APP and Ab production, 
but may also affect overall cellular proteostasis and aberrant protein aggregation 
(Calafate et al., 2016; Cormont et al., 2003; Monzo et al., 2005; Moreau et al., 2014; 
Tian et al., 2013; Ubelmann et al., 2017).  In addition, these genes may play a vital 
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role in synaptic vesicle trafficking and recycling (Di Paolo et al., 2002; Dustin et al., 
1998; Harel et al., 2008).  EPHA1 is a critical gene involved in synapse formation 
and neurodevelopment.  Through involvement in cell membrane processes, EPHA1 
is implicated in immune function, and synaptic plasticity (Lai and Ip, 2009; Martínez 
et al., 2005; Sakamoto et al., 2011).  RIN3 encodes a protein that functions as a 
guanine nucleotide exchange for small GTPases, including Rab5.  RIN3 stimulates 
and stabilizes Rab5 on early endocytic/endosomal vesicles (Kajiho et al., 2003; 
2011; Nixon, 2017).  In addition, APOE and CLU are important regulators of 
endocytosis, capable of binding a variety of endocytic lipoprotein receptors (Bu, 
2009; Byun et al., 2014).  A more detailed discussion of endocytic sAD risk genes 
and endosomal-lysosomal dysfunction in AD is provided below. 
 
Endosomal-lysosomal trafficking dysfunction in AD 
 
 The endocytic pathway is integral to the normal functioning of neurons.  
Through endocytosis neurons respond to extracellular trophic factors; recycle 
plasma membrane receptors and other integral membrane proteins in response to 
neurotransmitters; and relay extracellular signals to intracellular biosynthetic 
pathways (Cosker and Segal, 2014; Parton and Dotti, 1993).  By endocytosis, 
molecules from the cell surface (such as APP, neurotransmitter receptors, signaling 
molecules, etc.) are trafficked through a series of intracellular compartments, where 
they can be modified or degraded in a biologically meaningful way (Haass et al., 
2012; Hu et al., 2015; Nixon et al., 2000).  Upon internalization by endocytosis, cell 
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surface proteins are first sorted into early endosomes, where they can then be 
recycled back to the plasma membrane or TGN, or transported to late-endosomes 
and lysosomes for degradation (Figure 6) (Hu et al., 2015).  Endocytosed molecules 
can be recycled and sorted away from the degradative pathway in a few different 
ways (Figure 8):  Cargos can be recycled back to the PM in a fast and direct 
manner; or in slow recycling, where cargos are first directed to recycling endosomes 
before reaching the cell surface (Hu et al., 2015).  Additionally, cargos in endocytic 
compartments can be trafficked by the retromer complex, in a retrograde direction 
from the endosome to the TGN, or directly for the endosome back to the cell surface 
(Small and Petsko, 2015).  Endosomal and lysosomal compartments are 
characteristically acidic, necessary for the many degradative hydrolases and other 
proteases important for protein homeostasis, which function optimally in these acidic 
conditions (Hu et al., 2015).  The careful coordination of trafficking of cargos and 
vesicles through endosomal and lysosomal compartments is carefully controlled by a 
family of GTPase proteins called Rab proteins (Figures 6 and 8) (Doherty and 




Figure 8.  Endocytic trafficking into and out of the early endosome.   
Cargos (such as cell surface proteins or extracellular proteins) are sorted into 
the early endosome by endocytosis (mediated by Rab5).  There are 
subsequently three trafficking pathways out of the early endosome.  (1) 
Cargos may be trafficked towards the degradation pathway.  This results in 
the formation of intraluminal vesicles and degradation in the late endosome 
and lysosome.  (2) Cargos may be trafficked back to the cell surface.  This 
can occur rapidly and directly (mediated by Rab4) or through the recycling 
endosome (mediated by Rab11).  (3) In the retrograde pathway, cargos are 
trafficked back to the TGN in a process coordinated by the retromer complex.  
Given its role as a “central hub” in endocytic sorting, pathological changes in 
early endosome function/morphology can have broad and dramatic effects on 
overall intracellular trafficking and the endosomal-lysosomal system.  Adapted 




 As described above, APP is a type 1 transmembrane protein that is 
endocytosed and trafficked through the endosomal-lysosomal system.  Moreover, 
amyloidogenic versus non-amyloidogenic processing of APP occurs in a tightly 
regulated fashion almost entirely dependent upon its intracellular trafficking.  
Specifically, early endosomes are of particular relevance to AD, as it is thought that 
it is in these structures where APP meets b- and g-secretases to generate Ab (Haass 
et al., 2012).  Therefore, any perturbation in the endocytic pathway that alters the 
trafficking of APP and influences the time APP spends in endosomal compartments 
may have consequential effects on the development of AD pathology. 
 Early endosomal dysfunction is one of the earliest neuronal pathologies of AD 
observed in sAD patients prior to deposition of extracellular Ab (Cataldo et al., 2000; 
Ginsberg et al., 2010a; 2010b). These endosomal changes suggest that neurons 
may become intracellularly compromised much earlier than when overt Ab plaque or 
tau tangle pathology accumulates.  Early endosomes are a central hub in 
intracellular membrane and protein trafficking.  Imbalances in trafficking into- and out 
of this organelle may therefore have severe consequences on the overall health of a 
neuron (Small et al., 2017) (Figure 8).  While it remains elusive what exactly causes 
upstream early endosome dysfunction in AD pathogenesis, multiple studies which 
have focused on using non-human overexpression models have indicated that 
intracellular accumulations of APP fragments, either b-CTF or longer Abs (e.g., 
Ab42) may be the drivers (Jiang et al., 2010; Treusch et al., 2011; Xu et al., 2016).  
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As will be discussed in later chapters, this hypothesis remains to be adequately 
tested in human neurons, particularly in the absence of transgenic overexpression. 
 As described in detail above, genetic association studies have revealed 
variants in multiple different endocytic/endosomal trafficking-related genes (e.g., 
SORL1, BIN1, CD2AP, PICALM, RIN3, etc.) as strongly linked to late-onset sAD 
(Karch and Goate, 2015).  These genetic findings implicate, at least in some cases 
of AD, endocytic dysfunction as an initial primary upstream pathological event.  For 
example, SORL1 mutations or SORL1 knock-down/knockout reduces transport of 
cargos (including APP) out of endosomes via retromer-mediated routes (Andersen 
et al., 2005; Gustafsen et al., 2013; Reitz et al., 2011; Small and Petsko, 2015).  
This leads to dysregulated sorting of endosomal proteins, including APP, 
accelerated Ab generation and endosome enlargement (Andersen et al., 2005; 
Gustafsen et al., 2013; Reitz et al., 2011; Small and Petsko, 2015).  Similarly, BIN1 
and CD2AP also functions to traffic cargos out of early endosome (Ubelmann et al., 
2017).  BIN1 is important in shuttling cargos out of endosomes towards the cell 
surface via the recycling pathway, while CD2AP is important in mediating sorting out 
of early endosomes and towards the degradative pathway (Ubelmann et al., 2017).  
Deficiencies in retromer core proteins (VPS26, VPS35) as well as variants in other 
key retromer genes have been linked with AD (Small and Petsko, 2015).  These AD-
related changes in retromer biology are thought to reduce the overall function of 
retromer, leading to impaired sorting of cargos out of endosomes and 
dysfunction/enlargement of early endosomes.  Mutations in PICALM, which is an 
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important regulator of trafficking into the endosome, suggest that endocytic influx, 
and not just efflux, is also inherently linked to AD (Thomas et al., 2016).  
Furthermore, genetic associations with RIN3 directly implicate activity of Rab 
proteins, such as Rab5, as being associated with AD pathogenesis (Kajiho et al., 
2003; 2011; Xu et al., 2018).  
As mentioned above, neuronal APOE receptors are key regulators of 
endocytosis, thereby implicating APOE in endosomal dysfunction.  In studies 
investigating the pathogenicity of the APOE4 allele, it was found that APOE4 can 
result in endosomal enlargement by accelerating endocytosis and impair normal 
endosomal recycling (Chen et al., 2010; He et al., 2007; Li et al., 2012; McColl et al., 
2003; Nuriel et al., 2017b; Ye et al., 2005; Zhao et al., 2017).  APOE is one of many 
different lipid/cholesterol-associated genes linked with AD.  Interestingly, it is known 
that altering overall levels or trafficking of cholesterol in neurons also leads to 
alterations in endocytosis and endosomal enlargement (Jin et al., 2004; Marquer et 
al., 2014).    
Taken together, all of these lines of evidence provide a compelling case for 
endosomal dysfunction being a principle upstream pathological event.  Enlarged 
endosomes, caused by increased endocytosis or reduced recycling may also result 
in more APP residing in early endosomes, leading to greater amyloidogenic 
processing and Ab generation (Haass et al., 2012; Jiang et al., 2010; Small et al., 
2017). Whether or not endosomal dysfunction in sAD is a pathogenic mechanism 
converging on Ab production or is instead itself a principle driver of disease remains 
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unclear.  Furthermore, whether or not the early endosome abnormalities hallmark in 
late-onset AD are also common to fAD caused by APP and PSEN mutations is in 




 Much of the knowledge we have today about AD pathogenesis and 
underlying AD mechanisms has critically depended on the development of adequate 
and representative experimental model systems.  The breakthrough discoveries of 
familial mutations capable of causing early-onset AD (and FTD) has enabled the 
development of numerous in vivo and in vitro experimental model systems, with the 
hope that discoveries made in these systems would translate to more common sAD 
as well.  The most widely used models in the AD field have been transgenic mouse 
models.  These models have been instrumental in the discovery of many important 
disease mechanisms, however, as will be described below, they also are undeniably 
problematic.  The first ever APP transgenic mouse model was published in 1991 
(Quon et al., 1991), however it was not until 1995 that the first models actually 
demonstrating AD-associated amyloid pathology were published.  Specifically, these 
mice were called the PDAPP and Tg2576 mouse and were designed to 
transgenically overexpress human APP with either the Indiana (V717F) or Swedish 
(KM670/671NL) fAD mutations, respectively (Games et al., 1995; Hsiao et al., 1996; 
Rockenstein et al., 1995).  While in both of these models amyloid plaques similar to 
those in human AD patients are found in mouse brains by approximately 10-11 
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months of age, neither of these mice develop NFTs (or any robust tau pathology) nor 
have measurable neurodegeneration and neuronal loss.  This, of course, contrasts 
greatly with human patients, who have only a single heterozygous fAD APP 
mutation, yet develop a brain full of amyloid plaques, NFTs and have profound 
neuronal loss.  Similar problems were also seen in early PSEN1 transgenic models.  
Namely, overexpression of mutant PSEN1 (such as M146V) results in a predictable 
increase in longer Ab 42 peptides in the brain, however these mice don’t display any 
plaque pathology, NFTs, neurodegeneration, or cognitive deficits even at up to 2.5 
years of age (Duff et al., 1996; Qian et al., 1998).  Furthermore, even transgenic 
mice overexpressing both mutant human APP and PSEN1 fail to demonstrate any 
NFT pathology or robust neurodegeneration, despite the accelerated accumulation 
of Ab plaques in the brain (Borchelt et al., 1997; Holcomb et al., 1998).  The failure 
of these mouse models to recapitulate the seminal pathological features of human 
AD highlights how the use of mouse models in AD research may be confounding, 
and points to the many key differences between rodents and humans.  
 Years later, the first AD mouse model was developed that demonstrates both 
Ab as well as NFT pathology.  Specifically, it took the expression of three different 
mutant transgenes (APPswe, PSEN1-M146V and MAPT-P301L) to result in both 
hallmark clinical AD pathologies, with corresponding synaptic and cognitive 
changes.  This mouse is commonly known in the field as the triple-transgenic (or 
3xTg) mouse (Oddo et al., 2003).  The mere notion that it took additional 
overexpression of human tau (MAPT) with an FTD-causing familial mutation, further 
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highlights the differences between human and mouse tau biology, and raises 
questions as to the degree to which conclusions made from these mice are broadly 
relevant to human AD.  More recently, the first non-overexpression AD mouse 
models have been generated and used to study disease mechanisms.  Briefly, 
researchers replaced the mouse APP gene with human APP bearing up to 3 
different fAD mutations (APPswe, APP-I716F, APP-E693G), which is expressed at 
normal physiological levels controlled by the endogenous mouse APP promoter 
(Saito et al., 2014).  These mice develop aggressive amyloidosis and demonstrate 
plaque pathology starting at 2 months.  These mice also show microgliosis and 
increased numbers of reactive astrocytes, synaptic loss and cognitive impairment.  
However, likely due to the absence of mutant tau overexpression, APP knock-in 
mice fail demonstrate any NFT pathology, once again underscoring the limitations of 
even the “best” mouse models (Saito et al., 2014).  Most interestingly, the scientists 
behind this novel APP knock-in mouse reported that many of the phenotypes 
reported in APP overexpression models could not be reproduced in their system.  
This led the authors to conclude that up to 60 percent of the phenotypes identified in 
APP-overexpressing mice could in fact be artifacts of overexpression, therefore 
potentially calling into question the findings of thousands of past research papers 
(Saito et al., 2014). 
 In vitro cell culture models have also been abundantly used in the AD field.  In 
particular, these models have been instrumental in the understanding of the 
mechanism of Ab production, APP trafficking, and endosomal-related changes in 
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AD.  Many in vitro studies utilize primary cultures of mouse disease-vulnerable 
neurons, often comparing wildtype and transgenic mice overexpressing mutant 
human APP and or PSEN1 (Saraceno et al., 2013; Trinchese et al., 2004).  This 
approach has been instrumental in deciphering how APP is processed and trafficked 
in neurons, however, as described above, is confounded by overexpression of 
mutant protein in non-human cells.  Mouse primary neurons are somewhat difficult to 
maintain in culture, and therefore have in many cases been supplanted by the use of 
proliferating non-neuronal (and in many cases non-human) cell lines.  For example, 
human embryonic kidney cells (HEK) and mouse neuroblastoma (N2A) cells have 
been engineered to stably overexpress wildtype and mutant APP and/or PSEN1 
(Borchelt et al., 1996; Jiang et al., 2010; Kim et al., 2015; Tarassishin et al., 2004; 
Xu et al., 1997).  These models have revealed interesting insights into the potential 
pathogenicity of fAD mutations and have been widely used to investigate APP 
trafficking in wildtype and mutant conditions (Choy et al., 2012; Sannerud et al., 
2016; Sullivan et al., 2011).  Furthermore, overexpression of full-length APP and 
APP cleavage products have provided insight into the pathways contributing to 
endosomal dysfunction in AD (Jiang et al., 2010; Kim et al., 2015; Xu et al., 2016).   
In vitro non-neuronal cell culture models are often chosen for use as they are 
self-renewing and can be easily genetically manipulated.  Although these systems 
are scalable and easy to use, they also have considerable drawbacks.  As with most 
mouse models, in vitro cell culture models heavily rely on transgenic overexpression 
of fAD mutant APP and/or PSEN1, which is a dramatic departure from patients who 
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contain only a single heterozygous fAD mutation.  Moreover, studying AD 
phenotypes in non-neuronal cells calls into question whether findings are also 
applicable to neurons, which are post-mitotic, highly compartmentalized and polar.  
Importantly, in terms of studying intracellular trafficking, overexpression models are 
especially concerning, as the normal trafficking and processing of proteins (including 
APP which is intricately processed) is likely aberrantly affected by being present in 
cells at a saturating level. 
The abovementioned drawbacks of common in vivo and in vitro models 
highlight the imminent need for the generation of new model systems that are more 
physiologically comparable to the AD patient condition.  Specifically, being able to 
study AD processes in human neurons in the absence of overexpression will not 
only help to decipher which previously identified phenotypes may be relevant to 
human neurons but will undoubtedly enable the discovery of novel disease 
mechanisms or serve as a valuable platform for testing novel therapies.  Fortunately, 
with the recent development of iPSC and CRISPR/Cas9 technology, generating 
models that enable the study of genetically tractable human AD-vulnerable neurons 
is now feasible.   
 
Induced pluripotent stem cell (iPSC) technology 
 
 Yamanaka and colleagues first demonstrated that mouse fibroblasts could be 
reprogrammed into pluripotent embryonic-like cells.  They showed that expression of 
only 4 transcription factors (Oct4, Sox2, Klf4 and c-Myc) was sufficient to induce 
 
 41 
reprogramming in both mouse and human somatic cells into iPSCs (Park et al., 
2008; Takahashi and Yamanaka, 2006).  Since this initial discovery, many different 
protocols have been developed to generate iPSCs from a wide variety of donor cell 
types (fibroblasts, glia, B lymphocytes, amniotic fluid-derived cells, cells in blood and 
urine) and using a diversity of strategies (viral delivery of reprogramming factors, 
liposome or electroporation-mediated transfection of linear DNA, direct protein 
deliver, etc.) (Singh et al., 2015).  iPSCs are like embryonic stem cells (ESCs) in that 
they are self-renewing and are capable of differentiating all three germ layers 
(mesoderm, ectoderm and endoderm).  As a result, iPSCs are capable of generating 
virtually any cell type, including many different types of neurons similar to those 
found in the human brain.  The potential of this technology to propel biomedical 
science forward led Dr. Yamanaka to receive the 2012 Nobel Prize in Medicine. 
 iPSC technology provides great promise for modeling and studying 
monogenic diseases, such as fAD caused by APP or PSEN1 mutations.  Since the 
development of iPSC technology, dozens of papers have been published describing 
the use of iPSCs to study neurodegenerative diseases (Bahmad et al., 2017; Xie 
and Zhang, 2015; Yang et al., 2016).  Of these studies, several groups have utilized 
iPSCs for modeling AD.  Most studies proceeded in the following manner:  Dermal 
fibroblasts are isolated from skin biopsies of AD patients (with a known fAD mutation 
or with sAD).  At the same time, fibroblasts are also obtained from an unaffected 
individual to serve as a control.  These somatic cells are then reprogrammed into 
iPSCs, which can be differentiated into AD-vulnerable cells such as cortical neurons 
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following a variety of established protocols.  Using this approach, past studies have 
demonstrated that APP and PSEN1 fAD and even sAD patient-derived iPSCs 
display disease-relevant phenotypes associated with APP processing, Ab generation 
and tau pathology, and have even revealed potential new mechanisms underlying 
AD pathogenesis (Duan et al., 2014; Israel et al., 2012; Kondo et al., 2013; Moore et 
al., 2015; Muratore et al., 2014; Ortiz-Virumbrales et al., 2017; Shi et al., 2012; 
Sproul et al., 2014).   
 Patient-derived iPSCs have demonstrated the potential applications of this 
technology for modelling AD but many of these past studies are complicated by 
several outstanding technical issues.  One of the greatest and most poorly 
understood problems with human iPSCs is the donor-to-donor variability and cellular 
heterogeneity.  For example, in past studies using patient-derived iPSCs, it was 
found that some iPSC lines with an fAD mutation successfully demonstrated AD-
associated phenotypes while other iPSC lines (even with the same fAD mutation) 
failed to do so (Israel et al., 2012; Kondo et al., 2013).  This issue of clonal iPSC-line 
heterogeneity is concerning, as it raises the question of what the most appropriate 
control should be.  If phenotypic variability is common between different patient-
derived iPSC lines, then surely, variability exists across non-diseased “control” iPSC 
lines too.  This unexplained variation may come from the differences in genetic 
background between the diseased and healthy donors’ cells.  Therefore, one 
confounding factor in using patient-derived iPSCs and comparing them to control 
iPSCs is that it is generally unclear whether phenotypic differences seen are due to 
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a particular disease-associated mutation of interest or differences in genetic 
background between control and patient samples.  This is of particular importance 
when comparing subtle phenotypes, which may be expected in iPSC-derived 
neurons with only a single heterozygous mutation and no transgenic overexpression.  
Furthermore, iPSC-derived neurons are typically analyzed only approximately 30-60 
days after induction of differentiation, whereas patients with fAD mutations typically 
develop AD after approximately 40 years.  Therefore, an additional concern is that a 
single heterozygous mutation may not be sufficient to allow for subtle phenotypes to 
be resolved.   
Taken together, the drawbacks described above highlight the need to 
generate isogenic iPSC control and mutant cell lines differing only at the site of the 
mutation of interest.  Additionally, tools to be able to study mutations in both a 
heterozygous and homozygous context would be very helpful to amplify subtle 
disease-relevant phenotypes while maintaining physiological levels of mutant protein 
expression.  Fortunately, the recent developments in genome editing technology 
now means generating isogenic wildtype, homo- and heterozygous fAD mutant 
iPSCs is a possibility. 
 
CRISPR/Cas9 gene editing 
 
 For over a decade there has been a considerable effort made in developing 
gene editing technology for use in human cells, such as iPSCs.  These initially 
included zinc finger nucleases (ZFNs) as well as transcription activator-like effector 
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nucleases (TALENs), but more recently CRISPR/Cas9 has supplanted both of these 
early technologies.  While the potential utility of CRISPR/Cas9 gene editing 
technology in biomedicine is vast, one of the most promising uses of the technology 
is for engineering next-generation iPSC model systems that overcome confounding 
issues associated with patient-derived stem cell models. 
The bacterial CRISPR/Cas9 (clustered regularly interspaced short 
palindromic repeats /CRISPR-associated protein 9) system is a versatile tool for 
precise, sequence-specific gene editing in many organisms and model systems 
(Cho et al., 2013; Cong et al., 2013; Hruscha et al., 2013; Hsu et al., 2014; Jinek et 
al., 2013; Mali et al., 2013), including iPSCs (Hsu et al., 2014; Mali et al., 2013).  The 
CRISPR/Cas9 gene editing system, derived from the bacterial adaptive immune 
system in Streptococcus pyogenes (Horvath and Barrangou, 2010), consists of the 
nuclease Cas9 and a guide RNA, which directs Cas9 to the DNA target through a 20 
bp programmable sequence. The guide RNA targets Cas9 to a specific genomic 
locus by RNA-DNA base pairing adjacent to an NGG protospacer adjacent motif 
(PAM) on the DNA (Figure 9A). Both the presence of the PAM and guide RNA 
binding are required for Cas9 to introduce a site-specific double-strand break (DSB), 
which occurs 3 bp upstream of the PAM motif (Jiang et al., 2015; Marraffini and 
Sontheimer, 2010).  The CRISPR/Cas9 complex has been shown to be very efficient 
at introducing DSBs in the DNA of many cell types and model systems, commonly 
resulting in bi-allelic modifications (Canver et al., 2014; Dow et al., 2015; Platt et al., 
2014).  In most cases these DSBs are repaired by the non-homologous end-joining 
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(NHEJ) pathway, leading to nonspecific insertions, deletions or other mutations, 
commonly referred to as ‘indels’ (Hsu et al., 2014; Jinek et al., 2013). This is 
convenient for generating gene knockouts, which are most easily created by non-
specific modification of both alleles by NHEJ (Figure 9B).   
 
Figure 9.  CRISPR/Cas9 gene editing. 
A) CRISPR/Cas9 gene editing works by targeting to any genomic NGG 
(PAM) sequence a guide RNA (commonly a single guide RNA called an 
sgRNA) and Cas9 nuclease.  This results in a double-stranded DNA break 
(DSB).  B) DSBs are most commonly repaired by the error prone non-
homologous end-joining pathway (NHEJ), which results in random base 
insertions or deletions (called “indel” mutations).  C) In rare cases, the cell 
may utilize homology-directed repair (HDR), which makes use of a DNA 
template provided (such as a single stranded DNA oligo, ssODN) with 
homology to the sequence surrounding the DSB.  If this repair template is 
modified to contain a specific mutation of interest, that change will be 
incorporated into the edited genome. 
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In rare cases the cellular repair mechanism can utilize another DNA molecule, 
such as the homologous allele or an exogenously introduced DNA template, to 
repair the chromosome break by homology-directed repair (HDR)(Hsu et al., 2014).  
Introducing a modified donor template, such as a single-stranded oligo DNA 
nucleotide (ssODN), can yield intended base changes that can be utilized to knock-
in (KI) specific mutations (Cong et al., 2013; Horvath and Barrangou, 2010) (Figure 
9C). For example, patient derived iPSCs containing a fAD APP or PSEN1 mutation 
can be engineered using CRISPR/Cas9 to correct the pathogenic mutation back to 
the wildtype allele to generate isogenic control cell lines.  More promising, however, 
is the use of CRISPR/Cas9 editing in a standardized wildtype iPSC line, to introduce 
any disease-causing mutations desired and generate (heterozygous and 
homozygous) isogenic mutant iPSCs without ever needing to access patient 
material. Although CRISPR/Cas9 has already been extensively and efficiently used 
to study gene function by engineering gene knockouts (KO) through NHEJ (Jiang et 
al., 2015; Marraffini and Sontheimer, 2010; Wang et al., 2013), precise editing by 
HDR to engineer sequence-specific changes such as disease-causing point 
mutations is inefficient (Canver et al., 2014; Cong et al., 2013; Dow et al., 2015; Platt 
et al., 2014; Wang et al., 2013). This limitation has unfortunately prevented the 
widespread use of CRISPR/Cas9-mediated gene editing for use in disease 
modeling.  Furthermore, systematic, targeted introduction of base-changes by HDR 
at only a single allele using CRISPR/Cas9 had not been reported, making it difficult 
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to use this gene editing system for modeling the many important human diseases 
(such as fAD) that are caused or influenced by heterozygous changes.  
 
Overview of thesis work 
 
In this introduction, I have described how decades of research have mostly 
converged on altered APP metabolism, and more specifically Ab, as the key 
pathological trigger in AD.  This work has focused predominantly on studying causal 
fAD mutations in APP and PSEN1, using transgenic overexpression of mutant 
human protein in mouse models as an approach for deciphering how Ab may confer 
pathogenicity.  Despite the clear genetic link between APP, PSEN1 (or PSEN2) and 
Ab, it is still uncertain how a variety of mutations in one of three different genes 
causes a common disease. Furthermore, recent discoveries have called into 
question whether or not Ab is the only disease-associated pathological protein 
fragment important in the development of AD (Kim et al., 2015; Xu et al., 2016).  
This apparent complexity is underscored by the recent failures of clinical trials 
testing the efficacy of multiple novel anti-amyloid therapeutics (Egan et al., 2018; 
Mullard, 2017).  It is therefore now, more than ever, time to reassess the state of the 
AD research field and consider what experimental and technical improvements can 
be made to help better understand AD biology. 
Early on in our attempt to study neurodegeneration, our group presumed that 
to better understand the mechanisms underlying a uniquely human disease such as 
AD, it would be valuable to perform experiments in human tissue.  Naturally we 
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turned to using human iPSCs, which, as described above, can be used to generate 
human disease-vulnerable cortical neurons.  We were particularly drawn to the 
unresolved basic question in the field of how a large number of fAD mutations in 
APP and PSEN genes can result in a common disease signature.  Given the 
promise of CRISPR/Cas9 editing, we thought that instead of depending on the highly 
variable process of obtaining biopsies from rare fAD patients, reprogramming patient 
fibroblasts into iPSCs and differentiating cells into neurons, it would be helpful 
instead to generate a standardized wildtype iPSC line into which we could knock-in 
any fAD mutation we wished to study. With this approach in mind, the main goal of 
my thesis work was as follows: Use CRISPR/Cas9 gene editing and iPSC 
technology to determine in human neurons common cellular mechanisms 
underlying both APP and PSEN1 fAD mutations.   
Initially, I began my first CRISPR/Cas9 gene editing experiments in January 
2013, only days after the manuscripts detailing the first usage of the technology in 
human cells were made publicly available.  Quickly we realized that CRISPR/Cas9 
technology was particularly underdeveloped, specifically for its use in engineering 
specific sequence changes in stem cells.  In Chapter II, I will begin by describing two 
major prohibitive issues we noticed with using CRISPR/Cas9 in iPSCs.  Specifically, 
CRISPR/Cas9-mediated knock-in is incredibly inaccurate, and it is virtually 
impossible to efficiently generate both heterozygous and homozygous mutant knock-
in cell lines using standard approaches. I will describe how we overcame these 
issues by systematically interrogating patterns of HDR-mediated mutation 
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incorporation using next generation sequencing (NGS) technology ultimately to 
develop a universal framework for precise and efficient introduction of mutations with 
CRISPR/Cas9.  In Chapter III, I will expand on this established approach and 
discuss a related CRISPR/Cas9-based strategy we developed called CORRECT, 
which specifically enables scarless introduction of an intended sequence or 
mutation.   
Chapter IV will focus on describing how we actually implemented our novel 
CRISPR/Cas9 gene editing platform to generate and study a large and 
comprehensive panel of isogenic APP and PSEN1 fAD mutant iPSCs.  Probing 
differentiated mutant iPSC-derived neurons revealed unexpected overlapping 
common cellular and molecular AD-relevant phenotypes.  Specifically, using “-omics” 
technologies, we discovered that dysregulation of both AD- and endocytosis-
associated genes is a pathogenic feature common to APP and PSEN1 mutant cells.  
Endocytic dysfunction was confirmed in all mutant neurons analyzed and was shown 
to be specifically correlated with endogenous accumulation of β-CTF, and not 
changes in Ab levels. Furthermore, endosomal enlargement phenotypes could be 
pharmacologically rescued by inhibition of β-secretase, but not by treatment with 
novel g-secretase modulators.  Together these data reinforce a developing consensus 
in the AD field, namely, that β-CTF may be an important common product of APP 
metabolism that significantly contributes to AD pathology.  At the end of each chapter 
describing experimental results I will discuss the significance and implications of the 
work presented.  I will discuss how our work fits in the broader scientific literature and 
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describe some future research directions.  Chapter V will contain a final outlook and 
perspective of the work presented in this thesis, and Appendix I includes details of 
important methods and materials relevant to Chapters II-IV. 
 
 51 
CHAPTER II: EFFICIENT INTRODUCTION OF SPECIFIC 
HOMOZYGOUS AND HETEROZYGOUS MUTATIONS USING 
CRISPR/Cas9 
 
Background and rationale 
 
CRISPR/Cas9 is a versatile system for gene editing, which, when applied to 
iPSC technology, holds great potential for enabling the development of next-
generation model systems of neurodegenerative diseases such as AD.  Our goal 
was to leverage these two technologies and to use CRISPR/Cas9 to introduce a 
series of disease-causing fAD APP and PSEN1 mutations in wildtype human iPSCs.  
Moreover, we aimed to generate both homozygous and heterozygous knock-in cell 
lines, so that in differentiated AD-vulnerable cortical neurons, mutation-load 
dependent phenotypes could be adequately determined and subtle phenotypes 
could be more significantly exaggerated (in homozygous cells).   
At the time of our initial experiments using CRISPR/Cas9, little was known 
about how useful the technology would be for editing human stem cells.  When we 
started the project, the only published work on CRISPR/Cas9 editing was studies 
demonstrating that the CRISPR/Cas9 complex is very efficient at introducing DSBs 
in the DNA of many cell types (Canver et al., 2014; Dow et al., 2015; Platt et al., 
2014) and was convenient for generating gene knockouts, easily created by 
generating shifts in the reading frame of the targeted gene leading to premature stop 
codons on both alleles (Hsu et al., 2014; Jinek et al., 2013). This is because most 
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commonly after a DSB occurs, the broken chromosome is repaired by the error-
prone process of NHEJ, which does not allow introduction of specific sequence 
changes but rather random base insertions or deletions, also known as “indel” 
mutations (Hsu et al., 2014; Jinek et al., 2013).  Generating a specific sequence 
change, like the introduction of a single APP or PSEN1 fAD mutation, requires the 
cell to utilize a much rarer DNA repair mechanism called HDR (Hsu et al., 2014). 
Accomplishing this most commonly involves simultaneously introducing a modified 
DNA repair template, such as a single stranded oligonucleotide (ssODN), containing 
both homologous sequence to the genomic region around the DSB and the intended 
sequence changes, which can be incorporated into the edited genome (Figure 9).  
Unfortunately, we quickly realized CRISPR/Cas9-mediated mutation knock-in 
by HDR was incredibly difficult, and overcoming this problem needed to be the first 
major focus of our experimental efforts.  Furthermore, we expected these same 
issues were being faced by multiple groups around the world trying to implement 
CRISPR/Cas9 in their favorite model system.  Therefore, improving CRISPR/Cas9 
technology and developing a new approach for efficient and precise knock-in would 
be a widely valued effort.  The following results are adapted from our recent 






CRISPR/Cas-blocking mutations increase HDR accuracy by preventing re-
editing 
 
Knocking-in pathogenic mutations requires that only the amino acid change 
caused by these mutations occurs at a targeted locus, while the neighboring amino 
acids stay unaltered.  While attempting to introduce either the APPswe or PSEN1-
M146V fAD mutations into iPSCs using CRISPR/Cas9, we detected HDR by 
presence of an intended mutation provided via the cognate ssODNs, however most 
HDR events also contained unwanted indels (Figure 10).  This was a problematic 
result as such indels would lead to unwanted amino acid changes. 
 
Figure 10.  HDR is usually corrupted by unwanted indels.        
APP sequencing alignment showing concomitant HDR (blue arrow) and 
indels (orange arrow) after editing.   
 
 
The additional unwanted indels we noticed in HDR sequencing reads 
presumably resulted from the known high nuclease activity of CRISPR/Cas9 (Cong 
et al., 2013; Dow et al., 2015; Wang et al., 2013), which may continuously re-cut 
edited loci until sufficient modification by NHEJ prevents further targeting. If so, we 
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reasoned that this re-editing may be blocked by simultaneously introducing 
mutations into the NGG PAM sequence or guide RNA binding sequence, which 
CRISPR/Cas9 requires for targeting (Hsu et al., 2014), as shown in prokaryotes 
(Jiang et al., 2013).  The efficacy of potential blocking mutations had not yet been 
systematically studied in eukaryotic cells, therefore we tested their effect on HDR 
accuracy in our established wildtype human iPSCs (see Appendix I for info on iPSC 
generation) and, for comparison, HEK293T cells. We introduced Cas9-eGFP and a 
single-guide RNA (sgRNA) plasmid together with five pooled repair ssODN 
templates, which in addition to the APPswe or PSEN1-M146V pathogenic mutation 
also contained a putative silent CRISPR/Cas-blocking mutation (Figure 11A-B).  
Although we expect mutations in either of the guanines of the PAM to be most 
effective in blocking CRISPR/Cas9 activity because the PAM (NGG) sequence is 
required for Cas9 binding to DNA (O'Connell et al., 2014; O'Geen et al., 2015; Wu et 
al., 2014), insertion of silent mutations is not always possible at that site due to 
individual reading frames and codon usages of different edited loci.  Therefore, we 
tested CRISPR/Cas-blocking mutations at various positions upstream in the 20 bp 
guide RNA targeting sequence that are believed to disturb guide RNA hybridization 
to target DNA (Hsu et al., 2013; Pattanayak et al., 2013) and thus reduce 
CRISPR/Cas9 activity. As a control, we added an ssODN containing a silent 
mutation outside of the guide RNA targeting sequence, which allowed identification 






Figure 11.  Schematic of experimental setup for CRISPR/Cas-blocking 
mutation analysis. 
A) Experimental setup for gene editing analysis by NGS.  Cas9 and sgRNA 
expressing plasmids were transfected along with ssODNs.  GFP+ cells were 
sorted out by FACS and CRISPR/Cas9 editing was analyzed by NGS.  B) 
Schematic of pooled ssODNs used to test effects of CRISPR/Cas-blocking 
mutations.   
 
We analyzed genomic loci of Cas9-eGFP-expressing cells by Next 
Generation Sequencing (NGS) (See Appendix I for details of sequencing analysis) 
and determined the fraction of HDR reads (reads where there was incorporation of 
the pathogenic mutation on the ssODN template).  Overall HDR rates for these 
experiments were approximately 2-3% (data not shown).  Next, we filtered to 
determine the number of HDR reads that were “accurate”, i.e., without undesirable 





pathogenic and control mutation had further indel modifications at both loci, resulting 
in low levels of accurate HDR (only 6 to 35%; see Figure 12A-B). In contrast, the 
presence of a CRISPR/Cas-blocking mutation in the PAM dramatically increased 
accurate HDR rates in iPSCs and HEK293 cells at both loci (Figure 12A-B). The 
remaining “inaccurate” HDR reads all contained indel mutations, which were likely 
generated by NHEJ events prior to or during homology-directed repair that did not 
block further editing. Silent mutations in the sgRNA targeting site increased accurate 
HDR in both iPSCs and HEK293 cells at the APP locus, illustrating that for this 
locus, optimal guide RNA binding is crucial for CRISPR/Cas9 activity (Figure 12A). 
At the PSEN1 locus accurate HDR was only modestly increased by some of the 
guide RNA targeting site mutations (Figure 12B). This indicates that the activity of 
the PSEN1-targeting sgRNA is less affected by mutations at the guide RNA binding 
sequence.  Results did not differ when ssODN templates from the abovementioned 




Figure 12.  CRISPR/Cas-blocking mutations increase HDR accuracy. 
A-B) Percentages of accurate HDR (HDR only events, i.e., without 
concomitant indels) for blocking or control mutations at APP (A) and PSEN1 
(B) loci in pooled transfected iPSCs and HEK293 cells. Values represent 




Figure 13.  Analysis of CRISPR/Cas-blocking mutations using un-pooled 
ssODNs 
Accurate HDR editing rates (HDR only events, i.e., without concomitant 
indels) from 5 unpooled templates containing intended pathogenic and 
CRISPR/Cas-blocking or non-blocking control mutations.  Percentages of 
accurate HDR for reads containing B or C mutations at the APP (A) and 
PSEN1 (B) locus in HEK293 cells. Values represent mean ± SEM (n=3).  ND 
= not detected; n.s. = not significant.  ***P < 0.001, **P < 0.01, 1-way ANOVA.   
 
Single CRISPR/Cas-blocking had much reduced efficacy in the sgRNA target 
sequence at the PSEN1 locus compared to APP, suggesting the PSEN1 sgRNA can 
overcome minimal sequence mismatches.  We therefore tested the efficacy of using 
multiple blocking mutations positioned in the guide RNA target seed sequence and 
found an improvement of editing accuracy that was comparable to that of PAM-
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blocking mutations (Figure 14A).  This result corroborates previous studies, which 
found that multiple consecutive mismatches within the guide RNA seed sequence 
largely prevent targeting by the CRISPR/Cas9 complex (Hsu et al., 2013; Kuscu et 
al., 2014; Pattanayak et al., 2013).  Unfortunately, it may be impossible to use 
multiple consecutive sgRNA-blocking mutations that are silent.  Therefore, we tested 
the efficacy of using multiple silent blocking mutations in the guide-RNA target 
sequence.  We also found that improvements in editing accuracy comparable to that 
of PAM-blocking mutations were seen when multiple silent blocking mutations in the 
sgRNA sequence were incorporated (Figure 14B). Additionally, we confirmed that 
the frequency, position, and size of all indels detected in these abovementioned 
experiments followed the distribution expected from previous studies (Mali et al., 





Figure 14.  Multiple CRISPR/Cas-blocking mutations in the sgRNA target 
sequence increase editing accuracy. 
Accurate HDR editing rates (HDR only events, i.e., without concomitant 
indels) in a pool of transfected iPSCs determined for the PSEN1-M146V 
locus.  A) Introducing several blocking mutations within the first 6 bases of the 
guide RNA target sequence blocks re-editing as efficiently as PAM-altering 
CRISPR/Cas-blocking mutations. B) Accurate HDR editing rates using an 
ssODN with three interspersed silent guide RNA-altering CRISPR/Cas-
blocking mutations as a repair template in a pool of transfected iPSCs.  HDR 
events with only partial incorporation of blocking mutations result in reduced 
overall HDR-mediated editing accuracy (see top read, only ‘A’ incorporated).  






Figure 15.  Analysis of CRISPR/Cas9-induced indels in gene edited 
iPSCs and HEK293T cells. 
Plots depicting frequency of indels at each position around the targeted locus 
in all NGS reads with editing events from the analysis shown in Figure 12.  
Insertions are plotted at the location where they begin, and deletions are 
plotted across all deleted base positions (top).  Histogram illustrating 
distribution of indel sizes (bottom).   
 
Surprisingly, when studying the HDR events at APP and PSEN1 loci in detail, 
we noticed that between 6% and 11% of the HDR reads contained more than one 
CRISPR/Cas-blocking or non-blocking control mutation (Figure 16).  Since each 
ssODN repair template provides only one control or CRISPR/Cas-blocking mutation, 
the cells must have used multiple distinct ssODNs from the pool for repair, 
presumably in multiple rounds of HDR that occurred after repeated Cas9 editing.  
These data indicate that at a given locus at least 3 rounds of cut-and-repair events 
can occur before a genomic edit is final. This hypothesis is further supported by the 
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fact that at both loci these “double HDR” events more often contain a non-blocking 
control mutation than a CRISPR/Cas-blocking mutation (Figure 16).  
 
Figure 16. CRISPR/Cas-blocking mutations are incorporated in multiple 
rounds of re-editing. 
A-B) Proportion of NGS reads containing putative single, double, or triple 
HDR events (left) for APP (A) and PSEN1 (B).  Putative “double HDR” 
examples of the most frequent reads that either contain a non-blocking 
control mutation C with an additional CRISPR/Cas-blocking mutation B, or do 
not contain C and have two different CRISPR/Cas-blocking mutations 
(middle).  Reads that contain the non-blocking mutation (C+) are more 
frequently re-edited to incorporate a CRISPR/Cas-blocking mutation (“double 
HDR”) than reads containing a blocking mutation B instead of the non-
blocking mutation C (C-).  To facilitate data analysis, all replicates were 




Taken together, our results provide direct evidence that CRISPR/Cas9 will 
continuously re-edit a genomic locus, even after HDR occurs, until sufficient 
modification prevents further activity. This prevalent and deleterious process can be 
blocked by introducing a modified repair template with CRISPR/Cas-blocking 
mutations, preferably in the PAM. This simple modification can increase the number 
of accurately edited alleles up to tenfold (6% for non-blocking vs. 60% for blocking 
mutations at the PSEN1 locus, see Figure 12), which in diploid cells has the 
potential to increase the probability of editing both alleles accurately by 100-fold (6% 
x 6% = 0.36% vs. 60% x 60% = 36%, assuming independent editing of both alleles). 
Therefore, CRISPR/Cas-blocking mutations can dramatically influence the feasibility 
of a desired genome editing experiment. 
 
CRISPR/Cas9 editing results mostly in bi-allelic changes 
 
We tested our approach of simultaneous introduction of either the APPswe or 
PSEN1-M146V mutations together with CRISPR/Cas-blocking mutations by 
generating single-cell-derived clones of iPSCs. While we could readily isolate a 
number of clones with bi-allelic HDR-mediated incorporation of both pathogenic and 
CRISPR/Cas-blocking mutations without additional indels (data not shown), almost 
all clones that had seemingly undergone only mono-allelic mutation incorporation 
(HDR at only one allele as assessed using an RFLP assay; see methods Appendix 
I for details) contained unwanted indels at the “non-HDR” allele (Figure 17). 
Therefore, heterozygous lines could not be readily isolated by mono-allelic HDR 
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alone.  Previous studies have identified a similar tendency for CRISPR/Cas9 editing 
to mostly result in bi-allelic indel modifications (Dow et al., 2015; Wang et al., 2013).  
This tendency, in addition to the established known high activity of the 
CRISPR/Cas9 complex (Cong et al., 2013; Dow et al., 2015; Wang et al., 2013), 
makes it plausible that potential targets in a cell are all edited at a similar rate in the 
presence of Cas9 and sgRNA, thereby dramatically reducing the probability of 
isolating cells in which only one allele is edited by HDR while the other allele is 
unmodified.  This observation raised the question of how, if not by mono-allelic HDR, 





Figure 17.  Mono-allelic HDR clones contain indels on the other non-
HDR allele. 
A) Sanger sequencing reads of both APP alleles of a single-cell clone with 
mono-allelic HDR (blue arrow), determined using the PolyPeak Parser tool 
(see Appendix I). The non-HDR allele is altered by NHEJ in the sgRNA 
target sequence (orange arrow). B) Single-cell clones with HDR on one allele 
are mostly altered by NHEJ on the non-HDR allele (APP n=26, PSEN1 n=34).  





A monotonic inverse relationship between the rate of mutation incorporation 
and distance from the CRISPR/Cas9 cleavage site 
 
While studying deep sequencing data from genomes edited using ssODNs 
bearing both pathogenic and PAM-altering CRISPR/Cas-blocking silent mutations, 
we observed that sequencing reads that had incorporated a silent CRISPR/Cas-
blocking mutation by HDR did not always contain the pathogenic mutation (Figure 
18). These reads were most abundant when the pathogenic mutation and 
CRISPR/Cas9 cleavage site were not in close proximity.  This observation is 
consistent with earlier reports of a distance effect influencing mutation incorporation 
by HDR using other gene editing systems (Beumer et al., 2013; Elliott et al., 1998; 
Rivera-Torres et al., 2014; Taghian and Nickoloff, 1997; Yang et al., 2013).  More 
recent studies in mouse and human cancer cells (Bialk et al., 2015; Inui et al., 2014) 
suggested a similar effect for CRISPR/Cas9 editing, however, the molecular basis of 
this distance phenomenon, and how it depends on guide RNA sequence, repair 
template composition, base position or genomic context remains to be elucidated.  
We reasoned that if a predictable relationship between distance and mutation 
incorporation exists at multiple loci, it could be exploited to selectively control 
mutation incorporation at each allele based on probability alone.  In other words, if 
the two HDR events depicted by NGS reads in Figure 18 represented the two 






Figure 18.  Pathogenic mutation is not always incorporated by 
CRISPR/Cas9-mediate HDR. 
PSEN1 sequencing alignment showing HDR-mediated introduction of a 
CRISPR/Cas-blocking mutation (red arrow) with or without the pathogenic 
mutation (blue arrow).   
 
  To systematically characterize this distance effect, we performed an 
unbiased scan of oligo mutation incorporation rates at both the APP and PSEN1 
locus, using one sgRNA per locus combined with a pool of 20 different ssODNs. 
Each ssODN contained a unique CRISPR/Cas-blocking 3 bp barcode sequence (in 
this experiment we did not restrict ourselves to silent mutations) as well as a single 
intended point mutation at increasing distances from the CRISPR/Cas9 cleavage 
site (Figure 19A, oligo sequences can be found in Appendix I).  Cas9, sgRNA and 
ssODN pools were transfected into iPSCs and HEK293T cells. Gene editing 
outcomes at APP and PSEN1 loci was assessed by NGS, using the CRISPR/Cas-
blocking barcode sequence to identify reads with HDR-mediated incorporation of 
each ssODN. Strikingly, we found a clear monotonic inverse relationship between 
the rate of mutation incorporation and distance from the CRISPR/Cas9 cleavage site 
that did not differ significantly for APP and PSEN1 in either iPSCs or HEK293 cells 
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(Figure 19B-C). Moreover, when comparing 100bp ssODNs to longer ssDNA or 
dsDNA HDR repair templates the distance relationship was similar (Figure 20), 
suggesting that such a phenomenon is not influenced by the repair templates 
themselves but instead arises from an intrinsic property of the CRISPR/Cas9-
mediated DSB.  
 
 
Figure 19.  A monotonic inverse relationship between mutation 
incorporation and distance from the CRISPR/Cas9 cleavage site. 
A) Pooled ssODNs used to scan mutation incorporation rates based on cut-
to-mutation-distance. Barcode mutations (red) identify HDR-reads and 
mutation M position during NGS analysis.  B-C), A monotonic relationship 
underlies the rate of mutation M incorporation and cut-to-mutation distance 
during HDR in both iPSCs (B) and HEK293 cells (C) (n=4 for iPSCs, n=3 for 
HEK293); goodness of fit: R2(APP) = 0.75(iPSC) / 0.96(HEK293), R2(PSEN1) 
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= 0.94(iPSC) / 0.97(HEK293); curves for APP and PSEN1 are not significantly 




Figure 20.  Longer ssDNA or dsDNA HDR templates do not influence 
mutation incorporation probabilities related to cut-to-mutation distance. 
A) Schematic describing the generation of large ssDNA and dsDNA HDR 
repair templates for the PSEN1 locus (see Appendix I for more details). B) 
The monotonic relationship between incorporation of intended mutations (M) 
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by HDR and cut-to-mutation distance is not altered by providing longer 
ssDNA and dsDNA templates (n=2).  Red hashed trendline shows previously 
determined 100-nt oligo scan result (from Figure 19B) for comparison. 
 
 To address whether loci, guide RNA activity or ssODNs sequence differences 
also influence this relationship we utilized three sgRNA/ssODN pairs (see oligo 
sequences in Appendix I) to target a DSB at short, intermediate and long distances 
from the APPswe or PSEN1-M146V pathogenic mutation sites in iPSCs (Figure 21).  
Each ssODN repair template contained a silent CRISPR/Cas-blocking mutation in 
addition to the intended pathogenic mutation, and the presence of both mutations 





Figure 21.  Analysis of the "distance effect" using 3 independent 
sgRNA-ssODN pairs in iPSCs. 
A) Experimental setup using three sgRNA/ssODN pairs per locus with 
increasing cut-to-mutation distance.  Edited iPSCs were analyzed by NGS (or 
grown for clonal analysis in Figure 22).  B-C) Incorporation rate of APP and 
PSEN1 pathogenic mutations at increasing distance from the cut site targeted 
by three distinct sgRNA/ssODN pairs is governed by distance.  Incorporation 
rates (solid dots represent mean ± SEM, note SEM is too small to be visible, 
(n=3)) match almost exactly the curves for each locus previously determined 
by oligo scan (hashed trend line ± SD of raw data from Figure 19B).  ***P < 
0.001, 1-way ANOVA. 
 
As expected, we found that at both the APP and PSEN1 locus, sgRNAs 
targeting a DSB at short distances from the pathogenic mutation (2bp for APP-
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sgRNA12, 9bp for PSEN1-sgRNA5) resulted in very efficient incorporation of both 
mutations, whereas the rate of incorporation of the pathogenic mutation dropped 
significantly with increasing distance (Figure 21B-C).  Notably, the incorporation 
rates for each sgRNA/ssODN pair matched almost exactly the curves for each locus 
determined by the oligo scan data (Figure 19B, plotted as dashed lines in Figure 
21B-C). Together, the finding of similar distance-incorporation relationships for 
multiple independent sgRNAs, as well as multiple ssODN and longer repair 
templates at several genomic loci in two cell types suggests that a generalizable and 
predictable “distance effect” may govern incorporation of any intended sequence 
change during gene editing by HDR.    
 
Using the distance effect for efficient introduction of targeted homo- and 
heterozygous mutations 
 
Our data imply that the cut-to-mutation distance needs to be minimized for 
efficient homozygous incorporation of a mutation. For example, to yield 25% 
homozygous clones the probability of mutation incorporation per allele needs to be 
above 50% (50% x 50% = 25%), which requires a cut-to-mutation distance below 
approximately 10 bp (see Figure 19B-C).  The distance effect also predicts that as 
cut-to-mutation distances increase and probability of mutation incorporation drops, 
the odds of generating a mono-allelic alteration should increase.  To examine 
whether the distance effect could be exploited to not only introduce targeted 
homozygous but also heterozygous mutations, we first determined an overall 
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probability of mutation incorporation (i.e. single allele frequencies for pathogenic 
mutation) for iPSCs by combining our oligo scan data from APPswe and PSEN1-
M146V loci (determined in Figure 19B).  By assuming that HDR takes place 
independently at both alleles, we calculated the expected distance ranges that would 
favor homozygous, heterozygous and wildtype genotypes at a given distance by 
multiplying single allelic probabilities (Figure 22A, see Appendix I for details of 
calculation).  
 
Figure 22.  Exploiting the “distance effect” to predict zygosity using 
CRISPR/Cas9-mediated HDR in iPSCs. 
A) Predicted distance ranges for desired zygosities, calculated based on oligo 
scan data (Figure 19B and Appendix I).  B) Frequency of different APP and 
PSEN1 mutation genotypes in single cell clones with bi-allelic HDR of 
blocking mutations. Indicated zygosities fit to predicted values.  HDR clones = 
number of Sanger sequenced clones that had all undergone bi-allelic 





 To experimentally test these predictions, we derived single-cell clones from 
iPSCs electroporated with the three sgRNA/ssODN pairs as described in Figure 
21A.  We isolated clones that had undergone bi-allelic incorporation of the silent 
CRISPR/Cas-blocking mutation as determined by RFLP assay (approximately 2-3% 
of clones on average) and assessed their zygosity for the pathogenic mutation by 
Sanger sequencing (Figure 22B). Notably, we found that the rate of homo- and 
heterozygosity correlated well with our predictions based on the “distance effect” 
(Figure 22A). The APP sgRNA/ssODN pair targeting 2 bp away from the pathogenic 
mutation yielded 100% clones homozygous for the pathogenic mutation, whereas 
the APP sgRNA/ssODN pair targeting 23 bp away yielded more than twice as many 
heterozygous as homozygous clones. About half of the clones for this distance did 
not contain the pathogenic mutation on either allele.  The APP sgRNA/ssODN pair 
targeting 45 bp away from the mutations did not yield any clones containing the 
pathogenic mutation, even though this mutation was present in the ssODNs used as 
an HDR template (Figure 22B).  Similar results were also obtained for PSEN1 
(Figure 22B).  We noted that for PSEN1 sgRNA5 (cut-to-mutation distance 9 bp), 
more homozygous clones were generated than predicted based on distance (67% 
actual vs. 20-40% predicted). This may reflect differences in usage of the other allele 
as a repair template for HDR at some loci or arise from subtle differences in DSB 
response and repair.  Taken together, our results demonstrate that (1) choosing the 
optimal cut-to-mutation distance is crucial for efficient HDR-based genome editing, 
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and (2) the distance effect facilitates selection of the most efficient guide RNAs for 
engineering both homo- and heterozygous HDR-mediated gene modifications. 
 
Selection for heterozygous mutations using mixed HDR templates 
 
As shown above, the selection of a suitable guide RNA is limited not only by 
its specificity and activity for the targeted locus, but also by the requirement for a 
PAM close to the intended target site.  For a given sequence these requirements 
may be too restrictive and result in cases where no suitable guide RNA is available 
for homo- or heterozygous knock-in by our approach. Choosing a guide RNA with a 
targeting site more than 10 bp away from the mutation may still yield homozygous 
clones, albeit at much lower efficiencies, however obtaining heterozygous clones 
with a guide RNA that targets very close to the mutation site (<3 bp, Figure 22A) is 
highly unlikely.  
 We reasoned that this problem could be circumvented by equimolar mixing of 
two ssODNs that both harbor a CRISPR/Cas-blocking mutation, with only one 
containing the pathogenic mutation (Figure 23). We tested this approach on the 
APP locus using the most closely targeting sgRNA available, which in our previous 
analysis did not yield any heterozygous clones (APP-sgRNA12, see Figure 23A). 
When analyzing single cell-derived clones with bi-allelic incorporation of the 
CRISPR/Cas-blocking mutation by RFLP and Sanger sequencing, we did indeed 
find an appreciable number of clones heterozygous for the intended pathogenic 
mutation, thereby validating the approach.  Unexpectedly, we observed a higher 
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frequency of clones homozygous for the pathogenic mutation than the predicted 
50% (Figure 23A). This increased frequency is consistent with the increased 
incorporation rate of the ssODN containing both the CRISPR/Cas-blocking and 
pathogenic mutation, as determined by NGS of edited loci in pooled cells from the 
same experiment (Figure 23A).  The ssODN containing the pathogenic mutation 
might be favored because the mutation lies in the sgRNA seed sequence, which 
may more effective at blocking CRISPR/Cas as described above.  
This observation motivated us to test an alternative approach of again using 
APP-sgRNA12 and mixing two ssODNs that contained either only the intended 
pathogenic mutation, or a CRISPR/Cas-blocking mutation, but at identical positions 
in the sgRNA target site (Figure 23B). Strikingly, and as expected, nearly half of the 
clones were heterozygous for the pathogenic mutation at one allele and contained 
the CRISPR/Cas-blocking silent mutation at the other. Deep sequencing confirmed 
incorporation of both oligos at nearly equal rates (Figure 23B).  The rate of wildtype 
clones was not assessed, because the silent mutation present in the wildtype 
ssODN template did not introduce a restriction site for RFLP screening. However, 
given the ~50% ssODN incorporation rates determined by deep sequencing, about 
25% of HDR clones are predicted to be wildtype.  We also demonstrated at the 
PSEN1 locus the ability to mix repair templates to predictably and significantly 
increase the number of heterozygous clones obtained using the PSEN1 sgRNA that 
cleaves closest to the M146V mutation site (PSEN1-sgRNA5, Figure 23C).  
Together, these data support the strategy of using a mixture of two oligonucleotides 
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to introduce different sequences at each allele and thereby obtain desired 
heterozygous modifications in spite of the constraints of the targeted locus.   
 
 
Figure 23.  Introduction of heterozygous or homozygous mutations into 
iPSCs by using mixed HDR templates. 
A-B) Mixed ssODN editing approach at the APP locus with blocking 
mutations in both (A) or one (B) ssODNs (top); zygosity quantification of 
single-cell clones and incorporation rates of CRISPR/Cas-blocking mutation B 
and pathogenic mutation M determined by NGS analysis (bottom). Note that 
for the M/B approach in B, both oligos are incorporated at near equal levels, 
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as they have similar blocking activities, whereas for the M+B/B approach in A, 
the M+B ssODN is preferentially incorporated, presumably due to a 
synergistic blocking effect of both M and B. For the clone quantification in (B) 
the rate of wildtype clones was not assessed, because the silent mutation did 
not introduce a restriction site for screening. C) Mixed ssODN editing 
approach at the PSEN1-M146V locus (top).  Using an sgRNA with the 
smallest possible cut-to-mutation distance (PSEN1-sgRNA5, 9bp), two 
ssODNs were provided, each containing the same silent PAM-altering 
CRISPR/Cas-blocking mutation B, but only one containing the pathogenic 
mutation M.  Frequencies of pathogenic mutation genotypes in single cell 
clones with bi-allelic HDR of B (left) and incorporation rates of CRISPR/Cas-
blocking and pathogenic mutations by NGS (right). Note that due to the 9bp 
distance to the cleavage site, the incorporation of M is lower than 50% (as 





I began this chapter by highlighting a major problem with CRISPR/Cas9 gene 
editing technology, which, at the time of these studies, was not very well 
communicated.  Specifically, we noticed early in our utilization of CRISPR/Cas9 in 
wildtype iPSCs that not only was HDR-mediated mutation incorporation rare, it was 
incredibly inaccurate due to the innate high activity of the CRISPR/Cas9 complex.  
As a result, HDR-mediated mutation incorporation is almost always corrupted by 
additional unwanted indel mutations, making it nearly impossible to use 
CRISPR/Cas9 for precise gene editing in iPSCs.  Related to this is also the problem 
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of generating heterozygous clones, since the highly active CRISPR/Cas9 complex 
virtually always introduces unwanted indel mutations at the non-HDR allele in a 
single cell.  In the work described above, we overcame these two technological 
barriers and report a CRISPR/Cas9-based genome editing framework that allows for 
selective introduction of specific mono- and bi-allelic sequence changes with high 
efficiency.  
Utilizing human iPSCs and HEK293 cells, we first established that by 
simultaneously introducing a CRISPR/Cas9-blocking point mutation in the PAM or 
guide RNA binding sequence, accurate HDR-mediated incorporation of an intended 
pathogenic mutation can be significantly increased up to 10-fold per allele. Next, by 
systematically characterizing HDR-mediated mutation introduction at varying 
distance to the CRISPR/Cas9 cleavage site, we determined a predictable, 
monotonic inverse relationship between distance of an intended sequence change 
and its rate of incorporation, thereby corroborating and extending previous evidence 
of such a distance effect (Beumer et al., 2013; Bialk et al., 2015; Elliott et al., 1998; 
Inui et al., 2014; Rivera-Torres et al., 2014; Taghian and Nickoloff, 1997; Yang et al., 
2013).  Additionally, we exploited this relationship to derive distance ranges that 
enable the selection of the most suitable sgRNAs for the efficient generation of 
homo- and heterozygous clones. Furthermore, we demonstrated that heterozygous 
changes can also be achieved by reducing the relative concentration of the intended 
mutation in the repair template by mixing mutant with non-mutant repair templates. 
In this work we introduced pathogenic mutations, but it should be noted that our 
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approach of manipulating cut-to-mutation distance or repair template concentration 




The findings in this study establish a framework for efficient CRISPR/Cas9-
mediated introduction of targeted mono- and bi-allelic mutations into eukaryotic cells 
by characterizing the dynamics of homologous recombination and highlight the utility 
of this technology for studying genetic disorders.  The widespread use of 
CRISPR/Cas9 to induce specific genomic changes depends on strategies to 
increase homologous recombination, while at the same time reducing non-specific 
repair, such as NHEJ. Recently, several groups have demonstrated increased HDR 
rates by either cell cycle synchronization (Lin et al., 2014), activation of β3-
adrenergic-receptors (Yu et al., 2015), or shRNA knockdown or pharmacological 
inhibition of components of the NHEJ pathway (Chu et al., 2015; Maruyama et al., 
2015). Although these studies provide valuable improvements, they do not block 
CRISPR/Cas9 activity after HDR has occurred, which we show leads to repeated 
editing of genomic loci in a majority of cases due to the high activity of the 
CRISPR/Cas9 complex.  One approach to reduce this undesirable re-cutting may be 
to titrate down Cas9 or guide RNA levels to reduce overall activity or use a modified 
Cas9 that does not fully cleave the DNA (e.g., a nickase) (Ran et al., 2013). 
However, in our hands this resulted in a drop in overall HDR rates to a level that 
makes manual single cell clone picking impractical (data not shown).  We therefore 
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kept Cas9, sgRNA and ssODNs at a constant concentration at which HDR was most 
efficient. Our approach of using CRISPR/Cas-blocking silent mutations significantly 
increases accurate HDR events up to 10-fold for a given allele, with the potential to 
provide a nearly 100-fold increased probability of detecting desired HDR events at 
both alleles.  These dramatic benefits provided by CRISPR/Cas-blocking mutations 
can be combined with other complementary approaches described above to further 
improve HDR efficiency.   
 In addition to improving the rate of accurate HDR, understanding the 
dynamics of homologous recombination of a repair template at a genomic locus 
targeted by CRISPR/Cas9 is crucial to efficiently direct the outcome of such a 
targeting event. We addressed this by systematically interrogating HDR-mediated 
incorporation of multiple repair templates at two independent genomic loci in two 
different cell types by high-throughput NGS analysis. This unbiased approach 
allowed us to extend previous evidence for a distance effect (Beumer et al., 2013; 
Bialk et al., 2015; Elliott et al., 1998; Inui et al., 2014; Rivera-Torres et al., 2014; 
Taghian and Nickoloff, 1997; Yang et al., 2013) and define a specific inverse 
relationship between the distance of a base from the site of CRISPR/Cas9 cleavage 
and the rate of its incorporation by HDR.  The length of gene conversion tracts we 
determined for CRISPR/Cas9 editing in human iPSCs and HEK293 cells was very 
similar to tract length observed for TALENs in human iPSCs and other human cell 
types (i.e., incorporation drops significantly between 10-20 bp) (Rivera-Torres et al., 
2014; Yang et al., 2013), however, it differed markedly from that observed with zinc 
 
 82 
finger nucleases in Drosophila (over 3,000 bp) (Beumer et al., 2013) and restriction 
enzymes in rodent cells (80-200 bp) (Elliott et al., 1998; Taghian and Nickoloff, 
1997).  This divergence might reflect species differences, for example varying 
activities of repair pathways, or differences in the types of cleavage, e.g. sticky ends 
for restriction enzymes versus blunt ends for TALENs and CRISPR/Cas9, which 
may affect strand resection and repair.  Variations in analysis may also play a role, 
for example some studies used selection markers, which may increase the 
representation of rare events, especially if the number of analyzed clones is small. 
We therefore note that controlling zygosity by exploiting the distance effect may work 
best in systems where short gene conversion tracts are more likely, whereas oligo 
mixing is a more universally applicable approach. 
  The distance effect we observed for CRISPR/Cas9 editing in human cells 
seems likely to reflect intrinsic features of the repair mechanism since in our initial 
survey it did not depend markedly on cell type, genomic locus, guide RNA, or nature 
of the repair template. What determines this dependence on distance?  One 
possible explanation, described two decades ago in the context of restriction-
enzyme-induced transgene conversion by HDR in mouse ESCs (Elliott et al., 1998), 
is that different size deletions arise after nuclease-mediated DSBs and that only the 
part of the repair template overlapping these deletions is used during HDR.  If small 
deletions or resections are more common than large ones, this would result in fewer 
incorporations of mutations more distal to the cleavage site (Figure 24).  Our data 
support this idea, because they not only confirm that deletions are more likely small 
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than large and center around the Cas9-mediated DSB, but also indicate no 
significant change of the distance dependency by altering the size and type of HDR 
repair templates used.   
 
Figure 24.  Possible mechanism underlying the distance effect for HDR-
mediated mutation incorporation with CRISPR/Cas9. 
CRISPR/Cas9 causes a DSB at a genomic locus, which leads to variable size 
deletions or strand resections in different cells. Genomes with small deletions 
or resections are more common than large ones, which is reflected in the 
distribution of deleted bases after NHEJ (top left).  During HDR, only the part 
of the repair template overlapping this deletion may be used, which results in 
fewer mutations incorporations more distal to the cleavage site (bottom left, 
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Although it remains to be determined whether our proposed mechanism is the 
correct explanation, the observation of a reproducible and stereotyped distance 
effect has two major implications for the field of gene editing:  First, it demonstrates 
that HDR is most efficiently achieved by selecting a guide RNA that causes a DSB 
close to the intended sequence change. Second, it defines optimal distance ranges 
to generate mono- or bi-allelic modifications, significantly improving guide RNA 
selection procedures that until now have focused principally on on-target activity and 
predicted off-target effects. As we show, the most efficient way of obtaining a clone 
heterozygous for a pathogenic mutation is to introduce it together with bi-allelic 
CRISPR/Cas-blocking silent mutations, which prevent destruction of both alleles by 
NHEJ. The different zygosities at both alleles are achieved by reducing the 
probability of the introduction of the pathogenic mutation by either modulating 
distance between cleavage site and mutation (distance effect) or mixing pathogenic-
mutant and non-mutant oligos. 
 Our improved CRISPR/Cas9-based gene editing framework also streamlines 
the modeling of genetic diseases in human iPSC models, by avoiding typical 
drawbacks associated with use of patient-derived models.  These include scarce 
availability or low quality of patient cell lines with mutations of interest, particularly for 
rare diseases, as well as the potential for inefficient reprogramming and/or poor 
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somatic cell differentiation quality. Furthermore, making comparisons in isogenic cell 
lines prevents confounding genetic background effects (Bellin et al., 2012; Tiscornia 
et al., 2011).  Knocking-in pathogenic mutations in human disease-relevant cells is 
more physiological than overexpression, which is commonly used in transgenic 
animal or cellular disease models, and also permits study of heterozygous mutations 
that underlie many important human diseases. When performed in a standardized 
iPSC or embryonic stem cell line, our approach not only allows efficient generation 
of knock-in models, but also cross-comparison between lines with different 
mutations in the same genetic background.  
 Since the completion of the CRISPR/Cas9 studies presented in this thesis 
there has been a large amount of work to further develop and improve the gene 
editing field.  Specifically, the development of a new CRISPR technology, 
CRISPR/Cpf1 has offered promise for enabling efficient and precise sequence 
changes (Zetsche et al., 2015).  However, as will be described below, we believe 
there are considerable drawbacks to this new technology and Cpf1 may not be a 
widely useful replacement for CRISPR/Cas9.  Cpf1 is another bacterial RNA-guided 
nuclease which is a member of a class II CRIPSR/Cas system.  Cpf1 differs from 
Cas9 in many ways.  Cpf1 is a much smaller and simpler nuclease compared to 
Cas9 and is guided by a smaller sgRNA molecule than is needed for Cas9 targeting.  
Unlike Cas9, Cpf1 targets a T-rich PAM (TTTN) at the 5’ end of the sgRNA target 
sequence (Cas9 targets NGG at the 3’ end of the target sequence) and makes a 
staggered cleavage of the DNA at 19bp after the PAM on the targeted strand and 
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23bp on the other strand (Zetsche et al., 2015).  As a result, the DSB has 5’ 
overhangs (“sticky ends”).  The fact that Cpf1 results in a cleavage with overhangs in 
intriguing, as strand resection and overhang generation is known to be as an 
essential first step for initiating HDR (Elliott et al., 1998).  Furthermore, many 
researchers believe that the generation of sticky ends may greatly facilitate the 
insertion of much longer tracts of DNA more effectively.  Unfortunately, there have 
been no investigations in human cells (including stem cells) demonstrating whether 
Cpf1 indeed improves HDR rates or conversion tract length.  Furthermore, future 
studies would be necessary to determine whether the distance effect we determined 
for Cas9 editing in human cells holds true or is altered when instead using Cpf1. 
 There are potentially other drawbacks to using Cpf1 over Cas9.  Since Cpf1 
cleaves 19-23bp from the PAM site and since most editing events (HDR or indels) 
take place closest to the cut-site, repetitive editing is more likely, since modifications 
would less commonly alter the PAM and prevent re-editing.  Furthermore, if blocking 
mutations are also proven to be effective for Cpf1, then incorporating these 
mutations in the PAM, which is at a considerable distance from the cut site, may be 
difficult due to the distance effect.  Therefore, even if HDR rates are somewhat 
improved using Cpf1, the problems of re-editing and inaccurate HDR may be 
considerably worse when using Cpf1.  At this time, all of these concerns are 
speculative, and therefore additional studies are required to address them. 
 While CRISPR/Cas9, as reported here and by others, mostly generates bi-
allelic modifications, TALENs are capable of introducing heterozygous changes, 
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likely due to their known lower editing activities, such that when HDR occurs at one 
allele the unedited allele is spared from NHEJ.  However, compared to 
CRISPR/Cas9, efficient and widespread use of TALENs has been hampered by their 
difficult design and assembly, and the need for extensive clone screening because 
of lower editing rates (Ding et al., 2013).   The strategy we describe, by harnessing 
the efficiency of CRISPR/Cas9-based targeting with approaches to enabling precise 
control of zygosity, provides a more efficient method for introducing both homo- and 
heterozygous sequence changes in a predictable manner.  What’s more, this 
approach facilitates the simultaneous modification of several loci in the same 
standardized model systems, helping open important research avenues such as 
studying combinations of disease-associated mutations or risk factors to better 






Chapter III:  PRECISE AND EFFICIENT SCARLESS GENOME 
EDITING IN STEM CELLS USING “CORRECT” 
 
Background and Rationale 
 
While attempting to edit the APP and PSEN1 loci in human iPSCs, we noted 
that up to 95% of the genomes that had incorporated the intended sequence change 
by CRISPR/Cas9-mediated HDR were corrupted by additional indel mutations 
(described in Chapter II). These “inaccurate” edits arise from subsequent re-editing 
of a previously edited locus by the CRISPR/Cas9 complex (Figure 25A), which will 
re-cut target loci until they are sufficiently modified to prevent further detection by 
CRISPR.  We demonstrated that undesirable re-editing could be largely prevented 
by inserting mutations into HDR repair templates within sequences required by 
CRISPR/Cas9 for targeting (Figure 25B). These simple repair template 
modifications can increase editing accuracy up to 10-fold per allele, and therefore 
assuming independent allelic editing, may increase the probability of accurately 
editing both alleles in a single cell by up to 100-fold, which, for manual clone picking, 
can make the difference between a practical versus impractical genome editing 
experiment. Furthermore, we found that in most cases CRISPR/Cas9 editing in 
iPSCs is bi-allelic, because non-HDR edited alleles are virtually always disrupted by 
indels caused by NHEJ. Therefore, the only way to generate precise accurately 
edited iPSCs was to introduce CRISPR/Cas-blocking mutations at both alleles in the 




Figure 25.  Schematic summarizing editing outcomes and CRISPR/Cas-
blocking mutations in human stem cells. 
A) Following a CRISPR/Cas9-mediated double strand break (1) a majority of 
loci will be repaired through the error-prone NHEJ pathway resulting in 
random indel mutations (2).  In approximately 1-10% of cases HDR 
introduces an intended sequence change provided by a homologous DNA 
repair template (3).  However, this sequence change is accurate (i.e. not 
corrupted by additional CRISPR/Cas9 editing) only in a very small minority of 
cases (as low as 6% as described above) (4).  In the majority of the HDR 
events, the CRISPR/Cas9 complex will re-cut (5) and cause additional indels 
(up to 95% of HDR events at the PSEN1 locus as described above) (6).  (B) 
HDR-mediated editing using an sgRNA targeting near the APPswe  site (light 
blue arrow). Commonly, re-editing after incorporation of the intended APPswe 
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mutation by HDR results in inaccurately edited genomes (orange arrow).  
Introducing CRISPR/Cas-blocking mutations in the guide RNA target 
sequence or PAM prevents further target detection and re-cutting and 
therefore improves HDR accuracy up to 10-fold per allele.   
 
While the introduction of CRISPR/Cas-blocking mutations in coding regions 
should in most cases not cause any unexpected problems, as they can be silent 
(leaving the encoded amino acid unchanged), introducing these additional mutations 
into non-coding regions such as introns, regulatory regions or non-coding RNAs may 
have unwanted consequences.  Furthermore, introducing silent mutations in coding 
sequence at or near splice sites, splicing enhancers or inhibitors may cause 
unwanted effects.  In some cases, the use of additional mutations can be avoided by 
simply choosing guide RNAs where the intended sequence change doubles as a 
blocking mutation (if they lie within the PAM or guide RNA target sequence) but this 
is not universally applicable.  Therefore, there was a need to develop a strategy that 
takes advantage of the efficacy of CRISPR/Cas9 but can be utilized for scarless 
introduction of specific sequence changes by HDR, with the absence of additional 
CRISPR/Cas-blocking mutations.  The following work is adapted from our recent 
publications (Kwart & Paquet et al,. 2017; Paquet & Kwart et al., 2016). 
 
Scarless genome editing using CORRECT 
 
 To address this limitation, we devised a two-step gene editing strategy termed 
“CORRECT” (Consecutive Re-Guide or Re-Cas steps to Erase CRISPR/Cas-
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blocked Targets), which, by taking advantage of CRISPR/Cas-blocking mutations in 
both steps enables efficient “scarless” introduction of a single intended mutation 
sequence, while minimizing clone picking.  Moreover, each step of CORRECT is 
compatible with manipulating cut-to-mutation distance or using a mixed oligo 
approach (see Chapter II) to favor homo- or heterozygous mutation incorporation.  
We have developed two variants of CORRECT: re-Guide (Figure 26A) and re-Cas 
(Figure 26B). 
 
Figure 26.  Schematic describing scarless editing using CORRECT by 
re-Guide and re-Cas. 
(A)  For re-Guide editing a CRISPR/Cas-blocking mutation B in the guide 
RNA target sequence is introduced in addition to the intended mutation M 
with the MB template by HDR. B is subsequently removed in the second 
Phase using a modified guide RNA (re-sgRNA) with Cas9 and the CORRECT 
template, resulting in scarless introduction of the intended mutation M.  (B) 
For re-Cas editing a PAM-altering CRISPR/Cas9 blocking mutation is 
introduced in addition to the intended mutation M with the MB template by 
HDR. The altered PAM is targeted by VRER-Cas9 in Phase 2 resulting in 
scarless introduction of M alone.  In Phase 1 and Phase 2 of both CORRECT 
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variants CRISRP/Cas9-blocking mutations enable efficient and accurate 
scarless mutation incorporation. 
 
In both re-Guide and re-Cas, a blocking mutation B is introduced at both 
alleles together with the intended mutation M by an ssODN template (MB template) 
in the first phase, thus preventing unwanted indels. In the second phase a modified 
“CORRECT template” is used to remove the blocking mutations but preserve the 
intended mutation. While the re-Guide blocking mutations are located in the guide 
RNA targeting sequence and therefore prevent further targeting of the single guide 
RNA (sgRNA), the re-Cas blocking mutation prevents PAM detection by mutating 
the NGG (e.g., to NGCG). Targeted re-editing of the blocked locus is achieved in the 
second phase with a modified set of reagents: For re-Guide, a modified sgRNA (“re-
sgRNA”, targeting the 20bp sequence containing the introduced CRISPR/Cas-
blocking mutations) is used in combination with wildtype (WT) Cas9.  For re-Cas, the 
sgRNA from phase 1 is reused, but WT-Cas9 is replaced by a Cas9 variant (e.g., the 
recently described VRER-Cas9) (Kleinstiver et al., 2015), which targets the modified 
PAM sequence introduced as a blocking mutation in the first step (Figure 26A-B). 
Both variants utilize a modified repair template in phase 2 (CORRECT template), 
which removes the blocking mutations by HDR, but leaves the pathogenic mutation 
in place. By choosing guide RNAs with specific cut-to-mutation distance or using 
mixed repair templates strategically as described in the previous chapter, each step 




Assessing CORRECT feasibility in pooled gene editing experiments 
 
To test the feasibility and efficiency of CORRECT by both re-Guide and re-
Cas we selected two mutations to introduce (APPswe and APP-A673T) by either 
CORRECT variant based on the situation of the mutation site around the PAM or 
sgRNA target sequence (Figure 27).  We also determined restriction endonuclease 
sites that would be uniquely introduced by MB and CORRECT templates, which 
enable RFLP screening for accurately edited clones in each phase of CORRECT 
(Figure 27). 
 
Figure 27.  Experimental design for scarless mutation introduction 
using CORRECT. 
Design of MB and CORRECT ssODN repair templates that were designed for 
re-Guide (A) and re-Cas (B) experiments such that MB and CORRECT 
templates introduce different restriction sites for RFLP screening (shown with 




We began by generating two homozygous “MB” iPSC lines containing (1) the 
homozygous APPswe pathogenic mutation and a CRISPR/Cas-blocking mutation in 
the guide RNA target sequence, or (2) the APP-A673T (a protective APP mutation) 
and NGCG PAM-altering mutations (Figure 28A-B).  Using both the wildtype parent 
iPSCs as well as these MB iPSCs, we showed by SURVEYOR assay, combinations 
of WT-Cas9 and sgRNAs were highly active on their respective targets in wildtype 
unedited iPSCs, whereas combinations of WT-Cas9/re-sgRNA or VRER-
Cas9/sgRNA were not (Figure 28C, E).  In contrast, WT-Cas9/re-sgRNA efficiently 
targeted the modified locus in APPswe MB iPSCs, and VRER-Cas9/sgRNA 
efficiently targeted the modified locus in APP-A673T MB iPSCs (Figure 28C, E). As 
anticipated, WT-Cas9/sgRNAs combinations were virtually inactive on modified loci, 
illustrating efficient blocking of unwanted re-editing after HDR in all cases. We then 
attempted to specifically remove the blocking mutations from both MB cell lines by 
introducing CORRECT-templates and the above-mentioned combinations of WT-
Cas9/re-sgRNA or VRER-Cas9/sgRNA (Figure 28A-B), respectively, and measured 
the resulting allele frequencies by NGS. Strikingly, we detected the expected 
scarless genome editing events with high efficiency (Figure 28D, F). Thus, in this 
preliminary test of CORRECT, we demonstrated this approach enables increased 
editing accuracy provided by blocking mutations in each step, and at the same time 





Figure 28.  Assessing feasibility of CORRECT by pooled re-Guide or re-
Cas editing. 
A-B) Schematics depicting details of the two tested CORRECT approaches: 
In step 1 of re-Guide (A) the APPswe mutation was introduced together with a 
CRISPR/Cas-blocking guide RNA target mutation, which is to then be 
removed in step 2 using a re-sgRNA specific for the mutated sequence and 
WT-Cas9. In step 1 of re-Cas (B) the APP-A673T mutation was introduced 
together with a CRISPR/Cas-blocking PAM-altering NGCG mutation that is 
then removed in step 2 using the VRER Cas9 variant, which specifically 
detects the NGCG PAM.  We chose to incorporate the APP-A673T mutation 
using the very active APP-sgRNA12 to test CORRECT by re-Cas since the 
APPswe mutation is located in the target sequence of this sgRNA, which may 
block re-editing by CRISPR/Cas and could therefore complicate the 
interpretation of results. The APP-A673T mutation lies outside of the target 
sequence (B). In both cases, the blocking mutations were removed using a 
CORRECT ssODN repair template, which restored the original sequence at 
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the site of the blocking mutation (which blocks further re-cutting in this step) 
but retained the pathogenic APP mutation.  C, E) SURVEYOR assays 
showing specificity of WT-Cas9/WT-sgRNAs for WT targets, and WT-
Cas9/re-sgRNA (C) or VRER-Cas9/WT-sgRNA (E) for mutated loci. D, F) 
NGS quantification of genomes with intended incorporation of CORRECT 
templates by HDR in pooled iPSCs (n=2). 
 
Increasing HDR rates as a strategy to improve CORRECT efficiency   
 
 The greatest drawback of CORRECT is the need for two rounds of gene 
editing, single cell sorting, colony picking, screening and expansion.  All of these 
steps together add additional time, albeit most of this time is not “hands-on”.  As 
described in the previous chapter, bi-allelic HDR rates in single cell-derived iPSC 
clones was approximately 2%, which means in the first phase of CORRECT editing 
picking hundreds of colonies to obtain a handful of clones for subsequent quality 
control analysis and expansion prior to the next round of editing.  To minimize 
needing to pick hundreds of colonies more than one time, we sought to determine a 
simple strategy to significantly increase the rate of isolating HDR clones with minimal 
additional optimizations.  One approach we tested was to alter the FACS sorting 
paradigm we had previously established to isolate iPSCs that were electroporated 
with Cas9, sgRNA and ssODN repair templates.  As described above (and in 
Appendix I), we sorted out electroporated iPSCs that were expressing GFP, which 
is co-expressed from the Cas9 plasmid (we assumed GFP+ cells would have also 
taken up sgRNA plasmid and ssODNs as these other DNAs are significantly smaller 
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than the pCas9_GFP plasmid). In all of our early experiments we simply sorted out 
the entirety of the GFP+ population and analyzed all of those cells together, which 
would yield the approximately 2-3% biallelic HDR clones as described above (see an 
example in Figure 29)  
 
Figure 29.  Original approach for FACS enrichment of gene edited iPSCs 
and RFLP analysis. 
A-B) Enrichment of GFP-expressing iPSCs by FACS sorting. Note setup of 
gates based on GFP/DAPI-negative and GFP positive samples. Only live 
single GFP-positive cells were collected (top right panel).  C)  RFLP 
screening strategy (example for APPswe incporporation).  Bi-allelic HDR 
clones are pointed to by red arrows (~2%). HDR/HDR clones were confirmed 





  Given that the overall level of HDR depends on both CRISPR/Cas9 activity as 
well as presence of the ssODN repair template, we hypothesized that perhaps the 
population of cells that have the most CRISPR/Cas9 and repair template would also 
be the cells that have undergone the most number of desired HDR-mediated 
changes.  We tested what HDR rates would be in sorted GFP+ cell populations split 
based on either low, medium, or high GFP fluorescence intensity (Figure 30A).  In 
this proof-of-principle experiment, we chose to target the APPswe locus using APP-
sgRNA12 described in the previous chapter.  After isolating single cell-derived 
colonies and performing RFLP analysis to screen for HDR clones we noticed striking 
differences in the sorted populations (Figure 30B-C).  Specifically, both mono-allelic 
and bi-allelic HDR clones were most rare in the GFP low population (1% for each).  
In the GFP middle population there were more of both mono-allelic (7%) and bi-
allelic (2%) HDR clones.  Most strikingly, however, was the GFP high population, 
which had a remarkably high number of both mono-allelic (18%) and bi-allelic (17%) 
HDR clones.  Together, in the GFP high population, 47% of all clones picked had 
undergone HDR at one or more alleles. (Figure 30B-C).  These data were exciting, 
as we demonstrated that simply by changing the FACS gating strategy, we could 
dramatically increase the frequency of HDR clones thereby dramatically reducing the 
number of colonies that would need to be picked and screened to identify accurately 
edited iPSCs.  This approach has become an invaluable development that has 
enabled us to rapidly generate isogenic iPSCs by either a one-step or two-step (via 




Figure 30.  Enriching for high GFP intensity in electroporated iPSCs by 
FACS dramatically increases probability of identifying bi-allelic 
accurately edited HDR clones. 
A) FACS gating strategy to sort low, medium, or high GFP+ expressing 
iPSCs.  B) RFLP analysis from GFP low, medium and high expressing 
populations.  Red arrows indicate bi-allelic HDR clones.  Example shown for 
TfiI digestion indicating APPswe incorporation.  C) Quantification of mono-
allelic and bi-allelic HDR clones from 2 96-well plates of picked iPSC clones.  
HDR/HDR clones were confirmed to have accurate mutation incorporation by 
Sanger sequencing (not shown). 
 
Using CORRECT for generation of scarless mutant iPSCs 
 
With the confidence that CORRECT is a feasible method for scarless editing 
gained from the pooled analysis combined with the novel FACS gating approach we 
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identified for making identification of HDR clones more efficient, we set out to fully 
utilize CORRECT by re-Guide and re-Cas to generate scarless homozygous 
APPswe (re-Guide) and APP-A673T (re-Cas) iPSC lines.  We took the two “MB” 
clones we generated (see Figure 28 and Figure 31) and completed the second 
phase of CORRECT by re-editing the MB locus using the “CORRECT template” 
(Figure 31A-B).  After screening single cell-derived iPSC clones by RFLP analysis 
for incorporation of the CORRECT template, we successfully identified a number of 
accurately edited “M clones” that only contain the pathogenic or protective APP 
mutation and no other CRISPR/Cas-blocking mutations.  We picked only a few 
hundred clones in both phases of re-Guide and re-Cas and were able to efficiently 
identify several accurately edited clones in each step (Figure 31C). Taken together, 
this work demonstrates that CORRECT, which, by exploiting the use of highly 
efficacious CRISPR/Cas-blocking mutations in two rounds of genome editing, 
enables accurate, efficient and scarless introduction of specific base changes in 





Figure 31.  Derivation of scarless APP mutant isogenic iPSC clones by 
CORRECT. 
Genotypes of selected re-Guide (A) and re-Cas MB and M clones (B) were 
confirmed by Sanger sequencing.  C) Number of single-cell derived clones 
that had bi-allelic incorporation of the MB or CORRECT template for both re-
Guide and re-Cas experiments, as determined by RFLP assay and confirmed 
by Sanger sequencing. 
 
 
When to use CORRECT: Re-Guide or re-Cas 
 
The first decision to make is whether or not CORRECT is required to achieve 
the desired gene editing outcome.  If scarless editing is not required, for example at 
protein-coding loci where silent CRISPR/Cas-blocking mutations in PAM or sgRNA 
target sequence are effective and compatible (see above), the desired change can 
be achieved in a single round of gene editing without CORRECT. When this is not 
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possible, such as when studying a defined genetic mutation requires scarless 
editing, CORRECT is advisable. 
Next, one should determine whether the re-Guide or re-Cas variation is more 
suitable.  While PAM-blocking mutations utilized by the re-Cas variant may be more 
universally applicable, in our hands the re-Guide variant seemed to yield more 
efficient CORRECT editing (Figure 28D, F and Figure 31C). We therefore 
recommend to choose re-Guide or re-Cas based on the editing efficiencies of the 
available guide RNAs (for example, by performing Surveyor nuclease assays) and 
the position of their targeting site relative to the intended mutation M (Figure 32).  In 
the rare instance that the intended mutation falls within the two guanines of the NGG 
PAM site or within the guide RNA seed sequence (the first 7 to 13 bases upstream 
of the NGG (Jinek et al., 2012; Semenova et al., 2011)) the mutation itself will likely 
be blocking, making re-Guide or re-Cas unnecessary (unless one wishes to 
introduce a specific screening mutation for RFLP analysis).  However, CORRECT 
should be used when the intended mutation is upstream of the guide RNA seed 
sequence or downstream of the PAM.  First, a guide RNA should be chosen that 
minimizes the distance between cut site and intended mutation to ensure efficient 
incorporation (as described in Chapter II).  This also means the distance between 
the intended mutation M and the blocking mutation B should be minimized, as 
increasing the distance between these two mutations, for example by placing them 
on opposite sides of the Cas9 cut site, reduces probability of incorporation of both 
mutations together.  When the intended mutation is located within the first base of 
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the PAM or downstream of it, re-Cas should be utilized, whereas re-Guide should be 
employed when the intended mutation falls within or upstream of the 20-nt guide 
RNA sequence. A useful guide summarizing these experimental design tips is 
highlighted below (Figure 32). 
 
 
Figure 32.  Schematic summarizing criteria for selecting re-Guide versus 
re-Cas CORRECT variants.  
(A) Selection of the re-Guide or re-Cas variant of CORRECT depends on the 
intended mutation M position at the locus being targeted. Asterisk (*): If the 
intended mutation is not blocking, use re-Guide. 
 
Considerations for ssODN design:  MB and CORRECT templates 
 
For both re-Guide and re-Cas, an MB and a CORRECT template should be 
obtained.  These templates can be ordered as custom synthetic oligos ready for use 
with CORRECT.  We use 100-nt ssODN templates centered around the cut site, 
using the sequence of the non-targeted strand, i.e. the strand that has the same 
sequence as the guide RNA, to avoid base-pairing of guide RNA and repair oligo.  
However, recent evidence suggests that HDR repair can be further improved by 
using the sequence of the targeted strand and by optimizing repair template position 
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relative to the edited locus (Richardson et al., 2016). For re-Guide, the MB template 
should contain the intended mutation plus the CRISPR/Cas-blocking mutations in 
the guide RNA targeting site.  For re-Cas, the MB template should contain the 
intended mutation plus the NGG>NGCG (for VRER Cas9) PAM-altering 
CRISPR/Cas-blocking mutation.  For both re-Guide and re-Cas, the CORRECT 
template should retain the intended mutation sequence, but replace the 
CRISPR/Cas-blocking mutations with the original guide RNA or NGG PAM 
sequence (for re-Guide and re-Cas, respectively).  
 Ultimately, Sanger sequencing of the edited loci of individual iPSC clones 
must be performed to confirm accurate CORRECT editing.  However, to minimize 
the number of clones to be sequenced, we recommend incorporating restriction 
endonuclease sites by the intended or CRISPR/Cas-blocking mutation(s) in both the 
MB and CORRECT templates.  Alternatively, loss of a restriction endonuclease site 
by incorporation of either MB or CORRECT templates can be used to indicate 
accurately edited clones, however this may lead to identification of more false-
positive clones since indel mutations arising from NHEJ could also disrupt a 
restriction site if near the Cas9 cut site.  Following RFLP analysis only clones that 
demonstrate the expected DNA fragment lengths on an agarose gel will be 
sequenced. If necessary, unwanted additional mutations introduced in the MB 
template for screening purposes in the first round of editing can be removed with the 
CORRECT template in the second round of editing, and loss of restriction 
endonuclease cleavage can be used to identify edited clones.  
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Using re-Guide allows changing multiple bases in the guide RNA target 
sequence, which gives more flexibility for the introduction and/or removal of a 
restriction endonuclease site for clone screening by RFLP analysis. re-Cas requires 
a specific mutant Cas9 PAM in the MB template (e.g., NGCG for the VRER-Cas9), 
which may make the introduction of restriction endonuclease sites for screening 
more difficult to determine.  As illustrated above, we have applied re-Cas to 
introduce the A673T mutation in the wildtype APP locus with sgRNA12, and used 
RFLP-mediated screening to identify MB and M clones: First, we incorporated the 
VRER PAM and A673T mutation by the MB template (Figure 27).  These two 
changes (TGGATGC > TGCGTAC) generated a RsaI site (GTAC). In the second 
phase of editing, correcting the PAM back to the wildtype TGG sequence with the 
CORRECT template (TGCGTAC > TGGATAC) introduced a BciVI site (GGATAC). 
Alternatively, we could have used several other strategies.  For example, we could 
have used APP sgRNA2 for re-Cas (used for re-Guide scarless introduction of 
APPswe) by changing the wildtype PAM to incorporate the VRER PAM in the MB 
template (CTCAGGATAT>CTCCGCGTAT), which introduces a BstUI site (CGCG), 
and removes a DdeI site (CTNAG). The DdeI site can then be restored by correcting 
the PAM back to the wildtype AGG sequence by the CORRECT template.  In 
summary, we believe CORRECT is a framework for efficient scarless genome 





Applications of CORRECT and comparison with other methods 
 
Here we present the use of CORRECT for scarless introduction of disease-
associated homo- and heterozygous mutations into wildtype human iPSCs.  We 
have demonstrated that generating knock-in mutant iPSCs cell lines makes it 
possible to study disease-associated mutations in disease-relevant cell types, which 
has great impact on the broader field of disease modeling (Paquet et al., 2016).  
Moreover, CORRECT makes it possible to use CRISPR/Cas9-mediated gene 
editing to efficiently edit non-coding genomic sequence, where silent blocking 
mutations cannot be utilized.  CORRECT also provides alternatives for more 
effective editing of coding sequence, especially in cases where using silent blocking 
mutations is not possible either due to incompatibility with the reading frame or 
insufficient blocking activity.  Instead of generating knock-in cell lines, researchers 
may choose to obtain patient samples with known genomic mutations.  To generate 
isogenic wildtype control cell lines, CORRECT can easily be modified to replace 
patient-specific mutations with wildtype sequence by incorporating these 
modifications in the MB and CORRECT templates.  Furthermore, CORRECT has 
the added benefit that customizable sequences, such as restriction endonuclease 
recognition sites, can be introduced into MB templates, which allow simple RFLP 
screening analysis to identify correctly targeted clones.  
Gene editing with CORRECT is advisable when scarless editing is imperative 
to faithfully study a defined genetic mutation. If silent blocking mutations are effective 
and compatible with the locus, the desired change can be achieved in a single round 
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of gene editing without CORRECT. When scarless mutation introduction is desired, 
this can also be achieved in a single step using a repair ssODN containing only the 
intended sequence change, but no blocking mutation.  However, except in the rare 
case that the intended mutation doubles as a CRISPR/Cas-blocking mutation we 
would not recommend the latter strategy, because accurate editing efficiencies could 
be reduced up to 10-fold per allele (see Chapter II).  Although accurately edited 
clones can still be identified at this low editing efficiency by other cellular enrichment 
strategies such as sib-selection (Miyaoka et al., 2014), this requires laborious 
sequential cellular selection, clonal expansion and genomic analysis and therefore 
the overall time required for this approach is similar to CORRECT editing.    
Alternatively, one could use a different scarless genome editing approach 
such as the piggyBac transposon, which has been shown to be effective in human 
iPSCs (Yusa, 2013).  Similar to CORRECT, this method requires two rounds of 
genetic manipulation, clone picking and screening. Therefore, generating scarlessly 
edited clones with piggyBac would take approximately the same time as CORRECT.  
Since the piggyBac transposon system uses antibiotic resistance markers for 
screening, it facilitates isolating larger genomic changes, such as gene or exon 
insertions, or deletion of protein domains, which are usually very rare events. 
However, for smaller edits, such as base changes, CORRECT performs better in our 
hands for several reasons:  (1) transfection of the large piggyBac repair template in 
iPSCs and its genomic incorporation is inefficient; (2) editing with piggyBac requires 
a TTAA sequence near the target site of interest, which is more restrictive than the 
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NGG PAM requirement for Cas9 and could severely limit the number of targetable 
loci; (3) construction and cloning of the piggyBac targeting vector containing the 
intended sequence changes is laborious compared to simply ordering custom 
synthetic ssODNs, which are used as repair templates for CORRECT.  Finally, 
excision of the piggyBac transposon can be inefficient and lead to integration 
elsewhere in the genome, which requires subsequent southern blot analysis for 
quality control. 
More recently, a new CRISPR-based technology has been developed for 
scarless mutation incorporation called “base editing” (Gaudelli et al., 2017; Komor et 
al., 2016).  Briefly, this approach negates the necessity for Cas9-mediated DSB 
generation.  Specifically, a catalytically inactive version of Cas9 is tethered to a 
cytidine or adenosine deaminase, which can mediate C-G to A-T or A-T to C-G 
changes without DNA cleavage when targeted to a genomic locus by an sgRNA.  
This approach has its many advantages, namely, by bypassing DNA cleavage there 
is no NHEJ that occurs and therefore no problem of additional unwanted indels 
alongside desired changes or need for CRISPR/Cas-blocking mutations.  This 
means base editing can be performed in a single round of gene editing.  Although 
the efficacy of base editing in human stem cells remains to be adequately tested, 
studies in other cell types have shown high C to T and A to C editing efficiencies (up 
to 75% of cells).  While base editing holds great promise for use wide use in multiple 
scientific fields, it does have its disadvantages over our described one- or two-step 
gene editing approaches using Cas9-mediate HDR.  Specifically, the greatest 
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disadvantage is that base editing is unspecified, only occurring between a predicted 
sequence range near the sgRNA target site.  To adjust the editing window, different 
deaminases tethered to inactive Cas9 must be used.  This of course means that in 
order to be able to use base editing one would need the guide RNA sequence to 
match the necessary location for the optimal base editing range for a given 
deaminase, which may not always be possible depending on the genomic sequence.  
Furthermore, because the exact base being edited cannot be specified (only a 4-5 
nucleotide window (Gaudelli et al., 2017; Komor et al., 2016)) every single clone 
picked will have to be sequenced, as there is no way to introduce specific RFLP 
screening sites in addition to the desired mutation by base editing.  Lastly, while 
base editing may be effective for engineering a single C-G to A-T or A-T to C-G 
mutation, introducing multiple specific base changes (such as the double base 
change seen for the APPswe mutation) is difficult without two rounds of base editing.  
Therefore, while base editing holds great promise, any desired gene-edit involving 
more than one base change at this point should be done using CRISPR/Cas9-
mediated HDR in a one-step (using blocking mutations) or two-step (using 
CORRECT) approach.    
 
Limitations of CORRECT 
 
CORRECT currently works best in dividing cells in culture, limiting its use in 
vivo in animal models. The two rounds of genomic manipulations and clone picking 
required to generate pure cultures of accurately edited human stem cell lines with 
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CORRECT take approximately 3 months, twice as long as scarless editing without 
the benefit of blocking mutations. However, because CORRECT may increase the 
editing efficiency up to 100-fold, the longer time required is made up for by less 
manual labor, especially during the clone picking steps. In an extreme case, 
CORRECT would require picking only a couple hundred clones, while tens of 
thousands may be required if a CRISPR/Cas9 blocking-mutation strategy is not 
used. In the future CORRECT may be further streamlined by multiplexing both 
editing steps in a single cell pool, for example by using cell lines with inducible forms 
of wildtype or variant Cas9 (Dow et al., 2015).  
The two rounds of genome editing required for CORRECT may potentially 
increase the risk of off-target modifications. However, this potential increase will 
likely not expand the number of potential off-target sites, since the same (for re-Cas) 
or very similar (for re-Guide) guide RNAs are used in both editing steps.  
Furthermore, since using blocking mutations significantly increases editing accuracy, 
CORRECT facilitates isolating multiple clones for phenotypic comparison.  Finally, 
the VRER Cas9 variant used in phase 2 of re-Cas has only more recently been 
engineered and is far less studied.  Therefore, the degree of on-target activity and 
specificity at multiple genomic loci in a variety of cell types remains to be elucidated.  
We expect that as CRISPR/Cas9 technologies are further developed, variant Cas9 
enzymes will be enhanced with improved on-target activity and specificity 




Our two variants of CORRECT offer the choice of either using well-
characterized wildtype Cas9 in both steps together with a modified guide RNA (re-
Guide) or a Cas9 variant with altered PAM specificity in step 2, which benefits from 
using the same sgRNA in both steps, and potentially more robust blocking effects by 
the PAM mutation (re-Cas). In our laboratory, however, we have noticed reduced 
rates of HDR using the VRER Cas9 compared to wildtype Cas9 when employing 
CORRECT to target the amyloid precursor protein (APP) gene (see Figure 28D, F 
and Figure 31C).  Prior to choosing CORRECT by re-Guide or re-Cas the HDR 
efficiency for wildtype and mutant Cas9 can be determined at the intended locus of 
interest in a pool of transfected cells by either NGS detection of intended sequence 
incorporation (Paquet et al., 2016) or RFLP detection of a restriction endonuclease 
site introduced by an HDR template (Cong et al., 2013).  We recommend using the 
CORRECT variant that yields the highest HDR rates to minimize manual clone 
picking during each gene editing phase. Regardless of Cas9 variant used, 
CORRECT can be combined with novel NHEJ inhibitor and HDR improvement 
strategies (Chu et al., 2015; Lin et al., 2014; Maruyama et al., 2015; Richardson et 
al., 2016; Yu et al., 2015), as well as other recently published cellular enrichment 
methods (Miyaoka et al., 2014) to minimize clone picking and improve recovery of 






CHAPTER IV:  STUDYING ISOGENIC MUTANT APP AND PSEN1 
IPSC-DERIVED NEURONS REVEALS CONSERVED CELLULAR AD 
MECHANISMS 
 
Background and Rationale  
  
 The “amyloid cascade hypothesis” is the most prominent theory describing 
the pathogenesis of AD (Hardy and Higgins, 1992), and places Ab as the early key 
initiator of all downstream changes necessary for the development of AD.  This 
notion is most significantly supported by genetics, as more than 200 fAD mutations 
in APP, PSEN1 and PSEN2 – all genes associated with the generation of Ab – have 
been described to date.   While the effects of many of these mutations on Aβ 
production have been studied extensively, a common unifying mechanism by which 
fAD mutations lead to the development of AD has yet to be determined.  For 
example, fAD mutations in APP appear to have variable effects on Aβ production.  
fAD caused by APP duplication or N-terminal mutations, such as the widely studied 
APP Swedish mutation (APPswe), indiscriminately increase Aβs (Citron et al., 1992; 
Mullan et al., 1992; Rovelet-Lecrux et al., 2006). In contrast, APP C-terminal 
mutations that cluster around the g-secretase processing site appear to increase the 
amount of longer, more hydrophobic Aβs (such as Ab42), relative to shorter Aβs 
(such as Ab40), resulting in an increase in the Aβ 42:40 ratio with variable effects on 
total Ab production (Eckman et al., 1997; Herl et al., 2009) (Figure 7). Similarly, it is 
now widely agreed upon that mutations in PSEN1 also act to increase the Aβ 42:40 
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ratio, in some cases even decreasing total Ab production (Borchelt et al., 1996; 
Citron et al., 1992; Duff et al., 1996; Scheuner et al., 1996b). However, whether 
these relative changes correspond with increased total Ab42 production, decreased 
Ab40 production, or a combination of both remains debated (Kelleher and Shen, 
2017b).  Taken together, it remains unclear whether specific changes in APP 
processing are common amongst all APP and PSEN1 fAD mutations, and whether 
these potential common changes may be disease-relevant. 
 Aberrant changes in intracellular trafficking and the endocytic system have 
become another plausible common underlying pathological mechanism in AD.  
Genome-wide association studies and other human genetics approaches have 
consistently identified variants in genes associated with endocytic trafficking to be 
significantly associated with sAD risk (Giri et al., 2016; Karch and Goate, 2015).  
Endosomal pathologies have also been observed in post-mortem sAD patient brains 
and more recently in some cellular fAD models, and found to precede Aβ 
accumulation  (Cataldo et al., 2000; 2008; Israel et al., 2012; Raja et al., 2016; 
Woodruff et al., 2016).  Some studies have reported that early endosomal 
abnormalities seen in AD, such as enlargement of Rab5+ early endosomes, may be 
driven not by Aβ, but by b C-terminal fragments of APP (b-CTFs) (Jiang et al., 2010; 
Kim et al., 2015; Woodruff et al., 2016; Xu et al., 2016), but others have reported Aβ-
dependent endocytic trafficking defects (Treusch et al., 2011).  These studies are 
confounded by their use of non-human and/or non-neuronal cellular systems that 
rely on massive overexpression of AD-associated proteins.  Consequently, it 
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remains to be determined in human neurons with physiologically relevant APP and 
PSEN1 protein expression whether early endosomal abnormalities are a broadly 
unifying disease-relevant phenotype associated with different fAD mutations. 
 With these open questions in mind we took advantage of our established 
CRISPR/Cas9 gene editing frameworks described in Chapter II and Chapter III to 
generate and study a comprehensive panel of isogenic homozygous and 
heterozygous APP and PSEN1 fAD mutant human iPSCs.  Upon differentiation into 
human cortical neurons expressing APP and PSEN1 at endogenous levels, we 
tested whether these mutations result in any common disease-associated 
phenotypes. To address this question in an unbiased manner, we performed global 
transcriptomic profiling of APP and PSEN1 mutant neurons, which revealed common 
dysregulation in overlapping networks of AD-implicated genes as well as in 
endocytosis-associated genes. Directed by these global pathway changes, we 
identified functional early endosomal abnormalities in every homozygous pathogenic 
fAD mutant iPSC-derived neuron line we generated, as measured by Rab5+ early 
endosome enlargement, suggesting an effect of altered APP processing on the 
endosomal system.  We show that while APP and PSEN1 mutations have 
discordant effects on the precise processing of APP and production of Ab peptides, 
all fAD mutations studied cause a robust accumulation of longer Ab species (Ab43 
and/or Ab42) as well as b-CTF.  Taking advantage of established small molecules, 
we show that early endosome enlargement could be rescued by inhibition of b-
secretase (BACE), but not modulation of γ-secretase.  Importantly, we also confirm, 
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for the first time in human cortical neurons, that AD-associated Rab5+ early 
endosome enlargement is associated specifically with endogenous accumulation of 
b-CTF, and not longer Ab peptides or other APP CTF fragments.  Together, our 
study amplifies the relevance of Ab-independent endosomal defects as a common, 
early pathological feature of fAD, and supports growing evidence that β-CTF may be 
a significant contributor to AD pathology. 
 
Unbiased molecular profiling of fAD mutant neurons reveals transcriptional 
dysregulation of AD- and endocytic-associated genes. 
 
As outlined in Chapter II, we employed our novel CRISPR/Cas9 gene editing 
framework (Kwart et al., 2017; Paquet et al., 2016) to introduce two of the most 
widely studied fAD mutations (APPswe and PSEN1-M146V) in wildtype human 
iPSCs. In a preliminary analysis of differentiated disease-vulnerable neurons (details 
of differentiation can be found in Appendix I), we noticed disease-associated Ab-
related phenotypes that were different in APPswe neurons compared to PSEN1-
M146V neurons (Paquet et al., 2016).  To investigate whether these two different 
canonical fAD mutations result in any common disease-relevant phenotypes we 
performed unbiased global transcriptomic profiling of wildtype, homozygous APPswe 
and homozygous PSEN1-M146V iPSC-derived neurons by RNA sequencing (RNA-
seq).  Additionally, to exaggerate cellular and molecular changes in pathways 
affected by both APP and PSEN1 mutations, we profiled neurons from an additional 
Swe/M146V “double knock-in” iPSC line (also shown as “dAP” below) that we 
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generated (Figure 33), which contains both homozygous APPswe and PSEN1-
M146V fAD mutations. 
 
Figure 33.  Strategy for molecular profiling of isogenic APP and PSEN1 
fAD mutant neurons. 
Schematic describing strategy for generation of Swe/M146V double knock-in 
iPSCs and molecular profiling strategy.  APPswe and PSEN1-M146V iPSCs 
were generated using the CIRSPR/Cas9 strategy outlined in Chapter II (and 
see Appendix I).  Swe/M146V iPSCs were generated by re-editing PSEN1-
M146V homozygous iPSCs and introduction of the APPswe mutation using 
CRISPR/Cas9.  All iPSCs were differentiated and cultured until DIV80 then 
were used for molecular profiling. 
 
 We isolated RNA from mature (days in vitro 80 (DIV80)) wildtype and mutant 
iPSC-derived neurons and performed RNA sequencing (RNA-seq) (see Appendix I 
for sequencing library quality control analyses). We wished to determine at the 
whole-genome level what types of genes and gene pathways are being differentially 
regulated in mutant cells.  Therefore, we performed a differential expression analysis 
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to decipher all significantly differentially expressed genes in the three different 
mutant neuron cell lines compared to wildtype (FDR < 0.05 and |Log2FC| >1) 
(Figure 34A).  Intriguingly, over 32% of all differentially expressed genes (856 
genes) were common between one or more mutant cell lines, suggesting 
overlapping gene expression and pathway perturbations may be an underlying 
feature of both APP and PSEN1 fAD mutation pathogenicity (Figure 34B).  To get a 
handle on what these common differentially expressed genes are, we performed an 
unbiased gene-ontology (GO) pathway analysis on the 856 genes commonly 
dysregulated in the mutants compared to wild-type. The top most significantly 
enriched GO-terms were related to synaptic functioning, GPCR signaling, and 
neuronal development (Figure 34C).  Interestingly, we noticed that a handful of the 
genes in the top Synaptic Signaling GO-term hit were genes known previously to be 
involved in AD (e.g., CLU, APOE, SORL1, GRIN3A, etc.). This lead us to wonder 
whether there may be a more generalized change in expression of known AD-
associated genes in fAD mutant neurons compared to wildtype.  To assess 
expression patterns of AD-associated genes in our fAD mutant cell lines we curated 
a list of 114 putative “AD genes”, with identified AD-linked variants as determined by 
GWAS (downloaded from https://www.ebi.ac.uk/gwas/) (see Appendix I for complete 
list). We then determined the base Mean expression of these AD genes in our data 
to give us an overview of similarities and differences in AD gene expression between 
genotypes. Hierarchical clustering analysis revealed that P1SEN1-M146V and 
Swe/M146V double mutant neurons had more similar expression patterns of AD 
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genes, while APPswe neurons clustered more closely with wildtype neurons (Figure 
34D).   All mutant neurons were notably less correlated with wildtype cells.  By 
performing a hypergeometric statistical test, we found that AD genes were 
significantly enriched amongst all genes differentially expressed in APPswe, PSEN1-
M146V and Swe/M146V neurons compared to wildtype.  In fact, between 20-25% of 
analyzed AD genes were differentially expressed in each mutant cell line compared 
to wildtype (Figure 34E-G).  Individual gene expression of these 39 differentially 
expressed AD genes is shown (Figure 34F).  These data suggest APP and PSEN1 





Figure 34.  RNA-seq differential expression analysis reveals AD-
associated genes as dysregulated in fAD mutant neurons. 
A) MA-plots depicts the Log2FC (Y axis) and expression (TPM, X axis) of 
differentially expressed genes in mutant neurons compared to wildtype cells. 
B) Venneuler diagram showing the overlap of significantly differentially 
enriched genes in mutant neurons as compared to wild-type. Determined by 
R package DESEQ2. FDR < 0.05 & absolute Log2FC > 1.  C) Metascape GO 
analysis, plotted significance (log10 q-value) of top 500 enriched GO terms 
determined by overlapping gene lists (B).  X-axis = Ranked GO-term number; 
Y-axis = -log10 q-value per GO-term. D) Heatmap of p value for Euclidean 
distance analysis of AD gene expression in wildtype and mutant neurons. 
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Each tile represents a single replicate (n=3); as expected replicates from each 
genotype cluster closest together.  Scale represents the Euclidean distance 
between samples, calculated using the rlog-transformed values to avoid 
dominating the distance measure by a few highly variable genes.   E) Plotted 
hypergeometric p-values of AD genes enriched within all significantly 
differentially expressed genes (FDR < 0.05 & absolute LFC > 1).  Numbers in 
bars indicate number of AD genes enriched in differentially expressed gene 
sets.  F) Heatmap depicting expression (Log2 TPM) of all AD genes 
significantly differentially expressed in mutant neurons (from E).  G) Table of 
AD genes differentially expressed in mutant cells compared to wildtype.  
Column headers indicate in which mutant neurons listed AD genes are 
differentially expressed (all compared to wildtype). Determined by R package 
DESEQ2. FDR < 0.05 & absolute Log2FC > 1.  dAP = Swe/M146V double 
mutant. 
 
 Given that we were most interested in deciphering the molecular pathways 
commonly perturbed by both APP and PSEN1 mutations, we next sought to 
determine what gene expression differences are driven by APP and PSEN1 
mutation combination in Swe/M146V double mutant neurons compared to APPswe 
and PSEN1-M146V neurons alone.  Using our differential expression analysis data, 
we compared Swe/M146V neurons to APPswe and PSEN1-M146V single mutant 
neurons independently and noticed a considerable number of differentially 
expressed genes in each comparison.  There were substantially more significantly 
differentially expressed genes that either increased or decreased expression in 
double mutant neurons compared to single mutant neurons than in single mutant 
cells compared to wildtype.  For example, we found PSEN1 mutant cells had 963 
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differentially expressed genes compared to wildtype cells, but over 1.5 times more 
(1465 genes) when compared to Swe/M146V cells (Figure 35A-B compared to 
Figure 34A).  These patterns of gene expression differences suggest that the 
combination of fAD mutations in Swe/M146V neurons may be exaggerating or 
augmenting AD-relevant transcriptomic changes.  Interestingly, 60-70% of genes 
differentially expressed in double mutant cells compared to single mutant cells are 
non-overlapping, implying some unique “double-mutant effect” gene expression 
signature may exist compared to when mutations are expressed alone (Figure 35C).   
To better understand the nature of these changes, we performed another GO 
analysis, this time inputting the list of all genes significantly differentially expressed 
in Swe/M146V cells compared to single mutant neurons.  Remarkably, we noticed 
that of all the significant GO-terms identified a substantial number were associated 
with endocytosis and lipid trafficking (Figure 35D).  Of these enriched terms, the 
largest gene-sets included the annotated ontologies “early endosome” (P = 10-4), 
“endocytic vesicle” (P = 10-8) and “early endosome membrane” (P = 10-4).  
Moreover, between 20 and 30% of all genes that comprise these GO-terms were 
differentially expressed in our analysis. Together, approximately 100 unique 
differentially expressed endocytic-related genes were included in these enriched 
gene sets (see complete list of genes in Appendix I).  When we compared 
expression of these endocytic genes across all genotypes by hierarchical clustering, 
we found that PSEN1-M146V and Swe/M146V neurons cluster more closely 
together than with APPswe or wildtype neurons (Figure 35E), implying a similar 
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pattern of endocytic gene expression between these two genotypes.  Interestingly, 
APPswe neurons showed patterns of endocytic gene expression that were markedly 
uncorrelated with PSEN1-M146V and Swe/M146V neurons (see differences in 
Figure 35E heatmap), supporting the idea that while both fAD mutations may 
commonly affect endocytosis and endosomal related processes, they may do so by 
influencing different molecular pathways.  Expression levels of the top 45 expressed 
endocytic genes is shown in Figure 35F.   
Intriguingly, in addition to pinpointing the endocytic pathway, by comparing 
genes differentially expressed in double mutant neurons compared to single mutant 
neurons we also identified a substantial number of significantly enriched GO-terms 
associated with known AD processes and neurodegeneration (Figure 35G).  These 
data indicate that the combination of APP and PSEN1 mutations may further interact 
to activate AD-relevant downstream molecular neurodegenerative signaling 
pathways.    Taken together, these transcriptomic analyses indicate that our APP 
and PSEN1 fAD mutant human neurons demonstrate a common signature of AD-






Figure 35.  Genes differentially expressed in Swe/M146V neurons are 
associated with endocytic processes. 
A-B) Volcano plots representing adjusted p value (-Log10) over the Log2 fold 
change of Swe/M146V neurons compared to PSEN1-M146V (A) and 
APPswe (B) neurons. Each dot is representative of a gene ID. Differential 
analysis performed with R package DESEQ2.  Blue and purple dots represent 
genes that show significantly increased or decreased expression, 
respectively.  C) Venneuler diagram showing the overlap of significantly 
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differentially enriched genes in Swe/M146V mutant neurons as compared to 
PSEN1-M146V and APPswe neurons. Determined by R package DESEQ2. 
FDR < 0.05 & absolute Log2FC > 1.  D) Metascape GO analysis, plotted 
significance (log10 q-value) of enriched endocytic/trafficking GO terms 
determined by gene lists derived from (C).  Y-axis = -Log10 q-value per GO-
term.  Size of spot and number indicate number of differentially expressed 
genes enriched in each GO term.  E) Heatmap of p value for Euclidean 
distance analysis of endocytic gene expression in wildtype and mutant 
neurons.  Each tile represents a single replicate (n=3); as expected replicates 
from each genotype cluster closest together.  Scale represents the Euclidean 
distance between samples, calculated using the Log-transformed values to 
avoid dominating the distance measure by a few highly variable genes. F) 
Heatmap depicting expression (Log2 TPM) of top 45 expressed endocytic 
genes significantly differentially expressed in Swe/M146V mutant neurons 
compared to single mutant cells (from D).  dAP = Swe/M146V double mutant; 
PS = PSEN1-M146V. 
 
 
Early endosomal abnormalities are a unifying common phenotype in multiple 
APP and PSEN1 fAD mutant iPSC-derived neurons.  
 
 Although APPswe and PSEN1-M146V are two of the most widely studied 
mutations, they represent only a small fraction of the hundreds of fAD mutations that 
have been identified, many of which alter amino acids within different gene domains 
and contribute to variable clinical manifestations (Giri et al., 2016; Shea et al., 2016).  
In order to better understand whether endosomal dysfunction is a shared common 
phenotype across a variety of fAD mutations, we set out to generate a large and 
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comprehensive panel of isogenic mutant human iPSCs. We strategically chose to 
include in our study 3 different known APP mutations that are differentially 
distributed across the APP gene and predicted to differentially influence b-secretase- 
(APPswe), a-secretase- (APP-A692G) or g-secretase- (APP-V171G) related 
processing (Chartier-Harlin et al., 1991; Hendriks et al., 1992; Mullan et al., 1992) 
(Table 2 and see schematic in Figure 7).  Four PSEN1 mutations (PSEN1-M146V, 
PSEN1-L166P, PSEN1-M233L and PSEN1-A246E) distributed across the gene with 
different predicted severities were also selected for our analyses (Aldudo et al., 
1999; Alzheimer's Disease Collaborative Group, 1995; Moehlmann et al., 2002; 
Sherrington et al., 1995) (Table 2). Mutant iPSC lines were all generated by 
CRISPR/Cas9-mediated mutation knock-in using our established common wildtype 
parental cell line (see Appendix I), therefore making all additional cell lines studied 
completely isogenic and avoiding any contribution of non-specific phenotypes due to 
background genetic heterogeneity. iPSCs were then differentiated into human 
cortical neurons to study endosomal phenotypes (differentiation procedure described 




Table 2.  List of all isogenic mutant iPSC lines and mean age of AD 
onset. 
 
1- From DIAN study (Ryman et al., 2014) 
2- From (Moehlmann et al., 2002) 
 
It has now been demonstrated in a variety of different model systems that 
early endocytic dysfunction, such as an aberrant enlargement of Rab5+ early 
endosomes, may be a common upstream pathological hallmark feature of AD 
(Cataldo et al., 2000; 2008; Israel et al., 2012; Raja et al., 2016; Woodruff et al., 
2016).  However, it is unclear whether early endosome pathology can be assayed in 
isogenic mutant human iPSC-derived neurons, and not known whether it is common 
to multiple different APP and PSEN1 fAD mutations.  To explore this, we used high 
resolution and quantitative immunofluorescence to study Rab5+ early endosome 
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morphology in all our APP, PSEN1 and double knock-in mutant iPSC-derived 
neurons.  Strikingly, we noticed in all homozygous mutant neurons a significant 
increase in the size of Rab5+ early endosomes (Figure 36A-B), which also 
corresponded with increased fluorescence intensity (Figure 36C).  Interestingly, we 
did not see any consistent differences in the total number of Rab5+ early 
endosomes per cell across our panel of isogenic mutant iPSC-derived neurons 
(Figure 36D).   This endosome size change is specifically driven by an overall 
decrease in the number of small endosomes (<0.5µm2) and a much larger increase 
in the number of larger (>1µm2) endosomes (Figure 36E).  Interestingly, Rab5+ 
endosome enlargement was significantly exaggerated in the Swe/M146V double 
knock-in neurons compared to single homozygous and wildtype cells (Figure 36A-
B), suggesting the mutations in these two genes may pathologically converge on a 
common cellular mechanism. While heterozygous mutant cells did not all 
demonstrate significant differences in mean endosome area or frequency of 
enlarged endosomes, many heterozygous mutant neurons displayed intermediate 





Figure 36.  Early endosomal abnormalities are a shared APP-dependent 
common phenotype in APP and PSEN1 fAD mutant iPSC-derived 
neurons. 
A) Representative immunofluorescence images from homozygous mutant 
human neurons stained for Rab5 (green), MAP2 (red) and Hoechst (blue).  
The sizes of Rab5+ puncta were quantified using Imaris. B) All mutant cells 
demonstrate increased mean Rab5+ endosome size compared to wildtype. 
C) Mean fluorescence intensity of Rab5+ punta increases in all fAD mutatnt 
cells compared to wildtype.  D) Total number of Rab5+ early endosomes per 
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cell does not consistently change in each fAD mutant line.   Values represent 
mean ± SEM.  **P < 0.05 and ***P < 0.001, ****P < 0.0001, one-way ANOVA 
with comparison to wildtype.  ##P < 0.05 and ###P < 0.001, ###P < 0.0001, one-
way ANOVA with comparison to Swe/M146V.  E) The size distribution of 
Rab5+ puncta of all fAD mutant neurons compared to wildtype shows a shift 
from smaller to larger Rab5+ early endosomes.  Values represent mean ± 
SEM and P values represent two-way ANOVA with comparisons to wildtype.  
Mean endosome size (F) and frequency of large endosomes (G) of all 
heterozygous APP and PSEN1 mutant neurons compared to wildtype.  
Values represent mean ± SEM.  **P < 0.05 and ***P < 0.001, ****P < 0.0001, 
one-way ANOVA with comparison to wildtype.  ##P < 0.05 and ###P < 0.001, 
###P < 0.0001, one-way ANOVA with comparison to Swe/M146V WT = 
wildtype. n=12-20 cells analyzed.  Scale bar, 10µm. 
 
APP and PSEN1 fAD mutations increase accumulation of longer Abs and APP 
b-CTFs in human neurons. 
 
It is widely thought that fAD mutations contribute to AD pathogenesis by 
aberrantly affecting APP processing and Ab production.  Therefore, we next sought 
to characterized how APP and PSEN1 mutations affect APP metabolism and to 
pinpoint which APP peptides may represent a common correlate associated with 
endosomal dysfunction. APP is cleaved initially and most often by a-secretase at the 
cell surface, which, by cleaving within the amyloid portion of the protein, precludes 
the generation of Ab (Figure 37A).  To generate Ab, APP is first endocytosed, and 
within an early endocytic vesicle is subsequently cleaved by b-secretase cleavage 
enzyme (BACE), as the activity of BACE is favored by the acidic endocytic 
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environment.  BACE cleavage of APP produces APP b-CTF, which is then further 
processed by g-secretase to yield Abs of varying length (Figure 37A-B).  It is now 
widely accepted that the mechanism by which γ-secretase cleaves APP b-CTF is 
processive in nature. In short, γ-secretase cleaves b-CTF in 3-4 amino acid 
increments generating Abs of different lengths, most commonly 38 or 40 amino 
acids in length (Figure 37B) (Szaruga et al., 2017; Takami et al., 2009).  
When we analyzed various species of Ab secreted by mutant human cortical 
neurons, we noted only one common trend across all pathogenic fAD mutant lines.  
Levels of longer Abs, namely Ab43 and/or Ab42, were increased in cell culture 
supernatants of all APP and PSEN1 mutant neurons compared to wildtype cells 
(Figures 37C-D).  Levels of shorter Ab, however, were not changed in a consistent 
way across APP and PSEN1 mutant neurons. Specifically, all APP mutants had 
increased Ab38 compared to wildtype, whereas all PSEN1 mutants significantly 
decreased Ab38 (Figure 37E). Similarly, the APPswe and APP-A692G mutants 
increased Ab40, whereas all PSEN1 mutants decreased Ab40 (Figure 37F). 
Interestingly, the APP-V717G mutant, which lies at the g-secretase cleavage site, 
decreased Ab43 and Ab40 compared to wildtype, highlighting how this mutation 
shifts g-secretase processing toward the Ab42 and Ab38 pathway (Figures 37B, D 
and F). When levels of all Ab species measured were summed together to quantify 
total Ab levels compared to wildtype, APP and PSEN1 mutant cells again had 
opposite effects, with APPswe and APP-A692G mutants increasing total Ab, and all 
PSEN1 mutants decreasing total Ab (Figure 37G).  
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We next calculated the Ab 42:40 ratio, which has been widely used to 
determine AD severity in cases of both sAD and fAD.  We observed that the 
APPswe and APP-A692G mutants had no effect on the Ab 42:40 ratio, whereas the 
APP V717G mutants, and all PSEN1 mutants increased the Ab 42:40 ratio (Figure 
37H).  PSEN1-L166P most dramatically affected the Ab 42:40 ratio (~14-fold 
increase compared to wildtype), which corresponds with how clinically severe this 
mutation is known to be (age of onset in 20’s, Table 2). Interestingly, Swe/M146V 
double knock-in neurons demonstrated an Ab profile consistent with combinatorial 
effects of both the APPswe and PSEN1-M146V mutation, i.e., Swe/M146V neurons 
had substantially higher levels of all Ab peptides measured, as well as elevated Ab 





Figure 37.  APP and PSEN1 mutations increase production of longer Ab 
peptides. 
A) Schematic of APP processing and representation of distribution of APP 
mutations engineered as described in Table 1. B) Schematic of g-secretase 
processing of b-CTF to generate Abs of varying length. PSEN1 mutations 
depicted to represent the g-secretase cleavages processes that may be 
affected. C-H) Ab measurements in APP, PSEN1 and Swe/M146V double 
mutant neurons (DIV60-70) compared to wildtype. Represented as fold-
change compared to wildtype. Supernatants analyzed for C) Ab42, D) Ab43, 
E) Ab38 and F) Ab40 by ELISA. G) All Abs measured were summed together 
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to determine total Ab, and H) the ratio of Ab 42:40 was calculated.  Values 
represent mean (n=3 biological replicates) ± SEM **P < 0.05 and ***P < 
0.001, ****P < 0.0001, one-way ANOVA, outliers identified by ROUT method 
(Q = 1%). 
 
 Amyloidogenic processing of APP for Ab generation depends on b-secretase-
mediated generation of b-CTF, whereas non-amyloidogenic processing occurs when 
APP is instead first cleaved by a-secretase to generate a 16 amino acid shorter 
peptide called a-CTF. Both b- and a-CTF are substrates for subsequent cleavage by 
g-secretase.  Therefore, in addition to Ab production, fAD mutations, by affecting a-, 
b- and g-secretase cleavage, may also affect the metabolism of b- and/or a-CTF.  
When examining APP CTFs by Western blot, we noted the presence of five distinct 
bands, which have previously been reported to be the phosphorylated and 
dephosphorylated b-CTFs (C99/p-C99 and C89/p-C89) and a-CTFs (C83/p-C83), 
with C89 and p-C83 overlapping (Buxbaum et al., 1998) (Figures 38A-B).  We 
noticed that APP and PSEN1 mutants demonstrated variable effects on a-CTF 
metabolism (Figure 38C). However, all APP and PSEN1 mutant human neurons 
exhibited an accumulation of b-CTF (Figure 38D).  Swe/M146V neurons further 
demonstrated an additive effect of the PSEN1 and APP mutations on CTF 
accumulation, resulting in substantially higher levels of accumulated b-CTF 





Figure 38.  APP and PSEN1 fAD mutations increase accumulation of 
APP b-CTFs. 
a-CTF and b-CTF levels were analyzed by western blot in APP (A) and 
PSEN1 (B) mutant neurons and were quantified using densitometry (C and 
D).  Swe/M146V double mutant neurons were included in both blots for 
comparison.  Western blot densitometry values represent mean (n=3 
replicates) ± SEM **P < 0.05 and ***P < 0.001, ****P < 0.0001.  
 
 Taken together, these data demonstrate that although different APP and 
PSEN1 fAD mutations may variably affect APP processing and Ab generation, 
common trends across all mutations do exist.  Specifically, in all APP and PSEN1 
fAD mutant cells we detected increased levels of longer Abs and b-CTF, which are 
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therefore candidates for being critical APP-derivatives most relevant to the 
development of AD. 
 
Early endosomal enlargement in human fAD mutant neurons is dependent on 
APP processing and can be rescued by BACE inhibition.  
 
 fAD mutant iPSC-derived neurons all demonstrate endosome 
enlargement as well as elevated longer Abs and accumulation of b-CTF.  Therefore, 
if these cellular and biochemical changes are related, then genetic manipulations to 
lower Abs and b-CTF may reverse the endosomal phenotype. To test this we used 
our isogenic mutant iPSC line with the protective APP-A673T mutation knocked-in at 
both alleles (Jonsson et al., 2012; Kwart et al., 2017; Paquet et al., 2016).  The APP-
A673T mutation is directly adjacent to the APPswe mutation near the b-secretase 
processing site of APP (Figure 37A and Figure 7).  When we examined the various 
b-CTFs, we noted no change in total b-CTFs between APP-A673T and WT (Figure 
39B and D). However, APP-A673T mutant neurons demonstrated a shift in APP 
processing that trended (albeit not significantly) towards an increase in the 
production of non-amyloidogenic C89 b-CTFs (Figure 39B-C), along with a 
reduction in total Ab (Figure 39A). In addition, we studied an isogenic APP knockout 
(APP-KO) iPSC line that we generated using CRISPR/Cas9-mediated deletion of the 
conserved APP transcription start-site (see details on APP-KO iPSC generation in 
Appendix I).  As expected, APP-KO iPSC-derived neurons had undetectable levels 
of Ab (Figure 39A). When studying endosome morphology, APP-KO neurons 
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demonstrated a highly significant reduction in Rab5+ endosome size compared to 
wildtype; APP-A673T neurons also showed a trend towards reduction, but it was not 
significant (Figure 39E-F).  When analyzing the frequency distribution of endosome 
size, we found APP-KO neurons have a significant increase in the number of small 
endosomes (<0.5µm2) and reduction in the number of medium-sized endosomes 
(0.5-1µm2) (Figure 39G).  These results support the view that endosome pathology 
seen in APP and PSEN1 mutant neurons is indeed dependent on APP and its 
altered processing caused by fAD mutations, confirming recent findings. Taken 
together, these data further support the notion that amyloidogenic APP processing is 






Figure 39.  Rab5+ early endosomes enlargement is APP-processing 
dependent. 
Total Ab (A), Ab 42:40 ratios (B) as well as FL-APP and APP-CTFs (C) were 
measured in protective APP-A673T mutant and APP-KO neurons by ELISA 
and western blot, respectively.  D) APP-A673T shifts APP processing towards 
a-CTF generation. E) Representative immunofluorescence images from 
wildtype, APP-A673T and APP-KO stained for Rab5 (green), MAP2 (red) and 
Hoechst (blue).  F) Mean Rab5+ endosome area per cell (n=18-23 cells), and 
G) frequency distribution of endosome size.  Values represent mean ± SEM.  
**P < 0.05 and ****P < 0.0001, one-way ANOVA (F) or two-way ANOVA (G) 
with comparisons to controls.  ##P < 0.001, one-way ANOVA compared to 
wildtype. Scale bar, 10µm. 
 
 In pathogenic fAD mutant neurons, endogenous Ab and b-CTF levels can be 
manipulated by treatment with a b-secretase inhibitor (BACEi), which should prohibit 
 
 138 
amyloidogenic processing of APP.  We confirmed in Swe/M146V neurons, which 
demonstrated the largest increase in Ab production, that BACEi treatment 
significantly decreases total Ab production (Figure 40A), and almost completely 
prevents the generation of b-CTF in L166P homozygous neurons, which showed the 
largest increase in all detectable APP-CTFs (Figure 40B).  Interestingly, endosome 
enlargement seen in all APP and PSEN1 mutant iPSC-derived neurons was 
significantly rescued by BACEi treatment (Figure 40C-D).  Taken together, these 
rescue experiments further support that in human neurons, Rab5+ early endosome 
morphological changes seen in fAD are mediated by endogenous changes in APP 
processing caused by APP and PSEN1 mutations and can be rescued 




Figure 40. Rab5+ early endosomes enlargement can be rescued by 
BACEi treatment in fAD mutant neurons. 
A) Compared to DMSO control, BACEi treatment of Swe/M146V double 
mutant neurons nearly abolishes Ab production with concomitant reduction of 
b-CTF, as determined by western blot (B). Representative images of Rab5 
(green), MAP2 (red) and Hoescht (blue) staining (C) and quantification (D) 
showing BACEi treatment of homozygous mutant APP and PSEN1 neurons 
significantly reduces endosome size (n=10-20 cells).  The sizes of Rab5+ 
puncta were quantified using Imaris.  Values represent mean ± SEM.  **P < 
0.05 and ****P < 0.0001, two-way ANOVA with comparisons to controls.  




Rab5+ early endosomes enlargement is not rescued by reducing longer Ab 
peptides with a γ-secretase modulator. 
 
Although some previous studies have also implicated APP b-CTF as a 
plausible contributor to intracellular trafficking defects in AD (Jiang et al., 2010; Kim 
et al., 2015; Woodruff et al., 2016; Xu et al., 2016), other studies suggesting longer 
Abs are relevant to endocytic dysfunction have also been reported (Treusch et al., 
2011).  Many of these studies did not investigate AD-related endosomal defects in 
human neurons, were confounded by their use of non-physiological APP (or b-CTF 
or Ab) overexpression, or did not precisely separate the contribution of Abs from that 
of b-CTF.  We therefore aimed to determine in mutant iPSC-derived neurons with 
endogenous APP and PSEN1 expression whether endosome enlargement seen in 
fAD neurons is specifically associated with longer Abs and/or b-CTF.   
We tested the contribution to endosome dysfunction of longer Abs by treating 
neurons with a g-secretase modulator (GSM).  GSMs are a class of AD therapeutics 
engineered to alter g-secretase function without blocking activity (Crump et al., 2013) 
(inhibitors of g-secretase were found to be ineffective in clinical trials and actually 
made patient symptoms worse).  We tested the effect of a GSM on PSEN1-M146V, 
PSEN1-L166P and Swe/M146V homozygous mutant neurons, all of which 
accumulate longer Abs through a consistent loss of g-secretase processivity 
(Figures 37 and 38).  Wildtype neurons were treated for comparison.  GSM 
treatment had no apparent effect on total Ab production (Figure 41A), but in 
wildtype, M146V and Swe/M146V cells GSM resulted in a robust reduction of longer 
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Ab production concomitant with an increase in production of shorter Ab (Figure 41B-
F).  Interestingly, GSM treatment did not result in any significant overall changes in 
longer versus shorter Ab levels in PSEN1-L166P homozygous mutant neurons 
(Figure 41B).  This result is of particular interest, since the PSEN1-L166P mutation 
is the most severe mutation we studied (see Table 2), and suggests that this 





Figure 41.  Ab analysis of GSM treated wildtype and fAD mutant iPSC-
derived neurons.  
A) Wildtype and mutant neurons treated with a GSM does not alter total Ab 
production (Ab 38+40+42+43) but shifts processing to increase longer Abs 
(42+43) relative to shorter Abs (38+40) (B) compared to DMSO control.  C) 
Treatment of GSM results in Ab42 levels to be significantly reduced in all 
neurons except for PSEN1-L166P homozygous cells. D) GSM treatment 
results in a corresponding increase in Ab38 levels. E) Ab43 is more subtly 
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reduced in all neurons with treatment of GSM. F) Ab40 levels are relatively 
unchanged by GSM treatment compared to DMSO. Values represent mean 
(n=3 biological replicates) ± SEM. **P < 0.05 and ***P < 0.001, ****P < 
0.0001, two-way ANOVA, outliers identified by ROUT method (Q = 1%). 
 
GSM treatment did not affect b-CTF (or a-CTF) levels as analyzed by western 
blot (Figure 42A-B), highlighting how this class of drug selectively affects g-
secretase processivity (carboxypeptidase) and not endopeptidase (e) cleavage in 
human neurons (Figure 37B).  Remarkably, treatment with GSM failed to rescue the 
Rab5+ endosome enlargement in mutant neurons compared to control conditions 
(Figure 42C-D), suggesting that endogenous accumulation of longer Ab in fAD 




Figure 42.  GSM treatment does not affect APP-CTF levels nor rescue 
endosome enlargement in mutant neurons. 
GSM treatment does not alter a-CTF and b-CTF, as analyzed by western blot 
(A) and quantified by densitometry (B). Representative images of Rab5 
(green), MAP2 (red) and Hoescht (blue) staining (C) and quantification (D) for 
GSM treated PSEN1-M146V, L166P and Swe/M146V double mutant neurons 
(n=10-20 cells).  Values represent mean ± SEM. ns = not significant, two-way 




Increasing endogenous APP b-CTF in wildtype human neurons causes early 
endosome enlargement. 
 
 Recent studies have relied on using overexpression of APP b-CTF in either 
rodent neurons or non-neuronal cell lines to test whether APP b-CTF is sufficient to 
cause early endosome dysfunction (Jiang et al., 2010; Kim et al., 2015; Xu et al., 
2016).  APP b-CTF is a rare and transient intermediate APP metabolite, and its 
generation and trafficking is tightly regulated by concerted b-, a- and γ-secretase 
activity (Haass et al., 2012).  Therefore, b-CTF overexpression is not only non-
physiological, but more importantly may inadequately recapitulate the normal 
trafficking and biological relevance of the peptide.  We therefore aimed to study the 
effect of increasing endogenous APP b-CTF on early endosome morphology without 
overexpression in wildtype human iPSC-derived neurons pharmacologically.  
Wildtype neurons were treated with a γ-secretase inhibitor (GSi), which effectively 
eliminates secreted Ab production (Figure 43A).  Since g-secretase cleaves b-CTF 
to generate Ab, g-secretase inhibition also results in an accumulation of b-CTF in 
wildtype neurons (Figure 43B).  In wildtype neurons, g-secretase more commonly 
cleaves a-CTF, which exists at much higher levels than b-CTF.  Therefore, GSi 
treatment also much more robustly increases the levels of a-CTF compared to b-
CTF in human neurons (Figure 43B).  b-CTF only subtly differs from a-CTF, which 
lacks the N-terminal 16 amino acids of b-CTF.  To be able to separate b-CTF from 
a-CTF, we combined GSi and BACEi treatment, which results in an increase in 
levels of endogenous a-CTF but not b-CTF (Figure 43B).  We found that GSi and 
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BACEi treatment together did not affect endosome size, however treatment with GSi 
alone was sufficient to induce the enlargement of Rab5+ early endosomes 
compared to DMSO (Figure 43C-E).   
 
Figure 43.  Increasing endogenous APP b-CTF in wildtype human 
neurons causes Rab5+ early endosome enlargement. 
A) Wildtype neurons treated with a GSi nearly abolishes total Ab production. 
B) GSi treatment of wildtype neurons dramatically increases both a-CTF and 
b-CTF, while co-treatment of wildtype neurons with GSi and BACEi results in 
an increase of only a-CTF measured by western blot. Representative images 
of Rab5 (green), MAP2 (red) and Hoescht (blue) staining (C) and 
quantification (D) showing wildtype neurons treated with GSi results in 
significantly increased mean Rab5+ endosome size and number of larger (>1 
µm2) endosomes (E), while co-treatment with GSi and BACEi has no effect. 
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F) and G) treatment of APP KO neurons with GSi has no effect on endosome 
size compared to DMSO control. The sizes of Rab5+ puncta were quantified 
using Imaris.  Values represent mean ± SEM (n=16-19 cells). **P < 0.05 and 
***P < 0.001, **** P < 0.0001, one-way ANOVA (D), two-way ANOVA (E and 
G) or t-test (A and F) compared to control.  Comparisons in F and G are all 
not significant.  Scale bar, 10µm. 
 
 Lastly, to confirm that GSi and BACEi treatment are on-target and influencing 
endosome morphology through APP b-CTF, we repeated the GSi treatment in APP-
KO iPSC-derived neurons.  GSi treatment had no effect on Rab5+ early endosome 
size in APP-KO neurons (Figure 43F-G), indicating that GSi-induced endosome 
enlargement depends on APP and therefore most likely b-CTF.  In summary, these 
data confirm that pathological endogenous APP b-CTF accumulation seen in fAD 
mutant human neurons may be both sufficient and necessary for common early 




It has been known for nearly 30 years that mutations in APP and PSEN1 
cause AD, but precisely how these mutations in two distinct genes result in the same 
disease remains incompletely understood. In this study we generated a large panel 
of isogenic fAD mutant iPSC-derived neurons to study underlying common AD-
relevant pathological processes in human neurons.  Guided by unbiased molecular 
profiling, we found that select APP and PSEN1 mutant neurons share common sets 
 
 148 
of dysregulated genes enriched in pathways associated with AD and with 
endocytic/endosomal processes.  We expanded on these transcriptomic analyses to 
show functionally that all fAD mutant neurons studied displayed early endosome 
abnormalities, as assessed by assaying Rab5+ early endosome morphology. Since 
APP and PSEN1 converge mechanistically on APP processing, we studied APP 
metabolism in fAD mutant neurons to decipher the precise common disease-
associated APP peptide correlates, which may be relevant to endosome biology.  
We found that while APP and PSEN1 mutations tend to have largely dissimilar 
effects on APP metabolism, all mutations increase levels of longer, more 
hydrophobic Abs, as well as b-CTF.  Most importantly, we showed in human 
neurons that fAD-associated endosomal dysfunction is correlated specifically with 
accumulation of β-CTF, not increased longer Aβ peptide production. These results 
expand the understanding of disease-relevant phenotypes shared between APP and 
PSEN1 mutations and contribute to a growing body of literature implicating 
endosomal-lysosomal dysfunction and elevated b-CTF as a common underlying 




Our study relied on recently developed CRISPR/Cas9 technology to generate 
one of the largest and most diverse panel of human iPSC lines carrying autosomal 
dominant fAD APP and PSEN1 mutations knocked into a single wildtype parental 
cell line.  This approach has many advantages, including the ability to study 
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phenotypes in disease-relevant cell types by differentiating iPSCs into AD-vulnerable 
cortical neurons and studying these phenotypes under endogenous and more 
physiological levels of mutant protein expression.  Most importantly, this approach 
eliminates potential off-target contribution of reprogramming or differences in genetic 
background when comparing cell lines from non-isogenic donors. To date, multiple 
groups have used iPSC-derived neurons to study fAD, but these past investigations 
either used non-isogenic controls  (Israel et al., 2012; Liu et al., 2014a; Moore et al., 
2015; Nieweg et al., 2015; Sproul et al., 2014; Yagi et al., 2011), used 
overexpression of mutant transgenes (Honda et al., 2016; Koch et al., 2012), or 
narrowly focused on only one or two different fAD mutations (Karch and Goate, 
2015; Maloney et al., 2014; Oksanen et al., 2017; Ortiz-Virumbrales et al., 2017; 
Paquet et al., 2016; Woodruff et al., 2016; 2013).  In our study, using a 
CRISPR/Cas9 gene-editing framework that we recently described (Kwart et al., 
2017; Paquet et al., 2016), we engineered and studied 16 different isogenic iPSC 
lines with different mutations in APP and PSEN1 (Table 1), including an APP 
protective mutation and APP knock-out.  Additionally, using CRISPR/Cas9-mediated 
“double knock-in”, we report findings from an APPswe/PSEN1-M146V double 
mutant iPSC-line.  As with mouse models, we found that the combination of APPswe 
and PSEN1-M146V mutations causes more robust AD-relevant phenotypes, such as 
aberrant changes in APP processing and endosomal morphology.   In the future, this 
cell line may serve as a valuable platform for basic disease mechanism discovery as 
well as novel drug testing. With this comprehensive collection of fAD stem cell lines 
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in hand, we are well positioned to compare the effects of multiple different fAD 
mutations and identify relevant changes in APP metabolism and downstream cellular 
consequences that may have not previously been fully appreciated.   
We took advantage of these isogenic lines to carry out unbiased genome-
wide molecular profiling of mutant cells.  Our RNA-sequencing data, comprising 
differential expression and pathway analyses, will soon be made publicly available. 
These comprehensive datasets will assist future studies probing differential gene 
expression and pathway dysregulation in AD.  In the present study, we aimed to 
identify commonly perturbed disease-associated cellular processes. The fact that 
there are distinct genes differentially expressed in APP and PSEN1 mutant iPSC-
derived neurons is interesting but not entirely unexpected, since both APP and 
PSEN1 are integral to a variety of overlapping but also distinct cellular processes. It 
was of interest, then, that we found multiple common endocytic/endosomal 
trafficking-associated genes that were significantly differentially expressed in all fAD 
mutant neurons. Many of these trafficking-related genes have previously been 
implicated in late-onset AD risk (e.g., SORL1, CLU, APOE, etc.), suggesting there is 
a common network of cellular and molecular changes that may underlie both sAD 
and fAD pathogenesis.   
Our molecular profiling data support the emerging view that intracellular 
trafficking defects may be an important common pathological process associated 
with AD and other neurodegenerative diseases (Wang et al., 2014).  Less clear, 
however, is whether trafficking deficits broadly characterize both sAD and fAD 
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caused by APP and PSEN1 mutations.  Previous clinical work has strongly 
implicated early endosome dysfunction in sAD as a preclinical change preceding 
amyloid plaque and tangle deposition (Cataldo et al., 2000). A few studies 
investigating early endosomal-related defects in fAD have been reported, though 
they are limited by use of non-human and non-neuronal cell lines with 
overexpression or non-isogenic human iPSC-derived neurons, and are all limited by 
studying only a small number of fAD mutations (Israel et al., 2012; Kim et al., 2015; 
Muratore et al., 2014; Xu et al., 2016).  Our analysis using multiple different isogenic 
fAD APP and PSEN1 knock-in mutant human iPSC-derived neurons revealed the 
presence of significant Rab5+ early endosome enlargement in all lines, supporting 
endocytic changes as a potentially unifying pathological hallmark of AD. 
When characterizing the effects of APP and PSEN1 mutations on APP 
processing, we found that the total amounts of longer Ab species (Ab43 and/or 
Ab42) as well as b-CTFs were consistently elevated in a zygosity-dependent manner 
for all fAD mutant cell lines studied.  We found in neurons that mutations in APP at 
the b-secretase and a-secretase sites generally increase the total amount of Ab, as 
seen in the APPswe and APP-A692G mutants, respectively.  Furthermore, by 
shifting secretase processing, both APPswe and APP-A692G mutations increase 
levels of b-CTFs.  Interestingly, mutations at the g-secretase site of APP, such as 
APP-V717G, result in altered g-secretase processing of b-CTF, shifting the 
processing of Ab towards Ab42 and Ab38.  In addition, we found that the APP-
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V717G mutation also causes an accumulation of both a- and b-CTFs, suggesting 
that the mutation also globally impairs g-secretase peptidase cleavage.   
We strategically chose to study 3 different APP mutations, as these represent 
the vast majority of known APP fAD mutations which confer pathogenicity by 
modifying APP processing by either b-, a- or g-secretase.  Interestingly, there are a 
few APP mutations very close to the APP-A692G site (E693 and D694) that in past 
studies have been shown not to affect secretase cleavage of APP at all.  In fact, 
these mutations tend to result in clinically distinct versions of AD, namely, cerebral 
amyloid angiopathy (CAA), which unlike more widely studied forms of AD involves 
more vascular defects including strokes, hemorrhages and resulting cognitive 
decline (Bugiani et al., 2010; Grabowski et al., 2001; Levy et al., 1990; Van 
Broeckhoven et al., 1990).  In CAA, Ab (typically Ab40) accumulates in cerebral 
vessels and plaques are diffuse in the brain parenchyma (Bugiani et al., 2010; 
Timmers et al., 1990).  Past studies have mostly shown that these mutations have 
no effect on Ab production, but instead alter the propensity of Abs to aggregate and 
fibrillize (Van Nostrand et al., 2001; 2002; Wisniewski et al., 1991).  These mutations 
therefore should not affect production of b- or a-CTF and therefore may not 
influence endosome morphology, however this hypothesis has yet to be adequately 
tested.  Given the marked differences in clinical and symptomatic presentation 
between APP E693/D694 mutations and other APP fAD mutations near secretase 
processing sites, it is possible these different types of mutations reflect distinctly 
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different diseases, and endosome dysfunction/b-CTF may commonly underlie the 
pathogenicity of non-CAA types of AD.   
In contrast to APP, all PSEN1 mutations appear to alter the processing of 
APP by impairing g-secretase activity.  Previous studies probing the effects of 
PSEN1 fAD mutations have often converged on a common increase in the Ab 42:40 
ratio.  However, multiple conflicting studies have led to a debate whether this change 
in the ratio is caused by increasing Ab42, decreasing Ab40, or a combination of 
both. Moreover, given that multiple APP mutations have little or no effect on the Ab 
42:40 ratio, it is unclear how relevant this measure is to pathology.  Furthermore, 
recent studies have shown that some PSEN1 mutations may be so severe they 
result in complete loss of Ab40 and Ab42 generation (Veugelen et al., 2016; Xia et 
al., 2015), thereby underscoring the need to understand how all Ab peptides, 
including longer Abs such as Ab43, are affected by mutations in human neurons.    
Our analysis of specific Ab peptides is consistent with a growing appreciation 
in the field that PSEN1 mutations confer a partial loss of g-secretase processivity. In 
all PSEN1 mutant neurons, Ab42 and Ab43 were increased, while Ab38 and Ab40 
were correspondingly decreased, suggesting the mutations impair g-secretase ability 
to adequately process b-CTF and Abs into the shortest possible peptides. 
Furthermore, all PSEN1 mutant neurons displayed decreased production of total 
measured Ab, which may be a result of overall reduced g-secretase activity.  On the 
other hand, this may reflect a shift in production towards longer Ab peptides (e.g., 45 
or 46 amino acids) that our assay did not detect (Szaruga et al., 2017). Interestingly, 
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mutant neurons harboring the L166P mutation (one of the most aggressive fAD 
mutations known (Moehlmann et al., 2002)) demonstrated the most severe 
alterations in Ab production, particularly in a drastic increase in Ab43, and 
corresponding reduction in Ab40 and Ab38. As a result of these alterations in Ab 
production, the Ab 42:40 ratio, and even more so the Ab 42:38 and Ab 43:40 ratios 
(data not shown), were significantly increased. In addition, all PSEN1 mutants 
showed increased levels of b-CTF, which likely explains the corresponding reduction 
in total amount of Ab generated.  Importantly, a-CTF is also consistently increased in 
all PSEN1 mutant neurons, further suggesting global impairment of g-secretase 
processivity.  In this study we only analyzed 4 different PSEN1 mutations, however 
to date over 150 pathological PSEN1 fAD mutations have been discovered.  While 
new experimental evidence (including ours) continues to overwhelmingly converge 
on a common mechanism of pathogenicity involving loss of g-secretase processivity, 
it would still be meaningful to continue to assess how consistent our detected 
changes in Ab, CTF and endosome morphology are with other PSEN1 mutations, for 
example mutations that are known to more severely alter g-secretase activity and Ab 
production. 
Our study compared multiple mutations known to cause fAD in both APP and 
PSEN1 genes.  As mentioned before, mutations in another gene, PSEN2, have also 
been found to cause fAD.  Therefore, one outstanding question is whether or not the 
effects we see in APP and PSEN1 mutant neurons would also be seen in PSEN2 
mutant cells.  PSEN2 and PSEN1 are highly homologous and each can form the 
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catalytic subunit of the g-secretase complex (De Strooper et al., 2012).  In neurons 
expression of PSEN2 is much lower than PSEN1 (we also found this in our RNA-seq 
analysis) and many believe that there may be different substrate specificities for 
PSEN1- versus PSEN2-containing g-secretase (De Strooper et al., 2012; Sannerud 
et al., 2016).  There are over 150 mutations in PSEN1 known to cause fAD, whereas 
only about a dozen have been identified in PSEN2 (An et al., 2015).  As a result, 
PSEN1 has been much more studied in the literature.  Furthermore, PSEN2 
mutations tend to result in disease with later onset age and are less penetrant (An et 
al., 2015).  Many studies including in human iPSC-derived neurons, have concluded 
that similar to PSEN1 mutations, many mutations in PSEN2 also result in an 
increase in the Ab 42:40 ratio, which is most likely due to increased Ab42 and 
reduced Ab40 production (Ortiz-Virumbrales et al., 2017; Walker et al., 2005).  If this 
is indeed true, it is likely that impaired PSEN2-containing g-secretase would also 
result in an increase of both a- and b-CTF.  It has been recently shown that PSEN1 
and PSEN2 may most greatly differ in their subcellular localization and trafficking, 
with PSEN2-containing g-secretase complexes being much more highly 
concentrated in endosomal and lysosomal compartments (Sannerud et al., 2016).  
Given this differential localization it would be expected that impaired activity of 
PSEN2-containing g-secretase within endosomes may cause a significant 
accumulation of b-CTF within these compartments, since it is predominantly within 
endosomes where b-CTF is cleaved by g-secretase.  If this prediction holds true, I 
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would predict PSEN2 mutations disrupt endosome morphology similarly or even 
more severely than PSEN1 mutations. 
 We strategically combined widely available pharmacological agents to 
manipulate endogenous levels of both Abs and APP CTFs in our wildtype and 
mutant human neurons.  Specifically, under endogenous gene expression, we were 
able to isolate the effect of longer Abs from that of APP CTFs by using GSMs, and 
showed the effect of b-CTF could be discriminated from that of a-CTF using the 
combination of g-secretase inhibitor and b-secretase inhibitor.  Such simple 
pharmacological manipulations could easily be applied to other cellular systems that 
are similarly difficult to manipulate, such as primary rodent neurons.  Using these 
approaches, we show that Rab5+ endosome enlargement is associated with 
elevated b-CTF, not a-CTF or Ab.    
 It is interesting that b-CTF and a-CTF can have such dramatically different 
effects on early endosome morphology considering the two peptides only differ by 
16 N-terminal amino acids.  One recent study speculated that this difference in 
phenotype may be attributed to a unique gain of function by the 16 amino acids (Xu 
et al., 2016), whereas another similar study instead suggests the C-terminal 
YENPTY domain of APP (present in both a- and b-CTF) induces endosome 
enlargement by recruiting APPL1 and stabilizing Rab5 activity (Kim et al., 2015). 
Regardless of mechanism, a-CTF is known to mostly be generated at the cell 
surface, whereas b-CTF is mostly generated in the endosome (Haass et al., 2012).  
Therefore, compartmentalization of b-CTF in the endosome may enable specific 
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protein interactions that induce endosome abnormalities, while a-CTF at the cell 
surface may have no such effect.  
 Further studies are needed to help decipher the cellular consequences of 
early endosome morphological changes and how early endosome enlargement 
phenotypes contributes to neurodegeneration. Rab5+ early endosomes are 
important for the retrograde trafficking of trophic signals (such as NGF or BDNF) 
from the axon towards the cell body. Recent overexpression studies in rodent 
neurons demonstrated that APP-mediated Rab5+ early endosome enlargement 
slows normal axonal retrograde trafficking, potentially impinging on delivery of pro-
survival signals to the soma (Kim et al., 2015; Xu et al., 2016). In one example, 
researchers found evidence of neuronal atrophy as a consequence of early 
endosome enlargement (Xu et al., 2016). Whether similar results will be seen in 
human neurons or in vivo remains to be tested, and whether such deficits can trigger 
neurodegeneration is unclear.  
It is also possible that early endosome enlargement can feed into AD 
pathology in a different way. Specifically, it is possible that enlarged dysmorphic 
early endosomes provide a site for seeding aggregation of pathological proteins.  
For example, Ab, which is mostly generated within endocytic compartments, may be 
better able to form oligomers or fibrils in enlarged endosomes prior to extracellular 
release, augmenting plaque deposition. Furthermore, tau, which has recently been 
shown to be endocytosed and degraded through the endosomal-lysosomal system 
in human neurons (Evans et al., 2018), may also be more likely to aggregate within 
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enlarged early endosomes. As well, it has been shown that important lysosomal 
hydrolases, which normally traffic to the lysosome through the early to late 
endosome to carry out normal protein degradation, are dysregulated in cells with 
enlarged endosomes (Cataldo et al., 2008). Impaired trafficking of essential 
lysosomal hydrolases not only would impair overall proteostasis but may also 
augment pathological amyloid and tau protein aggregation or spreading. Human 
neurons provide a valuable system to evaluate the physiologically-relevant 
consequences of early endocytic defects. 
 In this study we interrogate a specific Ab-independent cellular phenotype 
driven by b-CTF. Although increasing attention is being directed towards b-CTF as a 
plausible key contributor to AD, a majority of studies continue to focus on the 
amyloid cascade hypothesis and the neurotoxicity of Ab. We found that levels of 
longer Abs are elevated in all fAD mutations studied.  Longer Abs, such as Ab42 and 
Ab43, are more hydrophobic and have greater propensity to aggregate and deposit 
within plaques. Although we ruled out the contribution of longer Abs to Rab5+ 
endosome enlargement, the effect of changes in Ab secretion and aggregation on 
neurodegeneration was not addressed. Interestingly, from the molecular profiling 
experiments, we also noticed that sets of genes associated with synaptic functioning 
and neurodegeneration were significantly differentially expressed in APPswe, 
PSEN1-M146V, and Swe/M146V  mutant neurons compared to wildtype (Figure 34 
and 35). Ab is thought to potentially be neurotoxic by impeding normal synaptic 
function, so the gene expression changes we detected in mutant cells may reflect a 
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compensatory change in gene expression to overcome the neurotoxic effect of 
pathological Ab production. It is also possible that the neurotoxicity of Ab is in part 
mediated through a non-cell autonomous mechanism, which was also not addressed 
in our study. Specifically, it has been shown recently that longer Ab peptides are 
capable of initiating an inflammatory response, for example through microglia 
activation (Hong et al., 2016; Sondag et al., 2009). Such an immune response has 
been suggested to lead to synapse degeneration and ultimately cell death. Future 
studies, such as co-culturing fAD mutant iPSC-derived neurons with wildtype and 
mutant human microglia, are necessary to determine whether the increased longer 
Abs produced by human fAD mutant neurons are capable of causing an immune 
response and neurodegeneration. 
 Our study raises the concern that GSMs and other anti-Ab therapies which 
are being developed and tested in the clinic all fail to target b-CTF and therefore 
may have no effect on rescuing endosomal abnormalities in AD. We and others 
have shown that inhibiting b-secretase, which reduces both Ab and b-CTF, rescues 
endosomal defects (Jiang et al., 2010; Woodruff et al., 2016).  Recent BACEi clinical 
trials have been prematurely ended as no significant positive outcomes were evident 
(Mullard, 2017), but these trials focused on patient groups that either already had 
significant AD neuropathology, or patients in a “prodromal” AD stage. The 
endosomal phenotypes we see in iPSC-derived neurons are detectable very early in 
development. Since early endosome dysregulation precedes any amyloid or tau 
pathology, it is likely that to target endosomal dysregulation, patients may need to be 
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treated prior to detectable AD pathology presentation. While future studies are 
necessary to understand the precise pathway through which b-CTF results in Rab5+ 
early endosome enlargement and dysregulation, interventions targeted at this 
pathway deserve consideration as a therapeutic strategy. 
 
Chapter V:  Concluding Remarks 
 
 The work presented in this thesis is all focused on addressing an open 
question in the field of AD, namely, how a multitude of mutations in APP and PSEN1 
genes commonly contribute to a singular pathological disease state.  We 
hypothesized that studying these different fAD mutations in a human neuronal model 
system with the absence of any transgenic overexpression would provide valuable 
insights and help clear up outstanding mechanistic debates.  However, first we 
needed to take the time necessary to generate the tools needed to develop such a 
“gold-standard” model system.  In doing so, we began to learn a lot about iPSCs and 
gene editing using CRISPR/Cas9.  We developed strategies to improve outcomes of 
CRISPR-mediated knock-in in human stem cells by studying how HDR-mediated 
repair works in these cells after a CRISPR edit.  In addition, we developed a novel 
framework for gene editing in iPSCs called “CORRECT”, which enables efficient and 
scarless mutation incorporation.  These findings have broad implications for multiple 
different scientific fields as useful tools for model system development and disease 
modeling.  More recently we have implemented our CRISPR/Cas9 framework to 
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study common features of diverse APP and PSEN1 mutations, as we initially 
intended to do.  By generating a comprehensive panel of 16 different fAD mutant 
iPSC lines, we deciphered how APP and PSEN1 mutations commonly contribute to 
early endosome dysfunction, which we showed to be correlated with APP b-CTF, 
rather than a-CTF or longer Abs. 
 In our analysis we looked at 3 different representative pathogenic APP 
mutations as well as 4 different PSEN1 mutations using isogenic human iPSC-
derived neurons.  Although there were some phenotypes that were not consistent 
across the APP and PSEN1 mutant cells, we did identify 3 common features that 
were similar across all mutant lines:   
1) Increased production of longer Abs (Ab43 and/or Ab42);  
2) Increased levels of APP b-CTF; 
3) Increased Rab5+ early endosome size. 
The identification of these common changes in APP processing across all mutant 
lines studied is significant, as past studies that may have simply focused on looking 
at the effect of mutations on total Ab or the Ab42:40 ratio would fail to capture these 
results.  What’s more, levels of these two types of APP-derived peptides may be 
more meaningful biomarkers than any other APP metabolite.  These phenotype 
consistencies, and more so the correlation between b-CTF and endosome 
dysfunction, provide compelling evidence that Ab may not be the only pathological 
player in development of AD, although the degree to which longer Ab peptides and 
endosome enlargement may synergize in neurodegenerative pathways has yet to be 
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studied.  Our results from studying 7 different mutations lays the groundwork 
necessary for pursuing additional studies that should assess for different mutations 
whether APP processing and endosome morphology is similarly affected.   
 Previous studies have demonstrated that overexpression of full-length APP or 
b-CTF is capable of inducing early endosome dysfunction, however all of this work 
had been performed in non-human and/or non-neuronal cellular systems.  
Furthermore, overexpressing APP or APP b-CTFs would also indiscriminately result 
in increased production of a-CTF and Abs in these cells, as both a-secretase and g-
secretase are fairly ubiquitously expressed.  Our approach has the advantage not 
only that we are studying phenotypes in human neurons with the absence of 
overexpression, but also, we can manipulate and precisely compare the effects of 
endogenous levels of both b-CTF versus a-CTF as well as longer versus shorter 
Abs on endosome dysfunction using pharmacology alone.  Specifically, we were 
able to separate the contribution of longer Abs from that of b-CTF by using GSM, 
which specifically reduces longer Ab levels without affecting b-CTF levels.  These 
experiments allowed us to conclude that increased longer Abs seen in mutant cells 
was unrelated to the common endosome enlargement phenotype we identified.  
Moreover, we were able to strategically isolate the effect of b-CTF from that of a-
CTF, which only differ in composition by their N-terminal most 16 amino acids.  
Specifically, we could increase both a-CTF and b-CTF levels using a g-secretase 
inhibitor, which we showed induces endosome enlargement.  However, this 
phenotype was fully rescued by the additional treatment of a b-secretase inhibitor, 
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which we showed depletes b-CTF without affecting a-CTF.  How b-CTF specifically 
contributes to endosome dysfunction while a-CTF has no effect remains a particular 
fascinating aspect of APP biology and needs be further investigated using human 
neurons in the future. 
 As described at length in previous chapters, a growing number of AD genetic 
studies have pointed to variants in endocytic-associated genes as important risk 
factors for sporadic AD development, including GWAS-identified trafficking-related 
genes such as SORL1, BIN1, PICALM.  Our study of fAD mutations in APP and 
PSEN1 and our finding of consistent changes in Ab, b-CTF and endosomes, begs 
the question of whether or not variants in AD risk-associated endocytic genes also 
lead to similar or even the same changes.  Future studies should take advantage of 
our CRISPR/Cas9 gene editing and iPSC platform to expand on our results by 
engineering disease-associated mutations in AD-relevant endocytic genes in iPSCs 
and studying APP processing and endosome dysfunction in differentiated neurons.  
Such future studies will help clarify whether our findings of common changes in Ab, 
b-CTF and early endosomes are unique to familial forms of AD or are more widely 
relevant to both genetically defined as well as spontaneous late-onset AD. 
  Other major questions remain unanswered, namely, what the cellular 
consequences of enlarged early endosomes may be and how endosome 
dysfunction contributes to neurodegeneration.  Our human iPSC-derived neuron 
model has its advantages, namely, the ability to study the effect of many different 
fAD mutations on APP processing and subtle cellular changes in a controlled 
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manner.  However, in its current state, the technology is ill-equipped to assess 
neurodegeneration.  Even in the most severe mutant iPSC-derived neurons we 
engineered with both APP and PSEN1 mutations present, cells can be maintained in 
culture for hundreds of days.  This is not so surprising, as it normally takes decades 
before fAD mutations result in noticeable disease phenotypes in humans.  
Therefore, it remains open in the field to determine ways to accelerate aging in these 
human neurons and to promote or activate pro-neurodegenerative pathways.  It 
would also be valuable to decipher novel strategies to mimic cellular stresses 
associated with AD, which may also be useful for actively promoting degeneration in 
these cells.  Once such technological advances are made, it would be valuable to 
see whether and how endosomal dysfunction contributes to neurodegeneration and 
degenerative signaling pathways.  Developing an in vitro platform to address the 
effect of endosomal dysfunction on neurodegeneration would be valuable in many 
ways, namely, for the discovery of novel AD-relevant cellular pathways as well as 




Appendix I: Materials and Methods 
 
sgRNA & Cas9-VRER plasmid design and construction.   
 
sgRNAs were designed using the Zhang lab CRISPR design tool 
(crispr.mit.edu). sgRNA sequences targeting APP or PSEN1 (Table 3) were cloned 
into plasmid MLM3636 (a gift from Keith Joung, Addgene # 43860) as previously 
described (Fu et al., 2013).  
 
Table 3.  List of sgRNAs sequences used in Chapters I, II and III. 
 
To generate the Cas9-VRER variant (Kleinstiver et al., 2015) with human 
codon usage, we introduced the 4 mutations into pCas9_GFP (a gift from Kiran 
Musunuru, Addgene plasmid # 44719). Briefly, we amplified fragments around the 
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intended mutation sites by PCR with mutated primers (Table 4), digested the 
plasmid with BamHI/BsrGI and fused all fragments by Gibson assembly. 
 
Table 4.  Primers for Gibson assembly of Cas9-VRER plasmid. 
 
 
Design of ssODN repair templates.   
 
100-nt ssODN repair templates (PAGE-purified, IDT) were designed with 
homologous genomic flanking sequence centered around the predicted 
CRISPR/Cas9 cleavage site and containing pathogenic and/or CRISPR/Cas-
blocking mutations. CRISPR/Cas-blocking silent mutations (i.e. that do not alter the 
amino acid sequence) were selected based on codon-usage of the edited gene by 
changing the codon to another codon already used in the same mRNA for the 
respective amino acid. All ssODNS used in the work described in this thesis are 




Table 5.  ssODNs used for analysis of CRISPR/Cas-blocking mutation 
efficacy (Chapter II). 
 
 





Table 7. ssODNs used to verify distance effect with independent 
sgRNAs (Chapter II). 
 
 
Table 8.  ssODNs used for single cell-derived clonal analysis of distance 
effect (Chapter II). 
 
 
Table 9. ssODNs used for oligo mixing strategy for increasing 
heterozygous clones (Chapter II). 
 
 




Generation of long ssDNA and dsDNA repair templates.   
 
To generate 200bp and 400bp ssDNA and dsDNA repair templates for repair, 
a 1000bp piece of the PSEN1 locus around the edited locus was first PCR-amplified 
and TOPO-cloned. Then, a library of 20 ssODN oligos or gBlocks (IDT) containing 
the required mutations was integrated into the TOPO-vector by Gibson assembly 
(NEB), resulting in a library of 20 plasmid templates, each containing CRISPR/Cas-
blocking barcode mutations and an intended mutation at varying cut-to-mutation 
distances (as described in Figure 19).  From each plasmid template, 200 bp and 
400 bp dsDNA PCR amplicons were generated (primers in Table 11) and mixed in 
equal amounts to generate pools of either size PCR template amplicons.  Template 
pools were then gel extracted to remove residual plasmid.  These were then re-
amplified by PCR and concentrated prior to transfection.  To generate ssDNA 
templates, dsDNA amplicons were generated as described above with 5’ 
phosphorylated forward primers.  Re-amplified dsDNA amplicons were then digested 
with Lambda Exonuclease (NEB) to generate ssDNA.  Reactions were column 
purified prior to transfection (see Figure 20 for graphical illustration).  
 





Wildtype iPSC line   
 
iPSCs were reprogrammed from human skin fibroblasts (Coriell Institute, 
Catalog ID: AG07889) of an 18-year old male individual using the Cytotune-iPS 
Sendai Reprogramming Kit (Life Technologies) according to the manufacturer’s 
instructions, following Rockefeller University Institutional Review Board approval. 
Informed consent was obtained from all subjects upon sample submission to Coriell 
Institute. Fibroblasts were confirmed to be wildtype for all studied loci by genotyping.  
Multiple clones were selected based on characteristic morphology. Genetic 
fingerprinting confirmed iPSCs were derived from corresponding fibroblast lines. 
Expression of pluripotency markers Oct4, Tra160, SSEA4 and Nanog was confirmed 
by immunofluorescence (Figure 44A). Clone 7889SA possessed a normal 
karyotype (Cell Line Genetics) and was characterized for typical iPSC properties and 
absence of Mycoplasma contamination (Figure 44B).   
Expression of pluripotency genes was analyzed by NanoString nCounter 
gene expression system using a pre-designed codeset (Kahler et al., 2013) (Figure 
44C).  Data was normalized to the geometric mean of three housekeeping genes 
(ACTB, POLR2A, ALAS1) using the nSolver Analysis Software v1.0 (NanoString).  
100 ng of total RNA from line 7889SA was compared to RNA extracted from the 
human ESC lines HUES9 (Cowan et al., 2004).  Gene expression for 7 pluripotency 
markers and the 4 Yamanaka factors introduced as Sendai transgenes (s-t) was 
compared. Note that the s-tSox2 probe detects some expression of endogenous 
Sox2, leading to larger values for both lines.   
 
 171 
In vivo pluripotency was confirmed by teratoma analysis as described (Kahler 
et al., 2013; Sproul et al., 2014).  Briefly, undifferentiated iPSCs were embedded into 
Matrigel and subcutaneously injected into the dorsal flank of immune-compromised 
mice (NOD-SCID Il2rg-null mice, Jackson Laboratory). Paraffin sections of the 
teratomas were subjected to hematoxylin and eosin (H&E) staining and structures 
characteristic for the three germ layers (ectoderm, mesoderm and endoderm) were 
identified by microscopy (Figure 44D). Animal work was approved by the Columbia 




Figure 44.  In vitro and in vivo characterization of the wildtype 7889SA 
human iPSC line. 
A) Immunofluorescence stainings of pluripotent stem cell markers.  B) iPSCs 
possess a normal human male karyotype.  C) Nanostring expression analysis 
of pluripotent stem cell genes in reprogrammed iPSCs compared to HUES9.  
D) In vivo differentiation and analysis of iPSC-derived teratoma containing 





Cell culture and transfection.   
 
iPSCs were maintained on irradiated MEFs (Globalstem) plated on cell 
culture plates coated with 0.1% gelatin and grown in HUESM (Knock-out Dulbecco’s 
modified Eagle’s Medium (KO-DMEM), 20% knock-out serum, 0.1 mM non-essential 
amino acids, 2 mM Glutamax, 100 U/mL-0.1 mg/mL penicillin-streptomycin (all Life 
Technologies), 0.1 mM 2-Mercaptoethanol (Sigma-Aldrich), 10 ng/mL FGF2 
(Stemgent), at 37 °C with 5% CO2.  Prior to transfection, iPSCs were transferred to 
Geltrex-coated (Life Technologies) cell culture plates and grown in MEF-conditioned 
HUESM containing 10 µM ROCK inhibitor (Stemgent). 
iPSCs were transfected with Cas9- and sgRNA-expressing plasmids, and 
ssODNs by electroporation. 2 million cells were resuspended in 100 µL cold 
BTXpress electroporation buffer (Harvard Apparatus) with 20 µg pCas9_GFP, 5 µg 
sgRNA plasmid, and 30 µg ssODN (100bp ssODN, PAGE-purified, IDT).  Cells were 
electroporated at 65 mV for 20 ms in a 1 mm cuvette (Harvard Apparatus).  After 
electroporation cells were transferred to Geltrex-coated cell culture plates and grown 
in MEF-conditioned HUESM containing ROCK inhibitor for 2 days.  In all 
transfections, 7889SA-derived iPSCs wildtype at genome-edited loci were used. 
Human embryonic kidney (HEK) 293T cells (Life Technologies) were maintained in 
DMEM with 10% FBS, 2 mM Glutamax and 100 U/mL-0.1 mg/mL penicillin-
streptomycin (all Life Technologies) at 37 °C with 5% CO2.  HEK293 cells were 
seeded on 12-well plates at 250,000 cells/mL.  When approximately 70% confluent, 
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HEK293 cells were transfected with 800 ng Cas9 plamid, 400 ng sgRNA plasmid 
and 1 µg ssODN Cells using X-tremeGENE 9 (Roche). 
 
Fluorescence activated cell sorting.   
 
All GFP positive cells regardless of expression levels were collected in the 
Rockefeller University Flow Cytometry Resource Center using a FACSAria II flow 
cytometer (BD Biosciences).  48h following transfection, cells were resuspended in 
PBS with 0.5% BSA fraction V solution, 10 mM HEPES, 100 U/mL-0.1 mg/mL 
penicillin-streptomycin (all from Life Technologies), 0.5 M EDTA, 20 mM glucose, 10 
ng/L DAPI in the presence of ROCK inhibitor for iPSC sorts.  For pooled cell NGS 
analysis 150,000 to 250,000 cells were collected and immediately frozen in liquid N2 
for further study.  For single-cell derived iPSC clonal analysis 30,000-60,000 GFP+ 
cells were immediately plated on a 10 cm plate of MEFs in HUESM and ROCK 
inhibitor following cell sorting.  
 
NGS analysis of HDR-mediated mutation incorporation.   
 
Genomic DNA was extracted from sorted cells and the genomic region 
around the CRISPR/Cas9 target site for APP and PSEN1 genes was amplified by 
PCR with primers positioned outside of the HDR repair template sequence to avoid 
template amplification for 25 cycles using Q5 polymerase (NEB) according to the 
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manufacturer’s protocol (PCR primers listed in Table 12). Primers contained 
additional sample-specific barcodes. 25 cycles were previously determined to be 
optimal for exponential amplification of the template as well as visibility for gel 
extraction (data not shown). To eliminate PCR byproducts and genomic DNA, PCR 
products were gel purified. 25-100 ng of pooled barcoded PCR products were 
submitted to the Rockefeller University Genomics Resource Center for targeted 
MiSeq (Illumina) 300 bp paired-end next generation sequencing with library 
preparation using the v3 reagent kit (Illumina).   
 




 Data analysis was performed using Galaxy (Blankenberg et al., 2010b; 
Goecks et al., 2010) (usegalaxy.org) or Unix-based software tools listed below 
(summarized in Figure 45).  First, quality of paired-end sequencing reads (R1 and 
R2 fastq files) was assessed using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc).  Raw paired-end reads 
were combined using Paired End ReAd MeRger (PEAR) (Zhang et al., 2014) to 
generate single merged high quality full-length reads. Reads with sample-specific 
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forward and reverse barcodes were de-multiplexed using the FASTX-Toolkit 
(Pearson et al., 1997) barcode splitter. The barcodes were then trimmed using seqtk 
(https://github.com/lh3/seqtk). Reads were then filtered by quality (using Filter 
FASTQ (Blankenberg et al., 2010a)) removing reads with a mean PHRED quality 
score under 30 and a minimum per base score under 24. Only reads shorter than or 
equal to the length of the PCR amplicons plus 40bp (to account for insertions) were 





Figure 45. Next-generation sequencing data analysis pipeline for HDR 
and indel detection. 
A) For all NGS experiments, raw forward and reverse paired NGS reads were 
first merged to obtain single high quality reads (tool: pear), de-multiplexed to 
separate experiment-specific barcoded reads (seqtk) then filtered to remove 
low quality reads.  B) For experiments using pooled oligos containing 
CRISPR/Cas-blocking mutations, reads were separated into wildtype (WT) 
and edited reads, which were then filtered to include only reads that had 
incorporated the pathogenic mutation (M+) (i.e. containing a pathogenic and 
CRISPR/Cas-blocking mutation).  To account for multiple HDR events after 
re-editing, reads were then separated into 32 unique categories covering 
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every possible combination of CRISPR/Cas-blocking mutations. C) Reads 
were aligned (bwa mem) and accurate HDR (perfect alignment) or indel 
distribution was reported (bam-readcount, R). HDR reads that had 
incorporated multiple CRISPR/Cas-blocking mutations were separately 
analyzed. D) For the mutation incorporation analyses performed in all other 
figures reads were filtered for the expected sequence and counted. 
 
 
For the accurate HDR and indel analysis in Chapter II reads were filtered to 
assess the presence of HDR or NHEJ-induced indels.  To isolate sequences with 
HDR, reads were first filtered to remove unedited wildtype reads.  Next, HDR reads 
containing intended APP or PSEN1 mutations were isolated by matching a 6-nt HDR 
motif around the pathogenic mutation.  HDR reads were then analyzed for 
incorporation of CRISPR/Cas-blocking mutations by matching 6 to 8-nt HDR motifs 
around each mutation and categorized into unique groups of reads containing all 
possible combinations (32) of CRISPR/Cas-blocking mutations to account for 
measurable HDR after re-editing (Figure 45B).  Each group of reads was then 
aligned to a corresponding reference sequence using bwa mem (Li and Durbin, 
2010) (which has been successfully used for this purpose by others (Dow et al., 
2015)) to determine the rate of accurate HDR and indel or substitution mutations 
(Figure 45C).  Reads with multiple blocking mutations were analyzed separately. 
Accurate HDR reads were calculated in each group as the percentage of HDR reads 
without indels. To determine indel frequency, size and distribution, all edited reads 
from each experimental replicate were combined and aligned, as described above.  
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Indels were then marked at each base using bam-readcount 
(https://github.com/genome/bam-readcount), quantified in R (www.R–project.org) 
and plotted using Graphpad Prism. 
In all other experiments assessing mutation incorporation for establishing the 
distance effect, reads were first filtered for experiment-specific barcode and quality 
as described above.  Next, reads were considered to have HDR if they matched the 
repair ssODN template plus an additional 3-nt genomic sequence on each side to 
ensure proper genomic context during HDR and contained the pathogenic mutation 
and/or CRISPR/Cas-blocking silent mutation (Figure 45D). n values represent 
independent biological replicates.   
To exclude a significant contribution of oligo synthesis and sequencing errors 
to our analysis, we sequenced PSEN1 PCR amplicons from APP-edited iPSCs, and 
repair ssODNs annealed to a complementary ssODN. Errors introduced by 
sequencing were 2.7% ± 0.1% per 100bp, and 2.3% ± 1.7% of the 100bp ssODN 
sequences contained errors. 
 
Calculation of optimal distance ranges for homo- or heterozygous genotypes.   
 
Mutation scan data for APP and PSEN1 loci determined by NGS for iPSCs 
from were combined to determine single allelic mutation incorporation probabilities 
pa as a function of cut-to-mutation distance (pamut).  The probability of wildtype 
incorporation (pawt) was determined as (pawt= 1-pamut).  Assuming gene editing and 
HDR at each allele in a single cell are independent events, we calculated the 
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zygosity probabilities (pz) for each allele combination given two alleles per cell.  
Specifically, probability of a homozygous, wildtype, and heterozygous zygosity was 
calculated as pzmut/mut=pamutxpamut, pzwt/wt=pawtxpawt and pzwt/mut = 2x(pawtxpamut), 
respectively.  These calculations were made using the entire range of data derived 
from Figure 19B, extrapolated for distance values above 36 and plotted in Figure 
22A as fit curve ± SD of raw values. 
 
RFLP analysis and Sanger sequencing for genotyping of single cell clones 
(Chapter II).   
 
To facilitate single cell clone genotyping, the ssODN HDR templates used for 
gene editing were designed to introduce a restriction endonuclease motif with the 
blocking or pathogenic mutation.  Genome edited single cell-derived iPSC clones 
grown on MEF-containing 10 cm plates (in HUESM + ROCK inhibitor) were manually 
picked into a single well of a U-bottom 96-well tissue culture plate in 100 µL HUESM 
+ ROCK inhibitor.  Cells were pelleted by centrifugation, and plates were 
immediately frozen in liquid N2 and stored at -80 °C. Genomic DNA was extracted as 
previously described44.  Briefly, cells were resuspended in 25 µL lysis buffer (0.75 µL 
10 mg/mL Proteinase K (Ambion), 2.5 µL 10X PCR buffer (Sigma-Aldrich), 
transferred to 96-well PCR plates and incubated at 55 °C for 4 h.  Proteinase K was 
inactivated by incubating plates at 96 °C for 10 min.   
To identify clones with HDR events the genomic region surrounding the 
APPswe or PSEN1-M146V,  loci were amplified (see primers in Table 13) by Taq 
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polymerase (Roche) and digested with restriction enzymes to screen for a novel 
restriction site introduced by the blocking or pathogenic mutation (primers, repair 
ssODNs and restriction enzymes used are listed in the above tables).  Digested 
DNA was analyzed by agarose gel electrophoresis.  The zygosity of the pathogenic 
mutation in clones that had undergone incorporation of the silent CRISPR/Cas-
blocking mutations was determined by Sanger sequencing (Genewiz).   
 
Table 13.  Primers used for RFLP and Sanger sequencing of single-cell 
derived clones (Chapter II) 
 
 
To determine the frequency and distribution of indels in mono-allelic HDR 
single cell clones with NHEJ at the other allele, Sanger sequencing reads were 
separated into single reads for HDR and indel-containing alleles using PolyPeak 
Parser (Hill et al., 2014).  Indel-containing reads were then combined into a single 






CORRECT   
 
Re-Guide and re-Cas utilize a two-step gene editing workflow: 2 million iPSCs 
were electroporated with sgRNA and Cas9 plasmids.  In addition, during the first 
step a ssODN containing the intended mutation (M) and a CRISPR/Cas blocking 
mutation (B) was introduced (MB template).  Cas9-eGFP expressing cells were 
FACS sorted and single cell iPSC clones were derived.  The presence of B and M 
mutations was detected by RFLP.  A single clone containing homozygous B and M 
mutations was then expanded for use in the second step of CORRECT.  These “MB 
iPSCs” were then electroporated with re-sgRNA and wildtype Cas9 plasmids (for re-
Guide) or wildtype sgRNA and mutant VRER Cas9 plasmids (for re-Cas).  In 
addition, at this step the CORRECT template was provided to remove blocking 
mutation B.  The efficacy of CRISPR/Cas blocking mutation removal was first 
determined by NGS.  To isolate scarless edited “M iPSC clones” the second step of 
CORRECT editing was performed and single-cell-derived colonies were picked and 
expanded as described above. Genotypes were confirmed by sanger sequencing.  
 
SURVEYOR assays   
 
gDNA was extracted from gene edited iPSCs as described above.  300-500 
bp around the gene edited locus were amplified by PCR using Herculase II (Agilent) 
and column purified.  PCR amplicons were rehybridized and treated with 
SURVEYOR nuclease according to the manufacturers directions (IDT).  Digested 
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DNA was separated on a 4-20% TBE polyacrylamide gel (BioRad) and imaged using 
SYBR Gold (Life Technologies).  Densitometry was performed using Image J.  
Percent indel quantification was based on relative band intensities using the formula 
100 x (1-(1-(b+c)/(a+b+c)1/2, where a is the undigested PCR product intensity and b 
and c are the intensities of each cleavage product (Ran et al., 2013). 
 
Isogenic APP and PSEN1 mutant iPSC lines. 
 
Generation of heterozygous and homozygous APP and PSEN1 isogenic 
mutant iPSC lines was done using a combination of “distance effect” and oligo 
mixing based approaches as described above. Briefly, sgRNA sequences (see 
sgRNA sequences for Chapter IV in Table 3) were selected and cloned into plasmid 
MLM3636. 100-nt PAGE-purified ssODN repair templates were designed with 
homologous genomic flanking sequence centered around the predicted CRISPR cut 
site and containing pathogenic and/or CRISPR-blocking mutations (Table 14). 
  
Table 14.  ssODNs used for generation of isogenic APP and PSEN1 




iPSCs were transfected with Cas9-GFP and gRNA-expressing plasmids, and 
ssODNs by electroporation. After electroporation, GFP+ cells were FACS sorted and 
grown until single cell-derived colonies were detectable and picked.  Identification of 
accurately edited iPSCs by RFLP analysis and Sanger sequencing was performed 
as described in (Kwart et al., 2017) using PCR amplification primers listed in Table 
15. In all electroporations, 7889SA-derived iPSCs wildtype at genome-edited loci 
were used.  Swe/M146V “double mutant” iPSCs were generated by a two-step 
editing approach. Homozygous PSEN1-M146V were re-edited to introduce the 
homozygous APPswe mutation.   
 
Table 15.  Primers used for RFLP analysis and Sanger sequencing of 
single-cell derived clones (Chapter IV). 
 
 
PSEN1-L166P, PSEN1-A246E and PSEN1-M233L iPSCs were generated in 
collaboration with Andrew Gregg, who recently presented preliminary data on these 
lines in his thesis (Gregg, 2017).  To generate the APP-KO iPSC line, wildtype 
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iPSCs were electroporated with Cas9-GFP and gRNA-expressing plasmid only and 
identification of clones with frame-shift deletions was carried out by TOPO-cloning 
(Figure 46).    One iPSC line per genotype was isolated and characterized. The 
newly established gene-edited lines displayed normal karyotypes and expressed 






Figure 46.  Generation of an APP-KO iPSC line. 
A) Schematic describing the main steps in generating an isogenic APP 
knockout iPSC clone using CRISPR/Cas9. (1) We targeted the first 
conserved transcription start site (red) by using a sgRNA targeting a double 
stranded break at the indicated site. This ATG start site is adjacent to the 
Cas9 cleavage site, and therefore following non-homologous end joining 









































































deleted. After isolating single cell-derived iPSC clones we can test loss for 
loss of ATG using an RFLP assay. We utilized the restriction enzyme NruI, 
which has a recognition sequence that includes the A of the ATG transcription 
start site. Therefore, we can look for loss of NruI cleavage as an indication of 
loss of ATG (2). (3) Following identification of putative knockout (loss of intact 
ATG) clones we utilized TOPO cloning technology to be able to analyze the 
editing outcome at each allele by Sanger sequencing. (4) Finally, to confirm 
knockout we performed a screen by western blot on iPSC lysates. B) An 
example of the RFLP assay from our gene editing experiment. Putative KO 
clones are highlighted in red. The clone we used in our experiments “P2A8” is 
indicated. C) TOPO cloning and Sanger sequencing alignment for each allele 
from the P2A8 KO clone compared to wildtype. Both alleles have a complete 
loss of the ATG sequence. D) Western blot analysis for full length APP (FL-
APP) for wildtype and P2A8 iPSCs. 
 
 
Cortical neuron differentiation   
 
iPSC-derived cortical neurons were generated as previously described 
(Paquet et al., 2016) with modifications.  Briefly, iPSCs were plated on 12-well tissue 
culture plates coated with Geltrex (Life Technologies) in MEF-conditioned HUESM 
with ROCK inhibitor.  When cells were 100% confluent, medium was replaced with 
neural induction (NI) medium (day in vitro 0 (DIV0)) and maintained for 8 days.  On 
DIV8 day cells were dissociated using Accutase (Life Technologies) and 
resuspended in NI medium at 30 million cells/mL.  Cells were plated on dried poly-L-
ornithine (Sigma-Aldrich) and laminin-coated (Life Technologies) 6-well plates in 200 
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µL spots.  Cells were left to adhere for ~45 min and NI medium was added.  On 
DIV10 NI was replaced with neural maintenance (NM) medium. Upon the 
appearance of neural rosettes, 20 ng/mL FGF2 was added for 2 days. When 
neurons started to form (~DIV21), rosettes were isolated manually after treatment 
with STEMdiff Neural Rosette Selection Reagent (STEMCELL Technologies) for 1 h. 
Rosettes were washed and plated on poly-L-ornithine/laminin-coated 6-well plates 
and grown for approximately 7 days. For cortical neuron maturation, ~675,000 
NPCs/mL were plated on 6- or 12-well poly-L-ornithine/laminin-coated plates and 
maintained in Neurobasal medium supplemented with B-27 serum-free supplement, 
2 mM Glutamax and 100 U/mL-0.1 mg/mL penicillin-streptomycin (all Life 
Technologies). For imaging experiments cells were plated in 24-well plates onto 
poly-L-ornithine/laminin-coated coverslips. During the first 7 days after plating, cells 
were treated with 10 µM DAPT (Sigma-Aldrich) to augment neuronal maturation, 
which was subsequently washed out with normal Neurobasal/B-27 medium. 
 
Cortical neuron characterization   
 
Canonical neural precursor cell markers (Nestin, Pax6, FoxG1, Otx2) and 
mature cortical neuronal markers (Tbr1, CTIP2, Satb2) were analyzed by 
immunofluorescence staining at DIV10 and DIV65, respectively (Figure 47A-B).  
Synapse marker expression was also analyzed by immunofluorescence at DIV65 
(Figure 47C). Electrophysiological properties of iPSC-derived cortical neurons were 
assessed between DIV71 and 85 using a submerged recording chamber mounted 
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on an Olympus BX51 microscope equipped for infrared-DIC microscopy (Figure 
47D-H). Neurons were perfused with 95% 02/5% CO2 equilibrated ACSF (in mM): 
119 NaCl, 2.5 KCl, 1.3 MgSO4, 2.5 CaCl2, 1 NaH2PO4, 26 NaHCO3 and 11 glucose. 
Whole-cell patch clamp pipettes (5 MΩ) were filled with (in mM): 123 K-gluconate, 
10 HEPES, 0.2 EGTA, 8 NaCl, 2 Na2ATP, 0.3 Na3GTP. Action potentials were 
elicited by step current injections and recorded in current-clamp mode (-65 mV).  
Properties (threshold, overshoot) of the largest action potential elicited in each cell 
were measured.  Spontaneous synaptic activity was recorded in voltage-clamp 
mode (-70 mV). Data was digitized at 10 kHz and recorded using a Multiclamp 700B 
amplifier and Clampex 10.3.0.2 software (Molecular Devices).  We also performed 
an analysis of Ab production as a function of differentiation state.  It was determined 
that Ab production is considerably maturation-dependent and therefore we chose to 




Figure 47.  Characterization of iPSC-derived cortical neurons. 
A-C) Immunofluorescence stainings of markers for neural precursors at 
DIV10 (A), cortical neurons at DIV65 (B) and functional synapses at DIV65 
(C).  Scale bars, 100 µm in A, B, 10 µm in C.  D) Evoked action potentials 
recorded in a neuron current-clamped to -65 mV.  E) Mean (± SEM) resting 
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membrane potential (Vrest), action potential threshold and action potential 
overshoot (DIV 71 – 85; n = 18).  Properties of the largest action potential 
elicited in each cell were measured.  F) Mean number of evoked action 
potentials increases with increasing stimulus strength.  G) Spontaneous 
synaptic activity recorded in a neuron voltage-clamped to -70 mV.  H) Mean 
(± SEM) frequency and amplitude of spontaneous excitatory postsynaptic 
currents (EPSCs) (DIV 71 - 85; n = 8).  I) Total secreted Ab levels from cells 
at different stages of the differentiation protocol.  
 
Drug treatments   
 
In all experiments, neurons were treated for 48h with 1 µM of drug in 0.1% 
DMSO. DMSO treatment alone was used as a vehicle control.  Drugs used were b-
Secretase inhibitor IV (Millipore), Compound E (Millipore). GSMs were obtained from 
Dr. Yeuming Li.  A previously published GSM, GSM-I, was used in all experiments 
(Crump et al., 2011). 
 
Whole transcriptomic RNA sequencing (RNA-seq) 
 
 RNA from DIV80 iPSC-derived neurons was extracted using Trizol 
(Invitrogen) and ribosomal RNA was removed with Ribo-Zero (Epicentre).  RNA was 
DNAse-treated (Roche) sequencing libraries were generated as recommended by 
the Illumina High-throughput TruSeq sample preparation guidelines.  3 biological 
replicates, each consisting of 2 technical replicates, were used for sequencing. 
Stranded RNAseq was performed using an Illumina HiSeq 2500 at the New York 
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Genome Center generating 125-bp paired-end reads.  Reads were aligned to the 
hg19 build of the human genome using Kallisto.  All read counts, TPM and 
differential expression analysis was performed on R (www.R-project.org) using 
packages “Tximport” and “DESEQ2” (bioconductor.org).  RNA-seq analysis was 
performed using R packages “ggplot”, “venneuler”, “pheatmap” or “pcaexplorer”. 
Quality control assessment of all RNA-seq libraries was performed as shown in 
Figure 48.  P-values to assess statistically significant overlap between the AD gene 
lists was calculated with a hypergeometric test.  The list of genes with AD-linked 
variants was obtained from https://www.ebi.ac.uk/gwas/ and is shown in Table 16. 
Gene expression heatmaps were generated using Prism.  Metascape (Tripathi et al., 
2015) (metascape.org) was used for GO pathway analysis and we included enriched 
terms down to q < 0.01 (p adjusted for multiple comparisons).  The list of 
differentially expressed endocytic-related genes determined from metascape and 
used for RNA-seq analyses is shown in Table 17.  Gene lists from Tables 16 and 17 
were used for hierarchical clustering analysis.  A summary of Metascape GO terms 
identified when studying differentially expressed genes in Swe/M146V neurons 




Figure 48.  RNA-seq library quality control analysis. 
A) Read depth (number of unique reads detected) of each biological replicate 
used for RNA-seq analysis.  B)  Diagonal: Distribution of each variable is 
shown via histogram for each of the respective iPSC-derived neuron 
genotypes of the RNA-sequencing libraries. Bottom panel: Scatter plot of log-
transformed read counts per gene, displaying the relationship between each 
genotype.  Upper panel: Correlation between RNA sequencing libraries per 
genotype, R = Pearson correlation coefficient. Abundance (TPM) averages 
per gene for all iPSC-derive neurons analyzed. C). Principal component 
analysis (PCA) plot displaying the projections of sample expression profiles 
 
 194 
demonstrating overall effects of experimental and batch effects. Each of the 
12 samples are plotted and spanned by their first two principle components. 
D) Scree plot of PC computed across samples.  E) Top and bottom loadings 
of genes contributing to overall variances in the data.  dAP = Swe/M146V 
double mutant. 
 
Table 16.  AD-linked genes used for hypergeometric test and 
hierarchical clustering analysis. 





























































































































Table 17.  Differentially-expressed endocytic-associated genes used for 
RNA-seq analysis. 














































































































































Table 18.  Sample of Metascape GO terms using input list of genes 
differentially expressed genes in Swe/M146V versus APPswe or PSEN1-
M146V neurons. 
 
GO Description LogP # Genes
GO:0012506 vesicle membrane -9.3237 142
GO:0030139 endocytic vesicle -8.2469 53
GO:0045055 regulated exocytosis -6.9176 132
GO:0030666 endocytic vesicle membrane -6.4054 33
GO:0043087 regulation of GTPase activity -6.1699 90
GO:1905954 positive regulation of lipid localization -4.791 18
GO:0005769 early endosome -4.4905 63
GO:0045807 positive regulation of endocytosis -4.3651 30
GO:0060627 regulation of vesicle-mediated transport -4.321 84
GO:0031901 early endosome membrane -4.2981 32
GO:0043547 positive regulation of GTPase activity -4.1397 72
GO:0005764 lysosome -3.9922 82
GO:0005085 guanyl-nucleotide exchange factor activity -3.7662 45
GO:1905952 regulation of lipid localization -3.758 24
GO:0006869 lipid transport -3.6272 60
GO:0032370 positive regulation of lipid transport -3.5763 13
GO:0043202 lysosomal lumen -3.5514 23
GO:0010876 lipid localization -3.4713 64
GO:0031904 endosome lumen -3.4072 10
GO:0030276 clathrin binding -3.3195 18
GO:0006897 endocytosis -3.1425 111
GO:0005096 GTPase activator activity -2.9432 50
GO Description LogP # Genes
GO:0043408 regulation of MAPK cascade -17.336 162
GO:0010942 positive regulation of cell death -12.425 139
GO:0043065 positive regulation of apoptotic process -9.9273 123
GO:0034599 cellular response to oxidative stress -6.6819 62
GO:0051403 stress-activated MAPK cascade -6.2771 58
GO:1901214 regulation of neuron death -6.1453 60
GO:0001540 amyloid-beta binding -5.8169 21
GO:0070997 neuron death -5.3607 63
GO:0007568 aging -5.0603 59
GO:0043523 regulation of neuron apoptotic process -5.0166 43
hsa04730 Long-term depression -4.7259 19
GO:0007254 JNK cascade -3.8813 32
GO Description LogP # Genes
GO:0007268 chemical synaptic transmission -25.663 163
GO:0098916 anterograde trans-synaptic signaling -25.663 163
GO:0099537 trans-synaptic signaling -25.495 163
GO:0099536 synaptic signaling -25.495 163
GO:0044456 synapse part -18.953 162
GO:0050808 synapse organization -15.28 84
GO:0050804 modulation of chemical synaptic transmission -14.766 85
GO:0099177 regulation of trans-synaptic signaling -14.766 85
GO:0098793 presynapse -13.557 91
GO:0098794 postsynapse -11.285 97
GO:0097060 synaptic membrane -11.014 75
GO:0007416 synapse assembly -10.988 48
GO:0050807 regulation of synapse organization -9.9973 48
GO:0045211 postsynaptic membrane -8.5185 57
GO:0050806 positive regulation of synaptic transmission -8.0496 39
GO:0048167 regulation of synaptic plasticity -7.9323 44
R-HSA-112315 Transmission across Chemical Synapses -6.4514 52
GO:0051965 positive regulation of synapse assembly -6.2848 23
GO:0042133 neurotransmitter metabolic process -6.1851 30
GO:0021766 hippocampus development -5.8958 24
hsa04724 Glutamatergic synapse -5.514 25
R-HSA-112314 Neurotransmitter receptors and postsynaptic signal transmission -5.5896 38
GO:0051588 regulation of neurotransmitter transport -5.3923 26
GO:0022843 voltage-gated cation channel activity -5.3309 35
GO Description LogP # Genes
R-HSA-500792 GPCR ligand binding -17.532 118
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger -15.145 67
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway -12.724 58
GO:0007264 small GTPase mediated signal transduction -11.322 106
R-HSA-418594 G alpha (i) signalling events -9.4897 88
GO:0051057 positive regulation of small GTPase mediated signal transduction -5.8572 20
GO:0016907 G-protein coupled acetylcholine receptor activity -5.4821 5
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway -5.3308 27
R-HSA-1296059 G protein gated Potassium channels -5.2913 12
R-HSA-1296041 Activation of G protein gated Potassium channels -5.2913 12
GO:0008528 G-protein coupled peptide receptor activity -4.7783 32
GO:0038037 G-protein coupled receptor dimeric complex -4.5999 5
GO:0097648 G-protein coupled receptor complex -4.5999 5
GO:0015467 G-protein activated inward rectifier potassium channel activity -4.6988 7
R-HSA-418597 G alpha (z) signalling events -3.5995 12
GO:0038042 dimeric G-protein coupled receptor signaling pathway -3.262 4
GO:0045028 G-protein coupled purinergic nucleotide receptor activity -3.1683 5
GO:0035589 G-protein coupled purinergic nucleotide receptor signaling pathway -3.1683 5
GO:0001608 G-protein coupled nucleotide receptor activity -3.1683 5
Synapse function
GPCR signalling




Immunocytochemistry and microscopy 
 
Cells were fixed in 4% paraformaldehyde, permeabilized in PBS/0.1% 
TritonX-100 and stained with primary and secondary antibodies (see below). For low 
resolution microscopy (all experiments excluding endosome analyses) stained cells 
were imaged on a Nikon Eclipse Ti inverted microscope and acquired using NIS 
Elements imaging software (Nikon).  For endosome analysis, stained cells were 
imaged on a DeltaVision inverted Olympus IX-70 microscope using a 100X oil 
objective with deconvolution. Rab5+ puncta quantifications were done using Imarus.  
Briefly, surface masks using the MAP2 staining to indicate neurons.  Rab5+ puncta 
detection and quantification was automated and programmed using the Imarus spot 
detection function. Fiji (www.Fiji.sc / National Institutes of Health) and Adobe 
Photoshop were used to pseudo-color images, adjust contrast, and add scale bars.  
 
Antibodies   
 
The following antibodies were used: Oct4 (1:500, Stemgent S090023), 
Tra160 (1:500, Millipore MAB4360), SSEA4 (1:500, Abcam ab16287), Nanog 
(1:500, Cell Signaling 4903), MAP2 (1:2000, Abcam 5392), Pax6 (1:300, Covance 
PRB-278P), Tuj1 (mouse 1:1000, Covance MMS-435P / rabbit 1:1000, Covance 
MRB-435P), Otx2 (1:100, Millipore AB9566), Nestin (1:200, Millipore 2C13B9), 
FoxG1 (1:300, Abcam ab18259), CTIP2 (1:300, Abcam ab18465), Tbr1 (1:500, 
Millipore AB2261), SatB2 (1:100, Abcam ab51502), MAGUK (1:100, NeuroMab 
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K28_86), Synapsin (1:200, Cell Signalling Technologies 5297), APP C-term 
(1:10000, Abcam Y188 ab32136) Rab5 (1:200, Cell Signalling Technologies), anti-
mouse/rabbit/rat/chicken Alexa Fluor 488/568/647 (Invitrogen 1:500.  
 
Amyloid-β measurements   
 
Aβ was measured in cell supernatant conditioned for 7 days (DIV62-72 
cortical neurons). Experiments were performed in 3 biological replicates. 
Supernatants from experiments collected at different time points were frozen at -80 
˚C.  Secreted Aβ1-38, Aβ1-40 and Aβ1-42 was measured with MSD Human (6E10) 
Aβ V-PLEX kits (Meso Scale Discovery) according to the manufacturer’s directions.  
Aβ1-43 was measured using a colormetric ELISA (Takara) according to the 
manufacturer’s directions. Secreted sAPPα and sAPPβ were also measured 
simultaneously, and from matching supernatants, with MSD sAPPα/sAPPβ kit (Meso 
Scale Discovery) according to the manufacturer’s directions. For all experiments, Aβ 
levels were normalized to total sAPP levels unless otherwise stated. 
 
Western Blotting  
 
Neurons were lysed using the NucleoSpin RNA/Protein kit (Macherey Nagel) 
and total protein was isolated according to the manufacturer’s instructions. Samples 
were run on Criterion™ Tris-Tricine 16.5% precast gels for SDS-PAGE at 125V (Bio-
Rad). Gels were then blotted using standard techniques onto an Odyssey 
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nitrocellulose membrane (LI-COR). Membranes were blocked in 5% non-fat dairy 
milk in TBS-T, and were probed with primary antibodies listed below. IRDye 
conjugated secondary antibodies (LI-COR) were used at 1:10,000. Proteins were 
detected using the Odyssey CLx Imaging System (LI-COR). 
 
Statistical Analysis   
 
Experimental data was analyzed for significance using Graphpad Prism. 
P < 0.05 was considered statistically significant. Sample sizes were chosen to be 
large enough to allow meaningful statistical analysis. In Chapter II, all experiments 
except the oligo scan were analyzed by one-way ANOVA followed by post testing 
with either Tukey’s test, if multiple values were compared to each other, or Dunnett’s 
method, if alterations were compared to controls. For the oligo scan, nonlinear 
regression analysis was performed to fit exponential decay equation model curves to 
experimental values; R square values were determined to test goodness of fit. To 
analyze if distance-incorporation relationships were significantly different for 
genomic loci, the rate constant k was determined for each individual data set and the 
k values of the two loci were compared using the unpaired t-test.  For experiments in 
Chapter IV, data were analyzed by one-way or two-way ANOVA (as indicated) 
followed by post testing with Dunnett’s method, as alterations were compared to 
controls.  Outliers were identified by the ROUT method (Q=1%).  T-tests were 




Appendix II:  Rights and Permissions 
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